{ "version": "2.2", "instance": { "vrax-20240331.htm": { "nsprefix": "vrax", "nsuri": "http://www.viraxbiolabs.com/20240331", "dts": { "inline": { "local": [ "vrax-20240331.htm" ] }, "schema": { "local": [ "vrax-20240331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd" ] } }, "keyStandard": 230, "keyCustom": 147, "axisStandard": 21, "axisCustom": 0, "memberStandard": 35, "memberCustom": 52, "hidden": { "total": 6, "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 1, "http://xbrl.sec.gov/dei/2023": 3, "http://www.viraxbiolabs.com/20240331": 2 }, "contextCount": 240, "entityCount": 1, "segmentCount": 87, "elementCount": 800, "unitCount": 12, "baseTaxonomies": { "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 624, "http://xbrl.sec.gov/dei/2023": 58, "http://xbrl.sec.gov/ecd/2023": 1 }, "report": { "R1": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition", "longName": "100010 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION", "shortName": "CONSOLIDATED STATEMENTS OF FINANCIAL POSITION", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_9be08593-8d60-4aaa-99ce-9632bea161ed", "name": "ifrs-full:Cash", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_9be08593-8d60-4aaa-99ce-9632bea161ed", "name": "ifrs-full:CurrentAssets", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "unique": true } }, "R3": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPositionParenthetical", "longName": "100020 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Parenthetical)", "shortName": "CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_9be08593-8d60-4aaa-99ce-9632bea161ed", "name": "ifrs-full:ParValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "ifrs-full:ParValuePerShare", "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true }, "uniqueAnchor": null }, "R4": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss", "longName": "100030 - Statement - CONSOLIDATED STATEMENTS OF LOSS AND OTHER COMPREHENSIVE LOSS", "shortName": "CONSOLIDATED STATEMENTS OF LOSS AND OTHER COMPREHENSIVE LOSS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:CostOfSales", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "unique": true } }, "R5": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity", "longName": "100050 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_c997217c-dfb2-43dc-bf70-b6afdadd7a5b", "name": "ifrs-full:NumberOfSharesOutstanding", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c997217c-dfb2-43dc-bf70-b6afdadd7a5b", "name": "ifrs-full:NumberOfSharesOutstanding", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "longName": "100060 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DepreciationAndAmortisationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "unique": true } }, "R7": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "longName": "995447 - Disclosure - Insider Trading Policies and Procedures", "shortName": "Insider Trading Policies and Procedures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactions1", "longName": "995457 - Disclosure - General information and reorganization transactions", "shortName": "General information and reorganization transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies", "longName": "995467 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureCriticalEstimatesAndJudgments", "longName": "995477 - Disclosure - Critical estimates and judgments", "shortName": "Critical estimates and judgments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRevenueFromContractsWithCustomers", "longName": "995487 - Disclosure - Revenue from contracts with customers", "shortName": "Revenue from contracts with customers", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTax", "longName": "995507 - Disclosure - Income tax", "shortName": "Income tax", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLossPerShare1", "longName": "995517 - Disclosure - Loss per share", "shortName": "Loss per share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureVatReceivable", "longName": "995527 - Disclosure - VAT Receivable", "shortName": "VAT Receivable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "vrax:DisclosureOfValueAddedTaxReceivableExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "vrax:DisclosureOfValueAddedTaxReceivableExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureInventories", "longName": "995537 - Disclosure - Inventories", "shortName": "Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DisclosureOfInventoriesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DisclosureOfInventoriesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosurePrepaidExpensesAndDeposits", "longName": "995547 - Disclosure - Prepaid Expenses and Deposits", "shortName": "Prepaid Expenses and Deposits", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosurePropertyPlantEquipmentNet", "longName": "995557 - Disclosure - Property, plant & equipment, net", "shortName": "Property, plant & equipment, net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIntangibleSoftwareNet", "longName": "995567 - Disclosure - Intangible Software, net", "shortName": "Intangible Software, net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureNotePayable", "longName": "995577 - Disclosure - Note Payable", "shortName": "Note Payable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DisclosureOfBorrowingsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DisclosureOfBorrowingsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilities", "longName": "995607 - Disclosure - Accounts payable and accrued liabilities", "shortName": "Accounts payable and accrued liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "vrax:DisclosureOfAccountsPayableAndAccruedLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "vrax:DisclosureOfAccountsPayableAndAccruedLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureDeferredRevenue1", "longName": "995617 - Disclosure - Deferred Revenue", "shortName": "Deferred Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "vrax:DeferredRevenueExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "vrax:DeferredRevenueExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeases", "longName": "995637 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DisclosureOfLeasesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DisclosureOfLeasesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactions", "longName": "995647 - Disclosure - Related party transactions", "shortName": "Related party transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRiskManagementOverview", "longName": "995657 - Disclosure - Risk management overview", "shortName": "Risk management overview", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquity", "longName": "995667 - Disclosure - Stockholder's equity", "shortName": "Stockholder's equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSubsequentEvents", "longName": "995677 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "995687 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "27", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "vrax:DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "vrax:DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "longName": "995707 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "vrax:DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatory", "div", "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "vrax:DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatory", "div", "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersTables", "longName": "995717 - Disclosure - Revenue from Contracts with Customers (Tables)", "shortName": "Revenue from Contracts with Customers (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxTables", "longName": "995727 - Disclosure - Income tax (Tables)", "shortName": "Income tax (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "vrax:DisclosureOfReconciliationOfIncomeTaxesAtStatutoryRatesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "vrax:DisclosureOfReconciliationOfIncomeTaxesAtStatutoryRatesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLossPerShareTables", "longName": "995737 - Disclosure - Loss per share (Tables)", "shortName": "Loss per share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:EarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:EarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureVatReceivableTables", "longName": "995757 - Disclosure - VAT Receivable (Tables)", "shortName": "VAT Receivable (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "vrax:DisclosureOfValueAddedTaxReceivableExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "vrax:DisclosureOfValueAddedTaxReceivableExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureInventoriesTables", "longName": "995777 - Disclosure - Inventories (Tables)", "shortName": "Inventories (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "vrax:DisclosureOfInformationAboutInventoriesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfInventoriesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "vrax:DisclosureOfInformationAboutInventoriesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfInventoriesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosurePrepaidExpensesAndDepositsTables", "longName": "995787 - Disclosure - Prepaid Expenses and Deposits (Tables)", "shortName": "Prepaid Expenses and Deposits (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "vrax:DisclosureOfPrepaidExpensesAndDepositsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "vrax:DisclosureOfPrepaidExpensesAndDepositsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosurePropertyPlantEquipmentNetTables", "longName": "995797 - Disclosure - Property, Plant & Equipment, Net (Tables)", "shortName": "Property, Plant & Equipment, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIntangibleSoftwareNetTables", "longName": "995807 - Disclosure - Intangible Software, Net (Tables)", "shortName": "Intangible Software, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables", "longName": "995837 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)", "shortName": "Accounts Payable and Accrued Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "vrax:DisclosureOfDetailedInformationAboutAccountsPayableAndAccruedLiabilitiesexplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "vrax:DisclosureOfAccountsPayableAndAccruedLiabilitiesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "vrax:DisclosureOfDetailedInformationAboutAccountsPayableAndAccruedLiabilitiesexplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "vrax:DisclosureOfAccountsPayableAndAccruedLiabilitiesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureDeferredRevenueTables", "longName": "995847 - Disclosure - Deferred Revenue (Tables)", "shortName": "Deferred Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "vrax:SummaryOfDeferredRevenueExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "vrax:DeferredRevenueExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "vrax:SummaryOfDeferredRevenueExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "vrax:DeferredRevenueExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureCommitmentsTables", "longName": "995857 - Disclosure - Commitments (Tables)", "shortName": "Commitments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true }, "uniqueAnchor": null }, "R40": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesTables", "longName": "995867 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "vrax:ScheduleOfAnnualRentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "vrax:ScheduleOfAnnualRentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsTables", "longName": "995877 - Disclosure - Related Party Transactions (Tables)", "shortName": "Related Party Transactions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRiskManagementOverviewTables", "longName": "995887 - Disclosure - Risk Management Overview (Tables)", "shortName": "Risk Management Overview (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "vrax:DisclosureOfMonetaryAssetsAndLiabilitiesDenominatedInForeignCurrenciesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "vrax:DisclosureOfMonetaryAssetsAndLiabilitiesDenominatedInForeignCurrenciesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityTables", "longName": "995897 - Disclosure - Stockholder's equity (Tables)", "shortName": "Stockholder's equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "vrax:DisclosureOfActivityRelatedToOutstandingWarrantsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "vrax:DisclosureOfActivityRelatedToOutstandingWarrantsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "longName": "995907 - Disclosure - General Information and Reorganization Transaction - Additional Information (Details)", "shortName": "General Information and Reorganization Transaction - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "C_9be08593-8d60-4aaa-99ce-9632bea161ed", "name": "ifrs-full:Cash", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_6b8d8977-4e06-4f91-9b05-a37dc87f6c1a", "name": "dei:EntityIncorporationDateOfIncorporation", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "unique": true } }, "R45": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfConsolidatedSubsidiariesDetails", "longName": "995917 - Disclosure - Summary of Significant Accounting Policies - Summary of Consolidated Subsidiaries (Details)", "shortName": "Summary of Significant Accounting Policies - Summary of Consolidated Subsidiaries (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "C_6b8d8977-4e06-4f91-9b05-a37dc87f6c1a", "name": "ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory", "div", "vrax:DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatory", "div", "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_6b8d8977-4e06-4f91-9b05-a37dc87f6c1a", "name": "ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory", "div", "vrax:DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatory", "div", "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "longName": "995927 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)", "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "vrax:NumberOfReportableSegments1", "unitRef": "U_Segment", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory", "div", "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "vrax:NumberOfReportableSegments1", "unitRef": "U_Segment", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory", "div", "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFunctionalAndPresentationCurrencyDetails", "longName": "995937 - Disclosure - Summary of Significant Accounting Policies - Functional and Presentation Currency (Details)", "shortName": "Summary of Significant Accounting Policies - Functional and Presentation Currency (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "C_6b8d8977-4e06-4f91-9b05-a37dc87f6c1a", "name": "ifrs-full:DescriptionOfFunctionalCurrency", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "td", "tr", "table", "vrax:DisclosureOfFunctionalAndPresentationCurrencyExplanatory", "div", "ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "div", "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_6b8d8977-4e06-4f91-9b05-a37dc87f6c1a", "name": "ifrs-full:DescriptionOfFunctionalCurrency", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "td", "tr", "table", "vrax:DisclosureOfFunctionalAndPresentationCurrencyExplanatory", "div", "ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "div", "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDisclosureOfEffectOfChangesInForeignExchangeRatesDetails", "longName": "995947 - Disclosure - Summary of Significant Accounting Policies - Disclosure of Effect of Changes in Foreign Exchange Rates (Details)", "shortName": "Summary of Significant Accounting Policies - Disclosure of Effect of Changes in Foreign Exchange Rates (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "C_b1c7772c-0f36-4aaa-a2cc-ec7669d6ae5c", "name": "ifrs-full:ClosingForeignExchangeRate", "unitRef": "U_GBP", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "div", "ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "div", "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b1c7772c-0f36-4aaa-a2cc-ec7669d6ae5c", "name": "ifrs-full:ClosingForeignExchangeRate", "unitRef": "U_GBP", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "div", "ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "div", "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails", "longName": "995957 - Disclosure - Summary of Significant Accounting Policies - Disclosure of Estimated Useful Lives of Property Plant and Equipment (Details)", "shortName": "Summary of Significant Accounting Policies - Disclosure of Estimated Useful Lives of Property Plant and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "C_687cf9a6-477c-4016-9bf2-2d40d4aeb246", "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "td", "tr", "table", "vrax:DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory", "div", "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "div", "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_687cf9a6-477c-4016-9bf2-2d40d4aeb246", "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "td", "tr", "table", "vrax:DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory", "div", "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "div", "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersScheduleOfDisaggregationOfRevenueFromContractsWithCustomersDetails", "longName": "995967 - Disclosure - Revenue from Contracts with Customers - Schedule of Disaggregation of Revenue from Contracts with Customers (Details)", "shortName": "Revenue from Contracts with Customers - Schedule of Disaggregation of Revenue from Contracts with Customers (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true }, "uniqueAnchor": null }, "R51": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetails", "longName": "995977 - Disclosure - Revenue from Contracts with Customers - Additional Information (Details)", "shortName": "Revenue from Contracts with Customers - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "vrax:NumberOfCustomer", "unitRef": "U_Customer", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "unique": true } }, "R52": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureKeyManagementCompensationAdditionalInformationDetails", "longName": "995987 - Disclosure - Key Management Compensation - Additional Information (Details)", "shortName": "Key Management Compensation - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "C_45fb117d-201a-41df-baa0-2606bf4dcef0", "name": "ifrs-full:AmountsPayableRelatedPartyTransactions", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "div", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true }, "uniqueAnchor": null }, "R53": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxReconciliationOfIncomeTaxesAtStatutoryRatesDetails", "longName": "995997 - Disclosure - Income Tax - Reconciliation of Income Taxes at Statutory Rates (Details)", "shortName": "Income Tax - Reconciliation of Income Taxes at Statutory Rates (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:ProfitLossBeforeTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "vrax:TaxEffectOfExpectedIncomeTaxRecovery", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "vrax:DisclosureOfReconciliationOfIncomeTaxesAtStatutoryRatesTableTextBlock", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "unique": true } }, "R54": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxSummaryOfNetDeferredTaxAssetLiabilityDetails", "longName": "996007 - Disclosure - Income Tax - Summary of Net Deferred Tax Asset (Liability) (Details)", "shortName": "Income Tax - Summary of Net Deferred Tax Asset (Liability) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "C_9be08593-8d60-4aaa-99ce-9632bea161ed", "name": "vrax:IntangibleAssetsOtherThanGoodwillDeferredTaxAssets", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "vrax:DisclosureOfNetDeferredTaxAssetLiabilityTableTextBlock", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9be08593-8d60-4aaa-99ce-9632bea161ed", "name": "vrax:IntangibleAssetsOtherThanGoodwillDeferredTaxAssets", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "vrax:DisclosureOfNetDeferredTaxAssetLiabilityTableTextBlock", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxSummaryOfTemporaryDifferencesDetails", "longName": "996017 - Disclosure - Income Tax - Summary of Temporary Differences (Details)", "shortName": "Income Tax - Summary of Temporary Differences (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "C_9be08593-8d60-4aaa-99ce-9632bea161ed", "name": "vrax:NonCapitalLossesAvailableForFuturePeriod", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "vrax:DisclosureOfNetDeferredTaxAssetLiabilityTableTextBlock", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_e37335de-c204-4388-bc7e-7c0d02e4057f", "name": "vrax:NonCapitalLossesAvailableForFuturePeriodFiniteLived", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "unique": true } }, "R56": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails", "longName": "996027 - Disclosure - Income Tax - Additional Information (Details)", "shortName": "Income Tax - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "C_9be08593-8d60-4aaa-99ce-9632bea161ed", "name": "ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "vrax:DisclosureOfNetDeferredTaxAssetLiabilityTableTextBlock", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "vrax:MaximumAmountToBeUtilizedOnLossCarryforwardInFutureYears", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "span", "p", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "unique": true } }, "R57": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLossPerShareScheduleOfLossPerShareDetails", "longName": "996037 - Disclosure - Loss per share - Schedule of Loss Per Share (Details)", "shortName": "Loss per share - Schedule of Loss Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:ProfitLossAttributableToOwnersOfParent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true }, "uniqueAnchor": null }, "R58": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLossPerShareAdditionalInformationDetails", "longName": "996047 - Disclosure - Loss per share - Additional Information (Details)", "shortName": "Loss per share - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLossPerShareScheduleOfDilutedLossPerShareDetails", "longName": "996057 - Disclosure - Loss per share - Schedule of Diluted Loss Per Share (Details)", "shortName": "Loss per share - Schedule of Diluted Loss Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:WeightedAverageShares", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true }, "uniqueAnchor": null }, "R60": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureVatReceivableSummaryOfVatReceivableDetails", "longName": "996067 - Disclosure - VAT Receivable - Summary of VAT Receivable (Details)", "shortName": "VAT Receivable - Summary of VAT Receivable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "C_9be08593-8d60-4aaa-99ce-9632bea161ed", "name": "vrax:UnfiledCurrentValueAddedTaxReceivables", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "div", "vrax:DisclosureOfValueAddedTaxReceivableExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true }, "uniqueAnchor": null }, "R61": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureVatReceivableAdditionalInformationDetails", "longName": "996077 - Disclosure - VAT Receivable - Additional Information (Details)", "shortName": "VAT Receivable - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "C_9be08593-8d60-4aaa-99ce-9632bea161ed", "name": "vrax:UnfiledCurrentValueAddedTaxReceivables", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "div", "vrax:DisclosureOfValueAddedTaxReceivableExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true }, "uniqueAnchor": null }, "R62": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureInventoriesSummaryOfInventoriesDetails", "longName": "996087 - Disclosure - Inventories - Summary of Inventories (Details)", "shortName": "Inventories - Summary of Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "C_45fb117d-201a-41df-baa0-2606bf4dcef0", "name": "ifrs-full:FinishedGoods", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "vrax:DisclosureOfInformationAboutInventoriesExplanatory", "div", "ifrs-full:DisclosureOfInventoriesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_45fb117d-201a-41df-baa0-2606bf4dcef0", "name": "ifrs-full:FinishedGoods", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "vrax:DisclosureOfInformationAboutInventoriesExplanatory", "div", "ifrs-full:DisclosureOfInventoriesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureInventoriesAdditionalInformationDetails", "longName": "996097 - Disclosure - Inventories - Additional Information (Details)", "shortName": "Inventories - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "C_9be08593-8d60-4aaa-99ce-9632bea161ed", "name": "ifrs-full:Inventories", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "ifrs-full:DisclosureOfInventoriesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "unique": true } }, "R64": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosurePrepaidExpensesAndDepositsSummaryOfPrepaidExpensesAndDepositsDetails", "longName": "996107 - Disclosure - Prepaid Expenses and Deposits - Summary of Prepaid Expenses and Deposits (Details)", "shortName": "Prepaid Expenses and Deposits - Summary of Prepaid Expenses and Deposits (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "C_9be08593-8d60-4aaa-99ce-9632bea161ed", "name": "vrax:PrepaidDirectorsAndOfficersInsurance", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "vrax:DisclosureOfPrepaidExpensesAndDepositsExplanatory", "div", "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9be08593-8d60-4aaa-99ce-9632bea161ed", "name": "vrax:PrepaidDirectorsAndOfficersInsurance", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "vrax:DisclosureOfPrepaidExpensesAndDepositsExplanatory", "div", "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosurePropertyPlantEquipmentNetSummaryOfPropertyPlantEquipmentNetDetails", "longName": "996117 - Disclosure - Property, Plant & Equipment, Net - Summary of Property, Plant & Equipment, Net (Details)", "shortName": "Property, Plant & Equipment, Net - Summary of Property, Plant & Equipment, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "C_9be08593-8d60-4aaa-99ce-9632bea161ed", "name": "ifrs-full:PropertyPlantAndEquipment", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_cadec282-7a66-4da3-bd8d-63e9ffdd20f3", "name": "ifrs-full:PropertyPlantAndEquipment", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "div", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "unique": true } }, "R66": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosurePropertyPlantEquipmentNetAdditionalInformationDetails", "longName": "996127 - Disclosure - Property, Plant & Equipment, Net - Additional Information (Details)", "shortName": "Property, Plant & Equipment, Net - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DepreciationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DepreciationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIntangibleSoftwareNetAdditionalInformationDetails", "longName": "996137 - Disclosure - Intangible Software, Net - Additional Information (Details)", "shortName": "Intangible Software, Net - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "vrax:CapitalizedSoftwareDevelopmentCosts", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "vrax:CapitalizedSoftwareDevelopmentCosts", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIntangibleSoftwareNetSummaryOfIntangibleSoftwareDetails", "longName": "996147 - Disclosure - Intangible Software, Net - Summary of Intangible Software (Details)", "shortName": "Intangible Software, Net - Summary of Intangible Software (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "C_45fb117d-201a-41df-baa0-2606bf4dcef0", "name": "ifrs-full:IntangibleAssetsAndGoodwill", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory", "div", "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory", "div", "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "unique": true } }, "R69": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIntangibleSoftwareNetScheduleOfSoftwareDevelopmentCostsDetails", "longName": "996157 - Disclosure - Intangible Software, Net - Schedule of Software Development Costs (Details)", "shortName": "Intangible Software, Net - Schedule of Software Development Costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "vrax:IntangibleAssetsUnderDevelopmentDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "td", "tr", "table", "vrax:ScheduleOfSoftwareDevelopmentCostsTableTextBlock", "div", "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "vrax:IntangibleAssetsUnderDevelopmentDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "td", "tr", "table", "vrax:ScheduleOfSoftwareDevelopmentCostsTableTextBlock", "div", "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureNotePayableAdditionalInformationDetails", "longName": "996197 - Disclosure - Note Payable - Additional Information (Details)", "shortName": "Note Payable - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "C_fd743bc9-44ed-4d60-b34c-1eb94953a7ad", "name": "ifrs-full:Borrowings", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "ifrs-full:DisclosureOfBorrowingsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_fd743bc9-44ed-4d60-b34c-1eb94953a7ad", "name": "ifrs-full:Borrowings", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "ifrs-full:DisclosureOfBorrowingsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails", "longName": "996207 - Disclosure - Accounts Payable and Accrued Liabilities - Schedule of Accounts Payable and Accrued Liabilities (Details)", "shortName": "Accounts Payable and Accrued Liabilities - Schedule of Accounts Payable and Accrued Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "C_9be08593-8d60-4aaa-99ce-9632bea161ed", "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "vrax:DisclosureOfDetailedInformationAboutAccountsPayableAndAccruedLiabilitiesexplanatory", "div", "vrax:DisclosureOfAccountsPayableAndAccruedLiabilitiesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9be08593-8d60-4aaa-99ce-9632bea161ed", "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "vrax:DisclosureOfDetailedInformationAboutAccountsPayableAndAccruedLiabilitiesexplanatory", "div", "vrax:DisclosureOfAccountsPayableAndAccruedLiabilitiesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureDeferredRevenueSummaryOfDeferredRevenueDetails", "longName": "996217 - Disclosure - Deferred Revenue - Summary of Deferred Revenue (Details)", "shortName": "Deferred Revenue - Summary of Deferred Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "C_9be08593-8d60-4aaa-99ce-9632bea161ed", "name": "ifrs-full:ContractLiabilities", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "vrax:DeferredRevenueExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true }, "uniqueAnchor": null }, "R73": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails", "longName": "996227 - Disclosure - Deferred Revenue - Additional Information (Details)", "shortName": "Deferred Revenue - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "C_9be08593-8d60-4aaa-99ce-9632bea161ed", "name": "ifrs-full:ContractLiabilities", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "vrax:DeferredRevenueExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true }, "uniqueAnchor": null }, "R74": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureCommitmentsScheduleOfCommitmentsForMinimumLeasePaymentsDetails", "longName": "996257 - Disclosure - Commitments - Schedule of Commitments for Minimum Lease Payments (Details)", "shortName": "Commitments - Schedule of Commitments for Minimum Lease Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "C_9be08593-8d60-4aaa-99ce-9632bea161ed", "name": "ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true }, "uniqueAnchor": null }, "R75": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "longName": "996267 - Disclosure - Leases - Additional Information (Details)", "shortName": "Leases - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:CashOutflowForLeases", "unitRef": "U_GBP", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_9be08593-8d60-4aaa-99ce-9632bea161ed", "name": "vrax:LeaseInsurance", "unitRef": "U_GBP", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "unique": true } }, "R76": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesScheduleOfAnnualRentDetails", "longName": "996277 - Disclosure - Leases - Schedule of Annual Rent (Details)", "shortName": "Leases - Schedule of Annual Rent (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "C_10c400a7-c885-4afc-bc3a-a82574103e8d", "name": "vrax:AnnualRentOnLeases", "unitRef": "U_GBP", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "vrax:ScheduleOfAnnualRentTableTextBlock", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_10c400a7-c885-4afc-bc3a-a82574103e8d", "name": "vrax:AnnualRentOnLeases", "unitRef": "U_GBP", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "vrax:ScheduleOfAnnualRentTableTextBlock", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R77": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesSummaryOfRightOfUseAssetsActivityDetails", "longName": "996287 - Disclosure - Leases - Summary of Right of Use Assets Activity (Details)", "shortName": "Leases - Summary of Right of Use Assets Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:AdditionsToRightofuseAssets", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "vrax:RightOfUseAssetsNet", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "unique": true } }, "R78": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesSummaryOfLeaseLiabilityActivityDetails", "longName": "996297 - Disclosure - Leases - Summary of Lease Liability Activity (Details)", "shortName": "Leases - Summary of Lease Liability Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "C_45fb117d-201a-41df-baa0-2606bf4dcef0", "name": "ifrs-full:LeaseLiabilities", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "vrax:DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesExplanatory", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "vrax:AdditionsToLeaseLiabilities", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "vrax:DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesExplanatory", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "unique": true } }, "R79": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesDetails", "longName": "996307 - Disclosure - Leases - Summary of Maturity of Lease Liabilities (Details)", "shortName": "Leases - Summary of Maturity of Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "C_9be08593-8d60-4aaa-99ce-9632bea161ed", "name": "ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_9be08593-8d60-4aaa-99ce-9632bea161ed", "name": "vrax:ImputedInterestOnLeaseLiabilities", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "unique": true } }, "R80": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartyPayablesDetails", "longName": "996317 - Disclosure - Related Party Transactions - Summary of Related Party Payables (Details)", "shortName": "Related Party Transactions - Summary of Related Party Payables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "C_45fb117d-201a-41df-baa0-2606bf4dcef0", "name": "ifrs-full:AmountsPayableRelatedPartyTransactions", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "div", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_12080213-7879-45b4-a7bb-ced94a7f3316", "name": "ifrs-full:AmountsPayableRelatedPartyTransactions", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "div", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "unique": true } }, "R81": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "longName": "996327 - Disclosure - Related party transactions - Additional Information (Details)", "shortName": "Related party transactions - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "C_45fb117d-201a-41df-baa0-2606bf4dcef0", "name": "vrax:AccruedBonus", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "vrax:DisclosureOfDetailedInformationAboutAccountsPayableAndAccruedLiabilitiesexplanatory", "div", "vrax:DisclosureOfAccountsPayableAndAccruedLiabilitiesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_72448726-92ff-4db1-b56c-c3336e3b37ff", "name": "vrax:AccruedBonus", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "unique": true } }, "R82": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartyCompensationForOfficersAndDirectorsDetails", "longName": "996337 - Disclosure - Related Party Transactions - Summary of Related Party Compensation for Officers and Directors (Details)", "shortName": "Related Party Transactions - Summary of Related Party Compensation for Officers and Directors (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "C_88440d81-6181-4f82-8a73-04a273f6fd7a", "name": "vrax:KeyManagementPersonnelSalary", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "vrax:RelatedPartyCompensationForOfficersAndDirectorsTextBlock", "div", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_88440d81-6181-4f82-8a73-04a273f6fd7a", "name": "vrax:KeyManagementPersonnelSalary", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "vrax:RelatedPartyCompensationForOfficersAndDirectorsTextBlock", "div", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R83": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails", "longName": "996347 - Disclosure - Risk Management Overview - Additional Information (Details)", "shortName": "Risk Management Overview - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "C_9be08593-8d60-4aaa-99ce-9632bea161ed", "name": "ifrs-full:MaximumExposureToCreditRisk", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9be08593-8d60-4aaa-99ce-9632bea161ed", "name": "ifrs-full:MaximumExposureToCreditRisk", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R84": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRiskManagementOverviewDisclosureOfMonetaryAssetsAndLiabilitiesDenominatedInForeignCurrenciesDetails", "longName": "996357 - Disclosure - Risk Management Overview - Disclosure of Monetary Assets and Liabilities Denominated In Foreign Currencies (Details)", "shortName": "Risk Management Overview - Disclosure of Monetary Assets and Liabilities Denominated In Foreign Currencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "C_9be08593-8d60-4aaa-99ce-9632bea161ed", "name": "ifrs-full:Cash", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_bc5c6b1b-e9f2-4ac7-869b-e929fe095857", "name": "ifrs-full:Cash", "unitRef": "U_CNY", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "vrax:DisclosureOfMonetaryAssetsAndLiabilitiesDenominatedInForeignCurrenciesExplanatory", "div", "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "unique": true } }, "R85": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "longName": "996367 - Disclosure - Stockholder's Equity - Additional Information (Details)", "shortName": "Stockholder's Equity - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "C_9be08593-8d60-4aaa-99ce-9632bea161ed", "name": "ifrs-full:NumberOfSharesAuthorised", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "ifrs-full:NumberOfSharesAuthorised", "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_b382e8aa-1256-455e-bf2e-0434417e49f8", "name": "ifrs-full:InterestExpenseOnDebtInstrumentsIssued", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "unique": true } }, "R86": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityRelatedToOutstandingWarrantsDetails", "longName": "996377 - Disclosure - Stockholder's Equity - Summary of Activity Related to Outstanding Warrants (Details)", "shortName": "Stockholder's Equity - Summary of Activity Related to Outstanding Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "C_5eca18d5-ef73-4380-bae1-721f73a95a3a", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "vrax:DisclosureOfActivityRelatedToOutstandingWarrantsExplanatory", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_2a68a882-a268-4f8d-bca4-386149342c0b", "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "vrax:DisclosureOfActivityRelatedToOutstandingWarrantsExplanatory", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "unique": true } }, "R87": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfCalculationOfFairValueOfAwardsUsingBlackscholesOptionpricingModelAffectedByStockPriceOnDateOfGrant", "longName": "996387 - Disclosure - Stockholder's Equity - Summary of Calculation of Fair Value of Awards using Black-Scholes Option-Pricing Model Affected by Stock price on Date of Grant as well as Assumptions (Details)", "shortName": "Stockholder's Equity - Summary of Calculation of Fair Value of Awards using Black-Scholes Option-Pricing Model Affected by Stock price on Date of Grant as well as Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DescriptionOfOptionLifeShareOptionsGranted", "unitRef": "U_Y", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "vrax:SummaryOfCalculationOfFairValueOfAwardsUsingBlackScholesOptionPricingModelAffectedByStockPriceOnDateOfGrantAsWellAsAssumptionsExplanatory", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9adf1967-0619-47f3-a4d5-dec5eb8ac9b3", "name": "ifrs-full:DescriptionOfOptionLifeShareOptionsGranted", "unitRef": "U_Y", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "vrax:SummaryOfCalculationOfFairValueOfAwardsUsingBlackScholesOptionPricingModelAffectedByStockPriceOnDateOfGrantAsWellAsAssumptionsExplanatory", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true, "unique": true } }, "R88": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStatusOfOutstandingStockOptionsAndChangesDetails", "longName": "996397 - Disclosure - Stockholder's Equity - Summary of Status of Outstanding Stock Options and Changes (Details)", "shortName": "Stockholder's Equity - Summary of Status of Outstanding Stock Options and Changes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "C_e143ec0d-3e55-4c57-8850-88ff51b49aae", "name": "ifrs-full:NumberOfOutstandingShareOptions", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "vrax:SummaryOfCalculationOfFairValueOfAwardsUsingBlackScholesOptionPricingModelAffectedByStockPriceOnDateOfGrantAsWellAsAssumptionsExplanatory", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_04657e14-1964-414a-913a-4abe07d4f4f0", "name": "ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "unique": true } }, "R89": { "role": "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "longName": "996407 - Disclosure - Subsequent Events - Additional Information (Details)", "shortName": "Subsequent Events - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "C_9be08593-8d60-4aaa-99ce-9632bea161ed", "name": "ifrs-full:NumberOfSharesIssued", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_6beb28f9-e5e0-47c8-8727-421eecd690cb", "name": "ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrax-20240331.htm", "unique": true } } }, "tag": { "vrax_AccountingJudgementsAndEstimatesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "AccountingJudgementsAndEstimatesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Judgements And Estimates [Abstract]", "documentation": "Accounting judgements and estimates." } } }, "auth_ref": [] }, "vrax_AccountsReceivableAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "AccountsReceivableAbstract", "lang": { "en-us": { "role": { "label": "Accounts receivable [abstract]", "documentation": "Accounts receivable." } } }, "auth_ref": [] }, "vrax_AccruedBonus": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "AccruedBonus", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Accrued bonus.", "label": "Accrued Bonus", "terseLabel": "Accrued bonuses" } } }, "auth_ref": [] }, "vrax_AccruedInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "AccruedInterestExpense", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureNotePayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest", "label": "Accrued Interest Expense", "documentation": "Accrued interest expense." } } }, "auth_ref": [] }, "vrax_AccruedPayrollTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "AccruedPayrollTax", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Accrued payroll tax.", "label": "Accrued Payroll Tax", "terseLabel": "Accrued payroll taxes" } } }, "auth_ref": [] }, "ifrs-full_AccumulatedDepreciationAndAmortisationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AccumulatedDepreciationAndAmortisationMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesSummaryOfRightOfUseAssetsActivityDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosurePropertyPlantEquipmentNetSummaryOfPropertyPlantEquipmentNetDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accumulated Amortization", "terseLabel": "Accumulated Depreciation", "label": "Accumulated depreciation and amortisation [member]" } }, "en": { "role": { "documentation": "This member stands for accumulated depreciation and amortisation. [Refer: Depreciation and amortisation expense]" } } }, "auth_ref": [ "r59", "r338", "r342", "r345", "r346" ] }, "ifrs-full_AccumulatedOtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AccumulatedOtherComprehensiveIncome", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "verboseLabel": "Accumulated other comprehensive income (loss )", "label": "Accumulated other comprehensive income", "totalLabel": "Total accumulated other comprehensive income" } }, "en": { "role": { "documentation": "The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]" } } }, "auth_ref": [ "r332" ] }, "ifrs-full_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss)" } }, "en": { "role": { "documentation": "This member stands for accumulated other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r329" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r285" ] }, "vrax_AdditionalFundsRaisedToAlleviateDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "AdditionalFundsRaisedToAlleviateDeficit", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional funds raised to alleviate deficit", "label": "Additional Funds Raised to Alleviate Deficit", "documentation": "Additional funds raised to alleviate deficit." } } }, "auth_ref": [] }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIntangibleSoftwareNetSummaryOfIntangibleSoftwareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions", "label": "Additions other than through business combinations, intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]" } } }, "auth_ref": [ "r93" ] }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosurePropertyPlantEquipmentNetSummaryOfPropertyPlantEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions", "label": "Additions other than through business combinations, property, plant and equipment" } }, "en": { "role": { "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]" } } }, "auth_ref": [ "r52" ] }, "vrax_AdditionsToLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "AdditionsToLeaseLiabilities", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesSummaryOfLeaseLiabilityActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions", "label": "Additions to lease liabilities", "documentation": "Additions to lease liabilities." } } }, "auth_ref": [] }, "ifrs-full_AdditionsToRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdditionsToRightofuseAssets", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesSummaryOfRightOfUseAssetsActivityDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Addition of Right-of-use assets", "terseLabel": "Additions", "label": "Additions to right-of-use assets" } }, "en": { "role": { "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]" } } }, "auth_ref": [ "r149" ] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AddressTypeDomain", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r291" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r291" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r291" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r291" ] }, "ifrs-full_AdjustedWeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustedWeightedAverageShares", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLossPerShareScheduleOfDilutedLossPerShareDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average number of ordinary shares and potential ordinary shares used as the denominator in calculating diluted loss per share", "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share", "terseLabel": "Diluted ordinary shares" } }, "en": { "role": { "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r86" ] }, "vrax_AdjustmentsForAccretionExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "AdjustmentsForAccretionExpense", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accretion expense", "label": "Adjustments for accretion expense", "documentation": "Adjustments for accretion expense." } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInInventories", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Adjustments for decrease (increase) in inventories" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]" } } }, "auth_ref": [ "r348" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInPrepaidExpenses", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for decrease (increase) in prepaid expenses", "terseLabel": "Prepaid expenses and deposits" } }, "en": { "role": { "documentation": "Adjustments for the decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Current prepaid expenses; Profit (loss)]" } } }, "auth_ref": [ "r350" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInTradeAccountReceivable", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable", "label": "Adjustments for decrease (increase) in trade accounts receivable" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r348" ] }, "vrax_AdjustmentsForDecreaseIncreaseInVatReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "AdjustmentsForDecreaseIncreaseInVatReceivable", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "VAT receivable", "label": "Adjustments for Decrease Increase In VAT Receivable", "documentation": "Adjustments for decrease increase in VAT receivable." } } }, "auth_ref": [] }, "vrax_AdjustmentsForGainOnDebtExtinguishment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "AdjustmentsForGainOnDebtExtinguishment", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Gain on debt extinguishment", "label": "Adjustments for gain on debt extinguishment", "documentation": "Adjustments for gain on debt extinguishment." } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeOtherThanContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInDeferredIncomeOtherThanContractLiabilities", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for increase (decrease) in deferred income other than contract liabilities", "terseLabel": "Deferred revenue" } }, "en": { "role": { "documentation": "Adjustments for the increase (decrease) in deferred income other than contract liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred income other than contract liabilities; Profit (loss)]" } } }, "auth_ref": [ "r348" ] }, "vrax_AdjustmentsForIncreaseDecreaseInOperatingAssetsAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "AdjustmentsForIncreaseDecreaseInOperatingAssetsAndLiabilitiesAbstract", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Net changes in operating assets & liabilities:", "label": "Adjustments for increase decrease in operating assets and liabilities [abstract]", "documentation": "Adjustments for increase decrease in operating assets and liabilities." } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued liabilities", "label": "Adjustments for increase (decrease) in trade accounts payable" } }, "en": { "role": { "documentation": "Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r348" ] }, "vrax_AdjustmentsForOtherExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "AdjustmentsForOtherExpense", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Other expense", "label": "Adjustments for Other Expense", "documentation": "Adjustments for other expense." } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForReconcileProfitLossAbstract", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:", "label": "Adjustments to reconcile profit (loss) [abstract]" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForSharebasedPayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForSharebasedPayments", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Adjustments for share-based payments" } }, "en": { "role": { "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r349" ] }, "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation (gain) loss", "label": "Adjustments for unrealised foreign exchange losses (gains)" } }, "en": { "role": { "documentation": "Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r227", "r349" ] }, "ifrs-full_AggregatedTimeBandsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AggregatedTimeBandsMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureCommitmentsScheduleOfCommitmentsForMinimumLeasePaymentsDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesScheduleOfAnnualRentDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Aggregated time bands [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used." } } }, "auth_ref": [ "r19", "r142", "r152", "r153", "r156", "r157", "r158", "r164", "r183", "r221", "r239", "r241" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r255", "r267", "r277", "r303" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r258", "r270", "r280", "r306" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r291" ] }, "currency_AllCurrenciesDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "AllCurrenciesDomain", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRiskManagementOverviewDisclosureOfMonetaryAssetsAndLiabilitiesDenominatedInForeignCurrenciesDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDisclosureOfEffectOfChangesInForeignExchangeRatesDetails" ], "lang": { "en-us": { "role": { "label": "All Currencies [Domain]" } } }, "auth_ref": [] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r298" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r262", "r271", "r281", "r298", "r307", "r311", "r319" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r317" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "ifrs-full_AmortisationMethodIntangibleAssetsOtherThanGoodwill": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AmortisationMethodIntangibleAssetsOtherThanGoodwill", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIntangibleSoftwareNetAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Useful life for amortization", "label": "Amortisation method, intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The amortisation method used for intangible assets other than goodwill with finite useful lives. [Refer: Intangible assets other than goodwill; Depreciation and amortisation expense]" } } }, "auth_ref": [ "r91" ] }, "vrax_AmortizationOfRightToUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "AmortizationOfRightToUseAssets", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of right-to-use assets", "label": "Amortization of Right-to-Use Assets", "documentation": "Amortization of right-to-use assets." } } }, "auth_ref": [] }, "vrax_AmortizationToRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "AmortizationToRightOfUseAssets", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesSummaryOfRightOfUseAssetsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Amortization To Right of use Assets", "documentation": "Amortization To Right of use Assets" } } }, "auth_ref": [] }, "ifrs-full_AmountIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AmountIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntity", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureKeyManagementCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consulting fees", "label": "Amount incurred by entity for provision of key management personnel services provided by separate management entity" } }, "en": { "role": { "documentation": "The amount incurred by the entity for provision of key management personnel services that are provided by a separate management entity. [Refer: Key management personnel of entity or parent [member]; Separate management entities [member]]" } } }, "auth_ref": [ "r74" ] }, "ifrs-full_AmountsPayableRelatedPartyTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AmountsPayableRelatedPartyTransactions", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureKeyManagementCompensationAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartyPayablesDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Total Related Party Payables", "terseLabel": "Related party transaction payable", "label": "Amounts payable, related party transactions" } }, "en": { "role": { "documentation": "The amounts payable resulting from related party transactions. [Refer: Related parties [member]]" } } }, "auth_ref": [ "r72", "r76" ] }, "vrax_AnneFosterMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "AnneFosterMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartyPayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Anne Foster", "label": "Anne Foster [Member]", "documentation": "Anne Foster." } } }, "auth_ref": [] }, "vrax_AnnualRentOnLeases": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "AnnualRentOnLeases", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesScheduleOfAnnualRentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual rent", "label": "Annual rent on leases", "documentation": "Annual rent on leases." } } }, "auth_ref": [] }, "ifrs-full_ApplicableTaxRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ApplicableTaxRate", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax rate", "label": "Applicable tax rate" } }, "en": { "role": { "documentation": "The applicable income tax rate." } } }, "auth_ref": [ "r45" ] }, "ifrs-full_Assets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Assets", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Assets", "periodStartLabel": "Assets at beginning of period", "periodEndLabel": "Assets at end of period", "totalLabel": "Total assets" } }, "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r16", "r133", "r134", "r135", "r198", "r201" ] }, "ifrs-full_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AssetsAbstract", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [abstract]" } } }, "auth_ref": [] }, "vrax_AtTheMarketOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "AtTheMarketOfferingMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "At-the-Market Offering", "label": "At-the-Market Offering [Member]", "documentation": "At-the-Market offering." } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r249", "r250", "r263" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r249", "r250", "r263" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r249", "r250", "r263" ] }, "vrax_AuthorizedShareCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "AuthorizedShareCapital", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Authorized share capital", "label": "Authorized share capital", "documentation": "Authorized share capital." } } }, "auth_ref": [] }, "ifrs-full_AverageForeignExchangeRate": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AverageForeignExchangeRate", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDisclosureOfEffectOfChangesInForeignExchangeRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average rate", "label": "Average foreign exchange rate" } }, "en": { "role": { "documentation": "The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies." } } }, "auth_ref": [ "r330" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r314" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r315" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r310" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r310" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r310" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r310" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r310" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r310" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "auth_ref": [] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r313" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r312" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r311" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r311" ] }, "ifrs-full_BalancesWithBanks": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BalancesWithBanks", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash at bank", "label": "Balances with banks" } }, "en": { "role": { "documentation": "The amount of cash balances held at banks." } } }, "auth_ref": [ "r352" ] }, "ifrs-full_BasicEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BasicEarningsLossPerShare", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLossPerShareScheduleOfLossPerShareDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "verboseLabel": "Basic loss per share attributable to Virax - ordinary shares", "terseLabel": "Basic net loss per share - Ordinary shares", "label": "Basic earnings (loss) per share", "totalLabel": "Total basic earnings (loss) per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } } }, "auth_ref": [ "r84", "r85" ] }, "ifrs-full_Borrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Borrowings", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureNotePayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Borrowings", "totalLabel": "Total borrowings", "terseLabel": "Borrowings" } }, "en": { "role": { "documentation": "The amount of outstanding funds that the entity is obligated to repay." } } }, "auth_ref": [ "r332" ] }, "ifrs-full_BorrowingsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BorrowingsAbstract", "lang": { "en-us": { "role": { "label": "Borrowings [abstract]" } } }, "auth_ref": [] }, "ifrs-full_BorrowingsInterestRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BorrowingsInterestRate", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureNotePayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Borrowings, interest rate", "terseLabel": "Fixed interest rate" } }, "en": { "role": { "documentation": "The interest rate on borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r354" ] }, "ifrs-full_BottomOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BottomOfRangeMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfCalculationOfFairValueOfAwardsUsingBlackscholesOptionpricingModelAffectedByStockPriceOnDateOfGrant" ], "lang": { "en-us": { "role": { "label": "Bottom of range [member]", "terseLabel": "Bottom of Range" } }, "en": { "role": { "documentation": "This member stands for the bottom of a range." } } }, "auth_ref": [ "r137", "r158", "r174", "r229", "r230", "r354" ] }, "vrax_BousteadSecuritiesLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "BousteadSecuritiesLlcMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Boustead Securities, LLC", "label": "Boustead Securities, LLC [Member]", "documentation": "Boustead securities, llc." } } }, "auth_ref": [] }, "vrax_BreakDateOfLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "BreakDateOfLeaseTerm", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Break date of lease term", "label": "Break date of lease term", "documentation": "Break date of lease term." } } }, "auth_ref": [] }, "dei_BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "BusinessContactMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Business Contact", "label": "Business Contact [Member]", "documentation": "Business contact for the entity" } } }, "auth_ref": [ "r250", "r263" ] }, "country_CN": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "CN", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "China", "label": "CHINA" } } }, "auth_ref": [] }, "currency_CNY": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "CNY", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRiskManagementOverviewDisclosureOfMonetaryAssetsAndLiabilitiesDenominatedInForeignCurrenciesDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDisclosureOfEffectOfChangesInForeignExchangeRatesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Renminbi", "terseLabel": "RMB", "label": "China, Yuan Renminbi" } } }, "auth_ref": [] }, "vrax_CameronLeeShawMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "CameronLeeShawMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartyPayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cameron Lee Shaw", "label": "Cameron Lee Shaw [Member]", "documentation": "Cameron Lee Shaw." } } }, "auth_ref": [] }, "vrax_CameronShawFormerChiefOperatingOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "CameronShawFormerChiefOperatingOfficerMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartyCompensationForOfficersAndDirectorsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cameron Shaw, Former Chief Operating Officer", "label": "Cameron Shaw, Former Chief Operating Officer [Member]", "documentation": "Cameron Shaw, Former Chief Operating Officer member." } } }, "auth_ref": [] }, "vrax_CameronShawMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "CameronShawMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cameron Shaw", "label": "Cameron Shaw [Member]", "documentation": "Cameron Shaw." } } }, "auth_ref": [] }, "ifrs-full_CapitalReserve": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CapitalReserve", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "verboseLabel": "Reserves", "label": "Capital reserve" } }, "en": { "role": { "documentation": "A component of equity representing the capital reserves." } } }, "auth_ref": [ "r332" ] }, "ifrs-full_CapitalReserveMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CapitalReserveMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Reserves" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing capital reserves." } } }, "auth_ref": [ "r329" ] }, "vrax_CapitalizedSoftwareDevelopmentCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "CapitalizedSoftwareDevelopmentCosts", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIntangibleSoftwareNetAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Capitalized software development costs", "documentation": "Capitalized software development costs." } } }, "auth_ref": [] }, "vrax_CapitalizedSoftwareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "CapitalizedSoftwareMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosurePropertyPlantEquipmentNetSummaryOfPropertyPlantEquipmentNetDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capitalized Software", "label": "Capitalized Software [Member]", "documentation": "Capitalized software member." } } }, "auth_ref": [] }, "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesSummaryOfRightOfUseAssetsActivityDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosurePropertyPlantEquipmentNetSummaryOfPropertyPlantEquipmentNetDetails" ], "lang": { "en-us": { "role": { "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r51", "r56", "r92", "r95", "r100", "r101", "r102", "r103", "r104", "r179", "r187", "r188" ] }, "ifrs-full_CarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CarryingAmountMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesSummaryOfRightOfUseAssetsActivityDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosurePropertyPlantEquipmentNetSummaryOfPropertyPlantEquipmentNetDetails" ], "lang": { "en-us": { "role": { "label": "Carrying amount [member]" } }, "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]" } } }, "auth_ref": [ "r56", "r95", "r100", "r102", "r103", "r179", "r187", "r188" ] }, "ifrs-full_Cash": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Cash", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRiskManagementOverviewDisclosureOfMonetaryAssetsAndLiabilitiesDenominatedInForeignCurrenciesDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Cash", "label": "Cash", "totalLabel": "Total cash" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]" } } }, "auth_ref": [ "r352" ] }, "ifrs-full_CashAdvancesAndLoansFromRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashAdvancesAndLoansFromRelatedParties", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from (payments to) related parties", "label": "Cash advances and loans from related parties" } }, "en": { "role": { "documentation": "The cash inflow from advances and loans from related parties. [Refer: Related parties [member]]" } } }, "auth_ref": [ "r347" ] }, "ifrs-full_CashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashAndCashEquivalents", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "totalLabel": "Total cash and cash equivalents", "periodStartLabel": "Cash at beginning of year", "periodEndLabel": "Cash at end of year" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } } }, "auth_ref": [ "r12", "r109", "r129" ] }, "ifrs-full_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashAndCashEquivalentsAbstract", "lang": { "en-us": { "role": { "label": "Cash and cash equivalents [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashEquivalents", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Cash equivalents", "totalLabel": "Total cash equivalents" } }, "en": { "role": { "documentation": "The amount of short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value." } } }, "auth_ref": [ "r352" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivities", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Cash flows from (used in) financing activities", "netLabel": "Net cash flows from (used in) financing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity." } } }, "auth_ref": [ "r105", "r111" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Cash flows from (used in) financing activities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivities", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "netLabel": "Net cash flows from (used in) investing activities", "label": "Cash flows from (used in) investing activities", "totalLabel": "Net cash used in investing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents." } } }, "auth_ref": [ "r105", "r111" ] }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) investing activities [abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivities", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows used in operating activities", "totalLabel": "Net cash used in operating activities", "label": "Cash flows from (used in) operating activities", "netLabel": "Net cash flows from (used in) operating activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]" } } }, "auth_ref": [ "r105", "r111" ] }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities:", "label": "Cash flows from (used in) operating activities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CashOutflowForLeases": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashOutflowForLeases", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesSummaryOfLeaseLiabilityActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Payment of lease liabilities", "terseLabel": "Lease expense", "label": "Cash outflow for leases" } }, "en": { "role": { "documentation": "The cash outflow for leases." } } }, "auth_ref": [ "r148" ] }, "vrax_CashlessWarrantsExercisedInExchangeForShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "CashlessWarrantsExercisedInExchangeForShares", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Cashless warrants exercised in exchange for shares.", "label": "Cashless warrants exercised in exchange for shares", "terseLabel": "Cashless warrants exercised in exchange for shares" } } }, "auth_ref": [] }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CategoriesOfRelatedPartiesAxis", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureKeyManagementCompensationAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartyCompensationForOfficersAndDirectorsDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartyPayablesDetails" ], "lang": { "en-us": { "role": { "label": "Categories of related parties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r75" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r289" ] }, "ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ChangesInDeferredTaxLiabilityAssetAbstract", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxSummaryOfNetDeferredTaxAssetLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Tax Assets (liabilities)", "label": "Changes in deferred tax liability (asset) [abstract]" } } }, "auth_ref": [] }, "srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ChiefExecutiveOfficerMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureKeyManagementCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Chief Executive Officer", "label": "Chief Executive Officer [Member]" } } }, "auth_ref": [] }, "srt_ChiefOperatingOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ChiefOperatingOfficerMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureKeyManagementCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Chief Operating Officer", "label": "Chief Operating Officer [Member]" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "vrax_ClassAOrdinarySharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "ClassAOrdinarySharesMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class A Ordinary Shares", "label": "Class A Ordinary Shares [Member]", "documentation": "Class a ordinary shares." } } }, "auth_ref": [] }, "vrax_ClassASharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "ClassASharesMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Class A Shares", "label": "Class A", "documentation": "Class A" } } }, "auth_ref": [] }, "vrax_ClassBOrdinarySharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "ClassBOrdinarySharesMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class B Ordinary Shares", "label": "Class B Ordinary Shares [Member]", "documentation": "Class b ordinary shares." } } }, "auth_ref": [] }, "vrax_ClassBSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "ClassBSharesMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Class B Shares", "label": "Class B", "documentation": "Class B shares." } } }, "auth_ref": [] }, "ifrs-full_ClassesOfAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfAssetsAxis", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Classes of assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r88", "r89", "r136", "r151" ] }, "ifrs-full_ClassesOfAssetsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfAssetsMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Assets [member]" } }, "en": { "role": { "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used." } } }, "auth_ref": [ "r88", "r136", "r151" ] }, "ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfEntitysOwnEquityInstrumentsAxis", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Classes of entity's own equity instruments [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r136" ] }, "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIntangibleSoftwareNetSummaryOfIntangibleSoftwareDetails" ], "lang": { "en-us": { "role": { "label": "Classes of intangible assets other than goodwill [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r96" ] }, "ifrs-full_ClassesOfInventoriesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfInventoriesAbstract", "lang": { "en-us": { "role": { "label": "Classes of current inventories [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfOrdinarySharesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfOrdinarySharesAxis", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLossPerShareScheduleOfLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Classes of ordinary shares [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r84" ] }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfPropertyPlantAndEquipmentAxis", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosurePropertyPlantEquipmentNetSummaryOfPropertyPlantEquipmentNetDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Classes of property, plant and equipment [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r57" ] }, "ifrs-full_ClassesOfShareCapitalAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfShareCapitalAxis", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStatusOfOutstandingStockOptionsAndChangesDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Classes of share capital [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r28" ] }, "ifrs-full_ClassesOfShareCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfShareCapitalMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStatusOfOutstandingStockOptionsAndChangesDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Share capital [member]" } }, "en": { "role": { "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used." } } }, "auth_ref": [ "r28" ] }, "ifrs-full_ClosingForeignExchangeRate": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClosingForeignExchangeRate", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDisclosureOfEffectOfChangesInForeignExchangeRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Closing rate", "label": "Closing foreign exchange rate" } }, "en": { "role": { "documentation": "The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery." } } }, "auth_ref": [ "r330" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r290" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r290" ] }, "vrax_CombinedPurchasePricePerOrdinaryShareAndOneAndAHalfOrdinaryWarrant": { "xbrltype": "perShareItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "CombinedPurchasePricePerOrdinaryShareAndOneAndAHalfOrdinaryWarrant", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Combined purchase price per ordinary share and one and a half ordinary warrant.", "label": "Combined purchase price per ordinary share and one and a half ordinary warrant", "terseLabel": "Combined purchase price per ordinary share and one and a half ordinary warrant" } } }, "auth_ref": [] }, "vrax_CombinedPurchasePricePerPreFundedWarrantAndOneAndAHalfOrdinaryWarrant": { "xbrltype": "perShareItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "CombinedPurchasePricePerPreFundedWarrantAndOneAndAHalfOrdinaryWarrant", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Combined purchase price per pre-funded warrant and one and a half ordinary warrant.", "label": "Combined purchase price per pre-funded warrant and one and a half ordinary warrant", "terseLabel": "Combined purchase price per pre-funded warrant and one and a half ordinary warrant" } } }, "auth_ref": [] }, "vrax_CommitmentAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "CommitmentAndContingencies", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Commitment and contingencies (Note 15)", "documentation": "Commitment and contingencies." } } }, "auth_ref": [] }, "vrax_CommitmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "CommitmentsAbstract", "lang": { "en-us": { "role": { "label": "Commitments [Abstract]", "documentation": "Commitments." } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r295" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r294" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r296" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r293" ] }, "ifrs-full_ComponentsOfEquityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComponentsOfEquityAxis", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityRelatedToOutstandingWarrantsDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Components of equity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r5" ] }, "ifrs-full_ComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComprehensiveIncome", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss", "label": "Comprehensive income" } }, "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } } }, "auth_ref": [ "r2", "r31", "r113", "r115", "r126", "r228" ] }, "ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComprehensiveIncomeAttributableToNoncontrollingInterests", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "verboseLabel": "Comprehensive loss attributable to non-controlling interest", "label": "Comprehensive income, attributable to non-controlling interests", "totalLabel": "Total comprehensive income, attributable to non-controlling interests" } }, "en": { "role": { "documentation": "The amount of comprehensive income attributable to non-controlling interests. [Refer: Comprehensive income; Non-controlling interests]" } } }, "auth_ref": [ "r2", "r34" ] }, "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComprehensiveIncomeAttributableToOwnersOfParent", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss attributable to Virax", "verboseLabel": "Comprehensive loss attributable to Virax", "label": "Comprehensive income, attributable to owners of parent" } }, "en": { "role": { "documentation": "The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]" } } }, "auth_ref": [ "r2", "r35" ] }, "ifrs-full_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComputerEquipmentMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosurePropertyPlantEquipmentNetSummaryOfPropertyPlantEquipmentNetDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Computer Equipment", "label": "Computer equipment [member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing computer equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r337" ] }, "ifrs-full_ConcentrationsOfRiskAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ConcentrationsOfRiskAxis", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Concentrations of risk [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r161" ] }, "ifrs-full_ConcentrationsOfRiskMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ConcentrationsOfRiskMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Concentrations of risk [member]" } }, "en": { "role": { "documentation": "This member stands for the concentrations of risk. It also represents the standard value for the 'Concentrations of risk' axis if no other member is used." } } }, "auth_ref": [ "r161" ] }, "ifrs-full_ConsiderationPaidReceived": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ConsiderationPaidReceived", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consideration paid (received)", "label": "Consideration paid (received)" } }, "en": { "role": { "documentation": "The amount of consideration paid or received in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Subsidiaries [member]]" } } }, "auth_ref": [ "r108" ] }, "vrax_ConsultingRevenuesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "ConsultingRevenuesMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Consulting Revenues", "documentation": "Consulting revenues." } } }, "auth_ref": [] }, "dei_ContactPersonnelEmailAddress": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ContactPersonnelEmailAddress", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Contact Personnel Email Address", "documentation": "Email address of contact personnel." } } }, "auth_ref": [] }, "dei_ContactPersonnelName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ContactPersonnelName", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Contact Personnel Name", "documentation": "Name of contact personnel" } } }, "auth_ref": [] }, "ifrs-full_ContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ContractLiabilities", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureDeferredRevenueSummaryOfDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Contract liabilities at beginning of period", "periodEndLabel": "Contract liabilities at end of period", "label": "Contract liabilities", "totalLabel": "Total Deferred Revenue", "terseLabel": "Total Deferred Revenue", "verboseLabel": "Deferred revenue" } }, "en": { "role": { "documentation": "The amount of an entity\u2019s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer." } } }, "auth_ref": [ "r138", "r141" ] }, "ifrs-full_ContractLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ContractLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Contract liabilities [abstract]" } } }, "auth_ref": [] }, "vrax_ContractualMaturitiesOfTradePayables": { "xbrltype": "durationItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "ContractualMaturitiesOfTradePayables", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contractual maturities of trade payables", "label": "Contractual maturities of trade payables", "documentation": "Contractual maturities of trade payables." } } }, "auth_ref": [] }, "vrax_ContributionToReservesForSettlementOfRelatedPartyPayables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "ContributionToReservesForSettlementOfRelatedPartyPayables", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Contributed capital - settlement of related party debt", "documentation": "Contribution to reserves for settlement of related party payables.", "label": "Contribution to Reserves for Settlement of Related Party Payables", "verboseLabel": "Remaining contribution to reserves" } } }, "auth_ref": [] }, "vrax_ConversionOfClassBOrdinarySharesInToClassAOrdinaryShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "ConversionOfClassBOrdinarySharesInToClassAOrdinaryShares", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion of class B ordinary shares into class A ordinary shares", "label": "Conversion of Class B Ordinary Shares In to Class A Ordinary Shares", "documentation": "Conversion of class B ordinary shares in to class A ordinary shares." } } }, "auth_ref": [] }, "vrax_ConversionOfConvertibleDebt": { "xbrltype": "sharesItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "ConversionOfConvertibleDebt", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion of convertible debt", "label": "Conversion of convertible debt", "documentation": "Conversion of convertible debt." } } }, "auth_ref": [] }, "ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CostOfInventoriesRecognisedAsExpenseDuringPeriod", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureInventoriesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories expensed to cost of revenue", "label": "Cost of inventories recognised as expense during period" } }, "en": { "role": { "documentation": "The amount of inventories recognised as an expense during the period. [Refer: Inventories]" } } }, "auth_ref": [ "r63" ] }, "ifrs-full_CostOfSales": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CostOfSales", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of revenue", "label": "Cost of sales", "negatedLabel": "Cost of sales" } }, "en": { "role": { "documentation": "The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories." } } }, "auth_ref": [ "r0", "r40" ] }, "ifrs-full_CounterpartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CounterpartiesAxis", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureContingentLiabilitiesAndContingentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Counterparties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r193" ] }, "ifrs-full_CounterpartiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CounterpartiesMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureContingentLiabilitiesAndContingentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Counterparties [member]" } }, "en": { "role": { "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used." } } }, "auth_ref": [ "r193" ] }, "ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CountryOfIncorporationOrResidenceOfSubsidiary", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfConsolidatedSubsidiariesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Jurisdiction", "label": "Country of incorporation of subsidiary" } }, "en": { "role": { "documentation": "The country in which a subsidiary of the entity is incorporated. [Refer: Subsidiaries [member]]" } } }, "auth_ref": [ "r79", "r81", "r118", "r122" ] }, "vrax_CourtArbitrationAwardAgainstSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "CourtArbitrationAwardAgainstSuppliers", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureContingentLiabilitiesAndContingentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Court arbitration award against supplier", "label": "Court Arbitration Award Against Suppliers", "documentation": "Court arbitration award against suppliers." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "ifrs-full_CreditRiskMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CreditRiskMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Risk", "label": "Credit risk [member]" } }, "en": { "role": { "documentation": "This member stands for the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. [Refer: Financial instruments, class [member]]" } } }, "auth_ref": [ "r159", "r160", "r161", "r236" ] }, "srt_CurrencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CurrencyAxis", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRiskManagementOverviewDisclosureOfMonetaryAssetsAndLiabilitiesDenominatedInForeignCurrenciesDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDisclosureOfEffectOfChangesInForeignExchangeRatesDetails" ], "lang": { "en-us": { "role": { "label": "Currency [Axis]" } } }, "auth_ref": [] }, "ifrs-full_CurrencyRiskMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrencyRiskMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRiskManagementOverviewDisclosureOfMonetaryAssetsAndLiabilitiesDenominatedInForeignCurrenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Exchange Risk", "label": "Currency risk [member]" } }, "en": { "role": { "documentation": "This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. [Refer: Financial instruments, class [member]]" } } }, "auth_ref": [ "r159", "r160", "r161", "r162", "r194" ] }, "vrax_CurrentAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "CurrentAccountsPayableAndAccruedLiabilities", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRiskManagementOverviewDisclosureOfMonetaryAssetsAndLiabilitiesDenominatedInForeignCurrenciesDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "AP and Accrued Liabilities", "totalLabel": "Current accounts payable and accrued liabilities", "verboseLabel": "Accounts payable and accrued liabilities", "label": "Current accounts payable and accrued liabilities", "documentation": "Current accounts payable and accrued liabilities." } } }, "auth_ref": [] }, "vrax_CurrentAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "CurrentAccruedLiabilities", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued liabilities", "label": "Current Accrued Liabilities", "documentation": "Current accrued liabilities." } } }, "auth_ref": [] }, "ifrs-full_CurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentAssets", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current assets", "totalLabel": "Total current assets" } }, "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } } }, "auth_ref": [ "r20", "r123", "r228" ] }, "ifrs-full_CurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentAssetsAbstract", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "auth_ref": [] }, "ifrs-full_CurrentDebtInstrumentsIssued": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentDebtInstrumentsIssued", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current debt instruments issued", "terseLabel": "Note payable" } }, "en": { "role": { "documentation": "The amount of current debt instruments issued. [Refer: Debt instruments issued]" } } }, "auth_ref": [ "r332" ] }, "vrax_CurrentDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "CurrentDeposits", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosurePrepaidExpensesAndDepositsSummaryOfPrepaidExpensesAndDepositsDetails" ], "lang": { "en-us": { "role": { "documentation": "Current deposits.", "label": "Current Deposits", "terseLabel": "Deposits" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "ifrs-full_CurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentLeaseLiabilities", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Current operating lease liabilities", "label": "Current lease liabilities" } }, "en": { "role": { "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r146" ] }, "ifrs-full_CurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentLiabilities", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Current liabilities", "negatedLabel": "Current liabilities", "totalLabel": "Total current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } } }, "auth_ref": [ "r21", "r125", "r228" ] }, "ifrs-full_CurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentLiabilitiesAbstract", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "verboseLabel": "Current liabilities:", "label": "Current liabilities [abstract]" } } }, "auth_ref": [] }, "vrax_CurrentOtherPrepaidExpensesAndDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "CurrentOtherPrepaidExpensesAndDeposits", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosurePrepaidExpensesAndDepositsSummaryOfPrepaidExpensesAndDepositsDetails" ], "lang": { "en-us": { "role": { "documentation": "Current other prepaid expenses and deposits.", "label": "Current Other Prepaid Expenses And Deposits", "terseLabel": "Other" } } }, "auth_ref": [] }, "vrax_CurrentPrepaidExpensesAndDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "CurrentPrepaidExpensesAndDeposits", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosurePrepaidExpensesAndDepositsSummaryOfPrepaidExpensesAndDepositsDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "verboseLabel": "Prepaid expenses and deposits", "label": "Current prepaid expenses and deposits", "documentation": "Current prepaid expenses and deposits.", "totalLabel": "Prepaid expenses and deposits" } } }, "auth_ref": [] }, "vrax_CurrentPrepaidSoftwareSubscription": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "CurrentPrepaidSoftwareSubscription", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosurePrepaidExpensesAndDepositsSummaryOfPrepaidExpensesAndDepositsDetails" ], "lang": { "en-us": { "role": { "documentation": "Current prepaid software subscription.", "label": "Current Prepaid Software Subscription", "terseLabel": "Prepaid software subscription" } } }, "auth_ref": [] }, "vrax_CurrentPrepaidVendorProducts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "CurrentPrepaidVendorProducts", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosurePrepaidExpensesAndDepositsSummaryOfPrepaidExpensesAndDepositsDetails" ], "lang": { "en-us": { "role": { "documentation": "Current prepaid vendor products.", "label": "Current Prepaid vendor products", "terseLabel": "Prepaid vendor products" } } }, "auth_ref": [] }, "ifrs-full_CurrentTradeReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentTradeReceivables", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureAccountsReceivableSummaryOfAccountsReceivableDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Current Accounts receivables", "terseLabel": "Accounts receivable", "label": "Current trade receivables" } }, "en": { "role": { "documentation": "The amount of current trade receivables. [Refer: Trade receivables]" } } }, "auth_ref": [ "r212", "r214" ] }, "ifrs-full_CurrentValueAddedTaxReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentValueAddedTaxReceivables", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureVatReceivableAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureVatReceivableSummaryOfVatReceivableDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total VAT receivable", "terseLabel": "VAT receivable", "label": "Current value added tax receivables" } }, "en": { "role": { "documentation": "The amount of current value added tax receivables. [Refer: Value added tax receivables]" } } }, "auth_ref": [ "r333" ] }, "vrax_CustomerConcentrationsRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "CustomerConcentrationsRiskMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk", "label": "Customer Concentrations Risk [Member]", "documentation": "Customer concentrations risk." } } }, "auth_ref": [] }, "ifrs-full_DateOfEndOfReportingPeriodOfFinancialStatementsOfSubsidiary": { "xbrltype": "dateItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DateOfEndOfReportingPeriodOfFinancialStatementsOfSubsidiary", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfConsolidatedSubsidiariesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Incorporation Date", "label": "Date of end of reporting period of financial statements of subsidiary" } }, "en": { "role": { "documentation": "The date of the end of the reporting period of the financial statements of a subsidiary." } } }, "auth_ref": [ "r117" ] }, "ifrs-full_DeferredIncomeIncludingContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DeferredIncomeIncludingContractLiabilities", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Deferred income including contract liabilities", "totalLabel": "Total deferred income including contract liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities representing income that has been received (or the amount is due) but is not yet earned, including contract liabilities. [Refer: Contract liabilities]" } } }, "auth_ref": [ "r332", "r334" ] }, "vrax_DeferredRevenueExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "DeferredRevenueExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureDeferredRevenue1" ], "lang": { "en-us": { "role": { "documentation": "Deferred revenue explanatory.", "label": "Deferred Revenue Explanatory", "terseLabel": "Deferred Revenue" } } }, "auth_ref": [] }, "ifrs-full_DeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DeferredTaxAssets", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxSummaryOfNetDeferredTaxAssetLiabilityDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred Tax Assets (liabilities)", "terseLabel": "Deferred Tax Assets (liabilities)", "label": "Deferred tax assets", "negatedLabel": "Deferred tax assets" } }, "en": { "role": { "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } } }, "auth_ref": [ "r13", "r17", "r47" ] }, "ifrs-full_DeferredTaxLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DeferredTaxLiabilityAsset", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxSummaryOfNetDeferredTaxAssetLiabilityDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net deferred tax asset (liability)", "terseLabel": "Deferred Tax Assets (liabilities)", "label": "Deferred tax liability (asset)", "periodStartLabel": "Deferred tax liability (asset) at beginning of period", "periodEndLabel": "Deferred tax liability (asset) at end of period", "netLabel": "Net deferred tax liability (asset)" } }, "en": { "role": { "documentation": "The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]" } } }, "auth_ref": [ "r47" ] }, "vrax_DepositOnLeases": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "DepositOnLeases", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deposit on leases", "label": "Deposit on leases", "documentation": "Deposit on leases." } } }, "auth_ref": [] }, "ifrs-full_DepreciationAndAmortisationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DepreciationAndAmortisationExpense", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation and amortisation expense", "negatedLabel": "Depreciation and amortisation expense", "totalLabel": "Total depreciation and amortisation expense" } }, "en": { "role": { "documentation": "The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives." } } }, "auth_ref": [ "r1", "r40", "r130", "r196", "r203", "r209" ] }, "ifrs-full_DepreciationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DepreciationExpense", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosurePropertyPlantEquipmentNetAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Depreciation", "terseLabel": "Depreciation expense", "label": "Depreciation expense" } }, "en": { "role": { "documentation": "The amount of depreciation expense. Depreciation is the systematic allocation of depreciable amounts of tangible assets over their useful lives." } } }, "auth_ref": [ "r330" ] }, "vrax_DepreciationOnDeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "DepreciationOnDeferredTaxAssets", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxSummaryOfNetDeferredTaxAssetLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation on deferred tax assets", "documentation": "Depreciation on deferred tax assets." } } }, "auth_ref": [] }, "ifrs-full_DepreciationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DepreciationPropertyPlantAndEquipment", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosurePropertyPlantEquipmentNetSummaryOfPropertyPlantEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "negatedTerseLabel": "Depreciation", "label": "Depreciation, property, plant and equipment", "negatedLabel": "Depreciation, property, plant and equipment" } }, "en": { "role": { "documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]" } } }, "auth_ref": [ "r54", "r58" ] }, "vrax_DescriptionOfAccountingPolicyForAccountsPayablesAndAccruedLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "DescriptionOfAccountingPolicyForAccountsPayablesAndAccruedLiabilitiesExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payables and accrued liabilities", "label": "Description Of Accounting Policy For Accounts Payables And Accrued Liabilities Explanatory", "documentation": "Description of accounting policy for accounts payables and accrued liabilities." } } }, "auth_ref": [] }, "vrax_DescriptionOfAccountingPolicyForAccountsReceivableExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "DescriptionOfAccountingPolicyForAccountsReceivableExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable", "label": "Description Of Accounting Policy For Accounts Receivable Explanatory", "documentation": "Description of accounting policy for accounts receivable." } } }, "auth_ref": [] }, "vrax_DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of preparation", "label": "Description Of Accounting Policy For Basis Of Preparation Explanatory", "documentation": "Description of accounting policy for basis of preparation." } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Employee benefits", "label": "Description of accounting policy for employee benefits [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment." } } }, "auth_ref": [ "r331" ] }, "ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value hierarchy", "label": "Description of accounting policy for fair value measurement [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for fair value measurement. [Refer: At fair value [member]]" } } }, "auth_ref": [ "r331" ] }, "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments", "label": "Description of accounting policy for financial instruments [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for financial instruments. [Refer: Financial instruments, class [member]]" } } }, "auth_ref": [ "r331" ] }, "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation", "label": "Description of accounting policy for foreign currency translation [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for foreign currency translation." } } }, "auth_ref": [ "r331" ] }, "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of assets", "label": "Description of accounting policy for impairment of financial assets [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for the impairment of financial assets. [Refer: Financial assets]" } } }, "auth_ref": [ "r331" ] }, "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax", "label": "Description of accounting policy for income tax [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for income tax." } } }, "auth_ref": [ "r331" ] }, "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Description of accounting policy for leases [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time." } } }, "auth_ref": [ "r331" ] }, "ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForMeasuringInventories", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Description of accounting policy for measuring inventories [text block]" } }, "en": { "role": { "documentation": "The description of the entity's accounting policy for measuring inventories. [Refer: Inventories]" } } }, "auth_ref": [ "r61" ] }, "vrax_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Principles of consolidation", "label": "Description Of Accounting Policy For Principles Of Consolidation Explanatory", "documentation": "Description of accounting policy for principles of consolidation." } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Property plant and equipment", "label": "Description of accounting policy for property, plant and equipment [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r331" ] }, "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognition", "label": "Description of accounting policy for recognition of revenue [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]" } } }, "auth_ref": [ "r331" ] }, "ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForSegmentReportingExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Segment information", "label": "Description of accounting policy for segment reporting [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for segment reporting." } } }, "auth_ref": [ "r331" ] }, "vrax_DescriptionOfAccountingPolicyForShareCapitalAndReservesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "DescriptionOfAccountingPolicyForShareCapitalAndReservesExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Share capital and reserves", "label": "Description Of Accounting Policy For Share Capital And Reserves Explanatory", "documentation": "Description of accounting policy for share capital and reserves." } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForWarrantsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForWarrantsExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for warrants [text block]", "terseLabel": "Warrants" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for warrants. Warrants are financial instruments that give the holder the right to purchase ordinary shares." } } }, "auth_ref": [ "r331" ] }, "ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for determining components of cash and cash equivalents [text block]", "terseLabel": "Cash" } }, "en": { "role": { "documentation": "The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r110" ] }, "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfCalculationOfFairValueOfAwardsUsingBlackscholesOptionpricingModelAffectedByStockPriceOnDateOfGrant" ], "lang": { "en-us": { "role": { "label": "Expected volatility, share options granted", "terseLabel": "Expected volatility" } }, "en": { "role": { "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time." } } }, "auth_ref": [ "r176" ] }, "ifrs-full_DescriptionOfExpiryDateOfTemporaryDifferencesUnusedTaxLossesAndUnusedTaxCredits": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfExpiryDateOfTemporaryDifferencesUnusedTaxLossesAndUnusedTaxCredits", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxSummaryOfTemporaryDifferencesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expiry Date Range", "label": "Description of expiry date of deductible temporary differences, unused tax losses and unused tax credits" } }, "en": { "role": { "documentation": "The description of the expiry date (if any) of deductible temporary differences, unused tax losses and unused tax credits for which no deferred tax asset is recognised in the statement of financial position. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } } }, "auth_ref": [ "r46" ] }, "ifrs-full_DescriptionOfFunctionalCurrency": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfFunctionalCurrency", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFunctionalAndPresentationCurrencyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Functional Currency", "label": "Description of functional currency" } }, "en": { "role": { "documentation": "The description of the currency of the primary economic environment in which the entity operates." } } }, "auth_ref": [ "r66", "r67" ] }, "ifrs-full_DescriptionOfOptionLifeShareOptionsGranted": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfOptionLifeShareOptionsGranted", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfCalculationOfFairValueOfAwardsUsingBlackscholesOptionpricingModelAffectedByStockPriceOnDateOfGrant" ], "lang": { "en-us": { "role": { "label": "Option life, share options granted", "terseLabel": "Expected term" } }, "en": { "role": { "documentation": "The option life of share options granted." } } }, "auth_ref": [ "r176" ] }, "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfCalculationOfFairValueOfAwardsUsingBlackscholesOptionpricingModelAffectedByStockPriceOnDateOfGrant" ], "lang": { "en-us": { "role": { "label": "Risk free interest rate, share options granted", "terseLabel": "Risk-free interest rate" } }, "en": { "role": { "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]" } } }, "auth_ref": [ "r176" ] }, "vrax_DescriptionOfShareConsolidation": { "xbrltype": "stringItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "DescriptionOfShareConsolidation", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Description of share consolidation", "documentation": "Description of share consolidation." } } }, "auth_ref": [] }, "vrax_DetailsOfQuantitativeInformationAboutLeaseLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "DetailsOfQuantitativeInformationAboutLeaseLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Details of quantitative information about lease liabilities [Abstract]", "documentation": "Details of quantitative information about lease liabilities." } } }, "auth_ref": [] }, "vrax_DetailsOfQuantitativeInformationAboutLeaseLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "DetailsOfQuantitativeInformationAboutLeaseLiabilitiesLineItems", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesSummaryOfLeaseLiabilityActivityDetails" ], "lang": { "en-us": { "role": { "label": "Details of quantitative information about lease liabilities [line items]", "documentation": "Details of quantitative information about lease liabilities." } } }, "auth_ref": [] }, "vrax_DetailsOfQuantitativeInformationAboutLeaseLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "DetailsOfQuantitativeInformationAboutLeaseLiabilitiesTable", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesSummaryOfLeaseLiabilityActivityDetails" ], "lang": { "en-us": { "role": { "label": "Details of quantitative information about lease liabilities [Table]", "documentation": "Details of quantitative information about lease liabilities." } } }, "auth_ref": [] }, "ifrs-full_DilutedEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DilutedEarningsLossPerShare", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLossPerShareScheduleOfLossPerShareDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted loss per share attributable to Virax - ordinary shares", "verboseLabel": "Diluted net loss per share - Ordinary shares", "label": "Diluted earnings (loss) per share", "totalLabel": "Total diluted earnings (loss) per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r84", "r85" ] }, "vrax_DilutedLossPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "DilutedLossPerShareExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLossPerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Diluted Loss Per Share", "label": "Diluted Loss Per Share Explanatory", "documentation": "Diluted loss per share." } } }, "auth_ref": [] }, "ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLossPerShareAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dilutive shares", "label": "Dilutive effect of share options on weighted average number of ordinary shares", "verboseLabel": "Potentially dilutive ordinary shares" } }, "en": { "role": { "documentation": "The potential dilutive effect on the weighted average number of ordinary shares that relate to the assumed exercise of the entity's share options." } } }, "auth_ref": [ "r340" ] }, "vrax_DirectorAndChiefOperatingOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "DirectorAndChiefOperatingOfficerMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureKeyManagementCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Director and Chief Operating Officer", "label": "Director And Chief Operating Officer [Member]", "documentation": "Director and Chief Operating Officer." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureCriticalEstimatesAndJudgments" ], "lang": { "en-us": { "role": { "terseLabel": "Critical Estimates and Judgments", "label": "Disclosure of accounting judgements and estimates [text block]" } }, "en": { "role": { "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]" } } }, "auth_ref": [ "r327" ] }, "vrax_DisclosureOfAccountsPayableAndAccruedLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "DisclosureOfAccountsPayableAndAccruedLiabilitiesExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued liabilities", "label": "Disclosure Of Accounts Payable And Accrued Liabilities Explanatory", "documentation": "Disclosure of accounts payable and accrued liabilities explanatory." } } }, "auth_ref": [] }, "vrax_DisclosureOfAccountsReceivableExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "DisclosureOfAccountsReceivableExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureAccountsReceivable" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable", "label": "Disclosure Of Accounts Receivable Explanatory", "documentation": "Disclosure of accounts receivable." } } }, "auth_ref": [] }, "vrax_DisclosureOfActivityRelatedToOutstandingWarrantsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "DisclosureOfActivityRelatedToOutstandingWarrantsExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of activity related to outstanding warrants.", "label": "Disclosure of activity related to outstanding warrants explanatory", "terseLabel": "Summary of Activity Related to Outstanding Warrants" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfBorrowingsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfBorrowingsExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureNotePayable" ], "lang": { "en-us": { "role": { "label": "Disclosure of borrowings [text block]", "terseLabel": "Note Payable" } }, "en": { "role": { "documentation": "The disclosure of borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r327" ] }, "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfCashAndCashEquivalentsExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureCashAndCashEquivalents" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Disclosure of cash and cash equivalents [text block]" } }, "en": { "role": { "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r327" ] }, "ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfChangesInAccountingPoliciesExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Disclosure of changes in accounting policies [text block]" } }, "en": { "role": { "documentation": "The disclosure of changes made to accounting policies by the entity." } } }, "auth_ref": [ "r327" ] }, "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalLineItems", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPositionParenthetical" ], "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalTable", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPositionParenthetical" ], "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to classes of share capital." } } }, "auth_ref": [ "r28" ] }, "ifrs-full_DisclosureOfCommitmentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfCommitmentsExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureCommitments" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments", "label": "Disclosure of commitments [text block]" } }, "en": { "role": { "documentation": "The disclosure of commitments." } } }, "auth_ref": [ "r327" ] }, "ifrs-full_DisclosureOfContingentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfContingentLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of contingent liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfContingentLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfContingentLiabilitiesLineItems", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureContingentLiabilitiesAndContingentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of contingent liabilities [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfContingentLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfContingentLiabilitiesTable", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureContingentLiabilitiesAndContingentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of contingent liabilities [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to contingent liabilities." } } }, "auth_ref": [ "r90" ] }, "vrax_DisclosureOfDetailedInformationAboutAccountsPayableAndAccruedLiabilitiesexplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "DisclosureOfDetailedInformationAboutAccountsPayableAndAccruedLiabilitiesexplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accounts Payable and Accrued Liabilities", "label": "Disclosure Of Detailed Information About Accounts Payable And Accrued LiabilitiesExplanatory", "documentation": "Disclosure of detailed information about accounts payable and accrued liabilities." } } }, "auth_ref": [] }, "vrax_DisclosureOfDetailedInformationAboutAccountsReceivableExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "DisclosureOfDetailedInformationAboutAccountsReceivableExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureAccountsReceivableTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Accounts Receivable", "label": "Disclosure Of Detailed Information About Accounts Receivable Explanatory", "documentation": "Disclosure of detailed information about accounts receivable." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsLineItems", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureNotePayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureNotePayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of borrowings." } } }, "auth_ref": [ "r354" ] }, "vrax_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureCashAndCashEquivalentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash and Cash Equivalents", "label": "Disclosure Of Detailed Information About Cash And Cash Equivalents Explanatory", "documentation": "Disclosure of detailed information about cash and cash equivalents." } } }, "auth_ref": [] }, "vrax_DisclosureOfDetailedInformationAboutLeasesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "DisclosureOfDetailedInformationAboutLeasesLineItems", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesScheduleOfAnnualRentDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about leases [line items]", "documentation": "Disclosure of detailed information about leases." } } }, "auth_ref": [] }, "vrax_DisclosureOfDetailedInformationAboutLeasesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "DisclosureOfDetailedInformationAboutLeasesTable", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesScheduleOfAnnualRentDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about leases [table]", "documentation": "Disclosure of detailed information about leases." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosurePropertyPlantEquipmentNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Property, Plant & Equipment, Net", "label": "Disclosure of detailed information about property, plant and equipment [text block]" } }, "en": { "role": { "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r57" ] }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of disaggregation of revenue from contracts with customers [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Disaggregation of Revenue from Contracts with Customers", "label": "Disclosure of disaggregation of revenue from contracts with customers [text block]" } }, "en": { "role": { "documentation": "The disclosure of the disaggregation of revenue from contracts with customers. [Refer: Revenue from contracts with customers]" } } }, "auth_ref": [ "r140" ] }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersScheduleOfDisaggregationOfRevenueFromContractsWithCustomersDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Disclosure of disaggregation of revenue from contracts with customers [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersScheduleOfDisaggregationOfRevenueFromContractsWithCustomersDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Disclosure of disaggregation of revenue from contracts with customers [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers." } } }, "auth_ref": [ "r140" ] }, "ifrs-full_DisclosureOfEarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfEarningsPerShareExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLossPerShare1" ], "lang": { "en-us": { "role": { "terseLabel": "Loss per share", "label": "Disclosure of earnings per share [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r87" ] }, "ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Effect of Changes in Foreign Exchange Rates", "label": "Disclosure of effect of changes in foreign exchange rates [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for the effect of changes in foreign exchange rates." } } }, "auth_ref": [ "r68" ] }, "vrax_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Estimated Useful Lives of Property Plant and Equipment", "label": "Disclosure Of Estimated Useful Lives Of Property Plant And Equipment Explanatory", "documentation": "Disclosure of estimated useful lives of property plant and equipment." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSubsequentEvents" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Disclosure of events after reporting period [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for events after the reporting period." } } }, "auth_ref": [ "r42" ] }, "ifrs-full_DisclosureOfFinancialAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFinancialAssetsLineItems", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Disclosure of financial assets [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFinancialAssetsTable", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Disclosure of financial assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to financial assets." } } }, "auth_ref": [ "r192" ] }, "ifrs-full_DisclosureOfFinancialRiskManagementExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFinancialRiskManagementExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRiskManagementOverview" ], "lang": { "en-us": { "role": { "terseLabel": "Risk management overview", "label": "Disclosure of financial risk management [text block]" } }, "en": { "role": { "documentation": "The disclosure of the entity's financial risk management practices and policies." } } }, "auth_ref": [ "r327" ] }, "vrax_DisclosureOfFunctionalAndPresentationCurrencyExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "DisclosureOfFunctionalAndPresentationCurrencyExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Functional and Presentation Currency", "label": "Disclosure Of Functional And Presentation Currency Explanatory", "documentation": "Disclosure of functional and presentation currency." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactions1" ], "lang": { "en-us": { "role": { "terseLabel": "General information and reorganization transactions", "label": "Disclosure of general information about financial statements [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for general information about financial statements." } } }, "auth_ref": [ "r7" ] }, "ifrs-full_DisclosureOfIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfIncomeTaxExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTax" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax", "label": "Disclosure of income tax [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for income taxes." } } }, "auth_ref": [ "r49" ] }, "vrax_DisclosureOfInformationAboutInventoriesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "DisclosureOfInformationAboutInventoriesExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureInventoriesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Inventories", "label": "Disclosure of information about inventories Explanatory", "documentation": "Disclosure of information about inventories." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureKeyManagementCompensation" ], "lang": { "en-us": { "role": { "terseLabel": "Key management compensation", "label": "Disclosure of information about key management personnel [text block]" } }, "en": { "role": { "documentation": "The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]" } } }, "auth_ref": [ "r327" ] }, "ifrs-full_DisclosureOfIntangibleAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfIntangibleAssetsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfIntangibleAssetsExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIntangibleSoftwareNet" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Software, net", "label": "Disclosure of intangible assets [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for intangible assets." } } }, "auth_ref": [ "r99" ] }, "ifrs-full_DisclosureOfIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfIntangibleAssetsLineItems", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIntangibleSoftwareNetSummaryOfIntangibleSoftwareDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfIntangibleAssetsTable", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIntangibleSoftwareNetSummaryOfIntangibleSoftwareDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of intangible assets." } } }, "auth_ref": [ "r96" ] }, "ifrs-full_DisclosureOfInventoriesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfInventoriesExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureInventories" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Disclosure of inventories [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for inventories." } } }, "auth_ref": [ "r65" ] }, "ifrs-full_DisclosureOfLeasesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfLeasesExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeases" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Disclosure of leases [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for leases." } } }, "auth_ref": [ "r154", "r155" ] }, "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of maturity analysis of operating lease payments [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureCommitmentsTables", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Summary of Maturity of Lease Liabilities", "terseLabel": "Schedule of Commitments for Minimum Lease Payments", "label": "Disclosure of maturity analysis of operating lease payments [text block]" } }, "en": { "role": { "documentation": "The disclosure of a maturity analysis of operating lease payments. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset." } } }, "auth_ref": [ "r153" ] }, "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureCommitmentsScheduleOfCommitmentsForMinimumLeasePaymentsDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of maturity analysis of operating lease payments [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureCommitmentsScheduleOfCommitmentsForMinimumLeasePaymentsDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of maturity analysis of operating lease payments [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the maturity analysis of operating lease payments." } } }, "auth_ref": [ "r153" ] }, "vrax_DisclosureOfMonetaryAssetsAndLiabilitiesDenominatedInForeignCurrenciesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "DisclosureOfMonetaryAssetsAndLiabilitiesDenominatedInForeignCurrenciesExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRiskManagementOverviewTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Monetary Assets and Liabilities Denominated In Foreign Currencies", "label": "Disclosure of Monetary Assets and Liabilities Denominated In Foreign Currencies Explanatory", "documentation": "Disclosure of monetary assets and liabilities denominated in foreign currencies." } } }, "auth_ref": [] }, "vrax_DisclosureOfNetDeferredTaxAssetLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "DisclosureOfNetDeferredTaxAssetLiabilityTableTextBlock", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Net Deferred Tax Asset (Liability)", "label": "Disclosure of net deferred tax asset liability [table text block]", "documentation": "Disclosure of net deferred tax asset liability." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period." } } }, "auth_ref": [ "r41" ] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of number and weighted average exercise prices of share options [text block]", "terseLabel": "Summary of Status of Outstanding Stock Options and Changes" } }, "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r172" ] }, "vrax_DisclosureOfNumberOfShareIssuedInVariousEntitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "DisclosureOfNumberOfShareIssuedInVariousEntitiesExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Number of Shares Issued", "label": "Disclosure Of Number Of Share Issued In Various Entities Explanatory", "documentation": "Disclosure of number of share issued in various entities." } } }, "auth_ref": [] }, "vrax_DisclosureOfPrepaidExpensesAndDepositsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "DisclosureOfPrepaidExpensesAndDepositsExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosurePrepaidExpensesAndDepositsTables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of prepaid expenses and deposits.", "label": "Disclosure Of Prepaid Expenses And Deposits Explanatory", "terseLabel": "Summary of Prepaid Expenses and Deposits" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosurePrepaidExpensesAndDeposits" ], "lang": { "en-us": { "role": { "label": "Disclosure of prepayments and other assets [text block]", "terseLabel": "Prepaid Expenses and Deposits" } }, "en": { "role": { "documentation": "The disclosure of prepayments and other assets. [Refer: Other assets; Prepayments]" } } }, "auth_ref": [ "r327" ] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosurePropertyPlantEquipmentNet" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant & equipment, net", "label": "Disclosure of property, plant and equipment [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for property, plant and equipment." } } }, "auth_ref": [ "r60" ] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosurePropertyPlantEquipmentNetSummaryOfPropertyPlantEquipmentNetDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosurePropertyPlantEquipmentNetSummaryOfPropertyPlantEquipmentNetDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of property, plant and equipment." } } }, "auth_ref": [ "r57" ] }, "vrax_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Lease Liability Activity", "label": "Disclosure of quantitative information about lease liabilities explanatory", "documentation": "Disclosure of quantitative information about lease liabilities explanatory." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of quantitative information about right-of-use assets [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Right of Use Assets Activity", "label": "Disclosure of quantitative information about right-of-use assets [text block]" } }, "en": { "role": { "documentation": "The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]" } } }, "auth_ref": [ "r151" ] }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesSummaryOfRightOfUseAssetsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of quantitative information about right-of-use assets [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesSummaryOfRightOfUseAssetsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of quantitative information about right-of-use assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to right-of-use assets." } } }, "auth_ref": [ "r151" ] }, "ifrs-full_DisclosureOfReclassificationsOrChangesInPresentationAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfReclassificationsOrChangesInPresentationAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of reclassifications or changes in presentation [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfReclassificationsOrChangesInPresentationLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfReclassificationsOrChangesInPresentationLineItems", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDisclosureOfEffectOfChangesInForeignExchangeRatesDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFunctionalAndPresentationCurrencyDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfConsolidatedSubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of reclassifications or changes in presentation [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfReclassificationsOrChangesInPresentationTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfReclassificationsOrChangesInPresentationTable", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDisclosureOfEffectOfChangesInForeignExchangeRatesDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFunctionalAndPresentationCurrencyDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfConsolidatedSubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of reclassifications or changes in presentation [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to reclassifications or changes in presentation." } } }, "auth_ref": [ "r6" ] }, "ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIntangibleSoftwareNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Intangible Software", "label": "Disclosure of reconciliation of changes in intangible assets and goodwill [text block]" } }, "en": { "role": { "documentation": "The disclosure of the reconciliation of changes in intangible assets and goodwill. [Refer: Intangible assets and goodwill]" } } }, "auth_ref": [ "r344" ] }, "vrax_DisclosureOfReconciliationOfIncomeTaxesAtStatutoryRatesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "DisclosureOfReconciliationOfIncomeTaxesAtStatutoryRatesTableTextBlock", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxTables" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Income Taxes at Statutory Rates", "label": "Disclosure of reconciliation of income taxes at statutory rates [Table text block]", "documentation": "Disclosure of reconciliation of income taxes at statutory rates." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfRelatedPartyExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfRelatedPartyExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactions" ], "lang": { "en-us": { "role": { "terseLabel": "Related party transactions", "label": "Disclosure of related party [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for related parties." } } }, "auth_ref": [ "r77" ] }, "ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfRevenueFromContractsWithCustomersExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRevenueFromContractsWithCustomers" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from contracts with customers", "label": "Disclosure of revenue from contracts with customers [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for revenue from contracts with customers." } } }, "auth_ref": [ "r143", "r144" ] }, "ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of risk management strategy related to hedge accounting [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingLineItems", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRiskManagementOverviewDisclosureOfMonetaryAssetsAndLiabilitiesDenominatedInForeignCurrenciesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of risk management strategy related to hedge accounting [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingTable", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRiskManagementOverviewDisclosureOfMonetaryAssetsAndLiabilitiesDenominatedInForeignCurrenciesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of risk management strategy related to hedge accounting [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the risk management strategy in relation to hedge accounting." } } }, "auth_ref": [ "r182", "r208" ] }, "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholder's equity", "label": "Disclosure of share capital, reserves and other equity interest [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for share capital, reserves and other equity interest." } } }, "auth_ref": [ "r29" ] }, "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Consolidated Subsidiaries", "label": "Disclosure of subsidiaries [text block]" } }, "en": { "role": { "documentation": "The disclosure of subsidiaries. [Refer: Subsidiaries [member]]" } } }, "auth_ref": [ "r80", "r82", "r132" ] }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Temporary Differences", "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [text block]" } }, "en": { "role": { "documentation": "The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]" } } }, "auth_ref": [ "r48" ] }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxSummaryOfTemporaryDifferencesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxSummaryOfTemporaryDifferencesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to temporary differences, unused tax losses and unused tax credits." } } }, "auth_ref": [ "r48" ] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityRelatedToOutstandingWarrantsDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfCalculationOfFairValueOfAwardsUsingBlackscholesOptionpricingModelAffectedByStockPriceOnDateOfGrant", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStatusOfOutstandingStockOptionsAndChangesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityRelatedToOutstandingWarrantsDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfCalculationOfFairValueOfAwardsUsingBlackscholesOptionpricingModelAffectedByStockPriceOnDateOfGrant", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStatusOfOutstandingStockOptionsAndChangesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements." } } }, "auth_ref": [ "r175" ] }, "ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTradeAndOtherReceivablesExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureVatReceivableTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of VAT Receivable", "label": "Disclosure of trade and other receivables [text block]" } }, "en": { "role": { "documentation": "The disclosure of trade and other receivables. [Refer: Trade and other receivables]" } } }, "auth_ref": [ "r327" ] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of transactions between related parties [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Related Party Payables", "label": "Disclosure of transactions between related parties [text block]" } }, "en": { "role": { "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]" } } }, "auth_ref": [ "r73" ] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureKeyManagementCompensationAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartyCompensationForOfficersAndDirectorsDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartyPayablesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of transactions between related parties [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureKeyManagementCompensationAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartyCompensationForOfficersAndDirectorsDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartyPayablesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of transactions between related parties [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to transactions between related parties." } } }, "auth_ref": [ "r75" ] }, "vrax_DisclosureOfValueAddedTaxReceivableExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "DisclosureOfValueAddedTaxReceivableExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureVatReceivable" ], "lang": { "en-us": { "role": { "terseLabel": "VAT Receivable", "label": "Disclosure Of Value Added Tax Receivable Explanatory", "documentation": "Disclosure of value added tax receivable." } } }, "auth_ref": [] }, "ifrs-full_DisposalsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisposalsPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosurePropertyPlantEquipmentNetSummaryOfPropertyPlantEquipmentNetDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Disposals", "label": "Disposals, property, plant and equipment", "negatedLabel": "Disposals, property, plant and equipment" } }, "en": { "role": { "documentation": "The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r53" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r250" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r249", "r250", "r263" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r249", "r250", "r263", "r299" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information:", "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information", "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r245" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r250" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r284" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "vrax_DrTomaszGeorgeChiefScientificOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "DrTomaszGeorgeChiefScientificOfficerMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartyCompensationForOfficersAndDirectorsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dr. Tomasz George, Chief Scientific Officer", "label": "Dr. Tomasz George, Chief Scientific Officer [Member]", "documentation": "Dr. Tomasz George, Chief Scientific Officer member." } } }, "auth_ref": [] }, "vrax_DueToShareHolderAndRelatedPartyPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "DueToShareHolderAndRelatedPartyPayable", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due to share holder and related party payable", "label": "Due to share holder and related party payable", "documentation": "Due to share holder and related party payable." } } }, "auth_ref": [] }, "currency_EUR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "EUR", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRiskManagementOverviewDisclosureOfMonetaryAssetsAndLiabilitiesDenominatedInForeignCurrenciesDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDisclosureOfEffectOfChangesInForeignExchangeRatesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Euro", "terseLabel": "EUR", "label": "Euro Member Countries, Euro" } } }, "auth_ref": [] }, "ifrs-full_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "verboseLabel": "Basic and diluted net loss per share to Virax shareholders", "label": "Earnings per share [abstract]" } } }, "auth_ref": [] }, "ifrs-full_EarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EarningsPerShareExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLossPerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Loss Per Share", "label": "Earnings per share [text block]" } }, "en": { "role": { "documentation": "The disclosure of earnings per share." } } }, "auth_ref": [ "r84" ] }, "ifrs-full_EarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EarningsPerShareLineItems", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLossPerShareScheduleOfDilutedLossPerShareDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLossPerShareScheduleOfLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Earnings per share [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_EarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EarningsPerShareTable", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLossPerShareScheduleOfDilutedLossPerShareDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLossPerShareScheduleOfLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Earnings per share [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to earnings per share." } } }, "auth_ref": [ "r84" ] }, "vrax_EffectsOfCurrencyTranslationLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "EffectsOfCurrencyTranslationLeaseLiabilities", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesSummaryOfLeaseLiabilityActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effects of currency translation", "label": "Effects of currency translation lease liabilities", "documentation": "Effects of currency translation lease liabilities." } } }, "auth_ref": [] }, "vrax_EffectsOfCurrencyTranslationRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "EffectsOfCurrencyTranslationRightOfUseAssets", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesSummaryOfRightOfUseAssetsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effects of currency translation", "negatedLabel": "Effects of currency translation", "label": "Effects of currency translation right of use assets.", "documentation": "Effects of currency translation right of use assets." } } }, "auth_ref": [] }, "ifrs-full_EmployeeBenefitsExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EmployeeBenefitsExpense", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "negatedLabel": "Employee benefits expense", "label": "Employee benefits expense", "totalLabel": "Total employee benefits expense", "terseLabel": "Stock-based compensation" } }, "en": { "role": { "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment." } } }, "auth_ref": [ "r1", "r40", "r209" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "CIK", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r247" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r247" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r326" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r247" ] }, "dei_EntityIncorporationDateOfIncorporation": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationDateOfIncorporation", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Date of incoporation", "label": "Entity Incorporation, Date of Incorporation", "documentation": "Date when an entity was incorporated" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r324" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r247" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r247" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r325" ] }, "ifrs-full_EntitysOwnEquityInstrumentsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EntitysOwnEquityInstrumentsMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Entity's own equity instruments [member]" } }, "en": { "role": { "documentation": "This member stands for equity instruments issued by the entity. It also represents the standard value for the 'Classes of entity's own equity instruments' axis if no other member is used." } } }, "auth_ref": [ "r136" ] }, "ifrs-full_EntitysTotalForRelatedPartiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EntitysTotalForRelatedPartiesMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureKeyManagementCompensationAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartyCompensationForOfficersAndDirectorsDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartyPayablesDetails" ], "lang": { "en-us": { "role": { "label": "Entity's total for related parties [member]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } } }, "auth_ref": [ "r75" ] }, "ifrs-full_EntitysTotalForSubsidiariesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EntitysTotalForSubsidiariesMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFunctionalAndPresentationCurrencyDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfConsolidatedSubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Entity's total for subsidiaries [member]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Subsidiaries' axis if no other member is used." } } }, "auth_ref": [ "r80", "r82", "r132" ] }, "ifrs-full_Equity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Equity", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders' equity", "periodEndLabel": "Equity, ending balance", "periodStartLabel": "Equity, beginning balance", "label": "Equity", "terseLabel": "Total stockholders' equity" } }, "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } } }, "auth_ref": [ "r16", "r24", "r112", "r114", "r133", "r134", "r135" ] }, "ifrs-full_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityAbstract", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' equity", "label": "Equity [abstract]" } } }, "auth_ref": [] }, "ifrs-full_EquityAndLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityAndLiabilities", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders' equity", "label": "Equity and liabilities" } }, "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } } }, "auth_ref": [ "r16" ] }, "ifrs-full_EquityAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityAndLiabilitiesAbstract", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "verboseLabel": "Liabilities", "label": "Equity and liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_EquityAttributableToOwnersOfParent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityAttributableToOwnersOfParent", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders' equity (Virax)", "label": "Equity attributable to owners of parent" } }, "en": { "role": { "documentation": "The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest." } } }, "auth_ref": [ "r15" ] }, "ifrs-full_EquityAttributableToOwnersOfParentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityAttributableToOwnersOfParentMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Total Stockholders' Equity (Virax)" } }, "en": { "role": { "documentation": "This member stands for equity attributable to the owners of the parent." } } }, "auth_ref": [ "r5" ] }, "ifrs-full_EquityMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityRelatedToOutstandingWarrantsDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity [member]" } }, "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } } }, "auth_ref": [ "r5" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r292" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r255", "r267", "r277", "r303" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r252", "r264", "r274", "r300" ] }, "vrax_EvanNortonIndependentDirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "EvanNortonIndependentDirectorMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartyCompensationForOfficersAndDirectorsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Evan Norton, Independent Director", "label": "Evan Norton, Independent Director [Member]", "documentation": "Evan Norton, Independent Director member." } } }, "auth_ref": [] }, "vrax_EventsAfterReportingPeriodMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "EventsAfterReportingPeriodMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Events after reporting period member.", "label": "Events after Reporting Period [Member]", "terseLabel": "Events After Reporting Period" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r298" ] }, "vrax_ExerciseOfOverallotmentOptionToPurchaseOrdinaryShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "ExerciseOfOverallotmentOptionToPurchaseOrdinaryShares", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of overallotment option to purchase ordinary shares", "label": "Exercise of Overallotment Option to Purchase Ordinary Shares", "documentation": "Exercise of overallotment option to purchase ordinary shares." } } }, "auth_ref": [] }, "ifrs-full_ExercisePriceShareOptionsGranted2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ExercisePriceShareOptionsGranted2019", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Exercise price, share options granted", "terseLabel": "Average price" } }, "en": { "role": { "documentation": "The exercise price of share options granted." } } }, "auth_ref": [ "r176" ] }, "vrax_ExistingWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "ExistingWarrants", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Existing warrants", "label": "Existing Warrants", "documentation": "Existing warrants." } } }, "auth_ref": [] }, "vrax_ExistingWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "ExistingWarrantsMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Existing Warrants", "label": "Existing Warrants [Member]", "documentation": "Existing warrants." } } }, "auth_ref": [] }, "vrax_ExistingWarrantsPurchasedExercisedAsCash": { "xbrltype": "sharesItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "ExistingWarrantsPurchasedExercisedAsCash", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Existing warrants purchased exercised as cash", "documentation": "Existing warrants purchased exercised as cash." } } }, "auth_ref": [] }, "ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ExpectedDividendAsPercentageShareOptionsGranted", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfCalculationOfFairValueOfAwardsUsingBlackscholesOptionpricingModelAffectedByStockPriceOnDateOfGrant" ], "lang": { "en-us": { "role": { "terseLabel": "Dividend yield", "label": "Expected dividend as percentage, share options granted" } }, "en": { "role": { "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted." } } }, "auth_ref": [ "r176" ] }, "vrax_ExpiryDateOfTemporaryDifferencesUnusedTaxLossesAndUnusedTaxCreditsExpiryDatePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "ExpiryDateOfTemporaryDifferencesUnusedTaxLossesAndUnusedTaxCreditsExpiryDatePeriod", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxSummaryOfTemporaryDifferencesDetails" ], "lang": { "en-us": { "role": { "documentation": "Expiry date of temporary differences unused tax losses and unused tax credits expiry date period.", "label": "Expiry Date Of Temporary Differences Unused Tax Losses And Unused Tax Credits Expiry Date Period", "terseLabel": "Expiry Date Range" } } }, "auth_ref": [] }, "ifrs-full_FeeAndCommissionExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FeeAndCommissionExpense", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Underwriting discounts and commissions", "label": "Fee and commission expense", "negatedTotalLabel": "Total fee and commission expense" } }, "en": { "role": { "documentation": "The amount of expense relating to fees and commissions." } } }, "auth_ref": [ "r336" ] }, "vrax_FiledCurrentValueAddedTaxReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "FiledCurrentValueAddedTaxReceivables", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureVatReceivableAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureVatReceivableSummaryOfVatReceivableDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Filed", "terseLabel": "Filed VAT receivable", "label": "Filed Current Value Added Tax Receivables", "documentation": "Filed current value added tax receivables." } } }, "auth_ref": [] }, "ifrs-full_FinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinishedGoods", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureInventoriesSummaryOfInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Current finished goods" } }, "en": { "role": { "documentation": "A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]" } } }, "auth_ref": [ "r215", "r339" ] }, "vrax_FionaFosterMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "FionaFosterMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartyPayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fiona Foster", "label": "Fiona Foster [Member]", "documentation": "Fiona Foster." } } }, "auth_ref": [] }, "ifrs-full_FixturesAndFittingsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FixturesAndFittingsMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosurePropertyPlantEquipmentNetSummaryOfPropertyPlantEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture & Fixtures", "label": "Fixtures and fittings [member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing fixtures and fittings that are not permanently attached to real property. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r219" ] }, "vrax_ForfeitureRate": { "xbrltype": "percentItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "ForfeitureRate", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfCalculationOfFairValueOfAwardsUsingBlackscholesOptionpricingModelAffectedByStockPriceOnDateOfGrant" ], "lang": { "en-us": { "role": { "documentation": "Forfeiture rate.", "label": "Forfeiture Rate", "terseLabel": "Forfeiture rate" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r259", "r271", "r281", "r307" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r259", "r271", "r281", "r307" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r259", "r271", "r281", "r307" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r259", "r271", "r281", "r307" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r259", "r271", "r281", "r307" ] }, "vrax_FormerNonExecutiveDirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "FormerNonExecutiveDirectorMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Former non-executive Director", "label": "Former non Executive Director [Member]", "documentation": "Former non executive director." } } }, "auth_ref": [] }, "currency_GBP": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "GBP", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRiskManagementOverviewDisclosureOfMonetaryAssetsAndLiabilitiesDenominatedInForeignCurrenciesDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDisclosureOfEffectOfChangesInForeignExchangeRatesDetails" ], "lang": { "en-us": { "role": { "label": "United Kingdom, Pounds", "terseLabel": "British Pound", "verboseLabel": "GBP" } } }, "auth_ref": [] }, "ifrs-full_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and administrative expense" } }, "en": { "role": { "documentation": "The amount of expense relating to general and administrative activities of the entity." } } }, "auth_ref": [ "r330" ] }, "ifrs-full_GeographicalAreasAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GeographicalAreasAxis", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Geographical areas [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r206", "r220", "r232", "r235" ] }, "ifrs-full_GeographicalAreasMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GeographicalAreasMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Geographical areas [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used." } } }, "auth_ref": [ "r206", "r220", "r232", "r235" ] }, "ifrs-full_GrossCarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GrossCarryingAmountMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesSummaryOfRightOfUseAssetsActivityDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosurePropertyPlantEquipmentNetSummaryOfPropertyPlantEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost", "label": "Gross carrying amount [member]" } }, "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]" } } }, "auth_ref": [ "r51", "r92", "r101", "r104", "r179", "r188", "r190", "r237" ] }, "vrax_GrossProceedsFromIssueOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "GrossProceedsFromIssueOfPrivatePlacement", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Gross proceeds from issue of private placement.", "label": "Gross proceeds from issue of private placement", "terseLabel": "Gross proceeds from issue of private placement" } } }, "auth_ref": [] }, "ifrs-full_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GrossProfit", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross profit", "netLabel": "Gross profit" } }, "en": { "role": { "documentation": "The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]" } } }, "auth_ref": [ "r210" ] }, "country_HK": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "HK", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hong Kong", "label": "HONG KONG" } } }, "auth_ref": [] }, "vrax_HkCoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "HkCoMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "HKCo", "label": "HK co [member]", "documentation": "Hk co." } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r249", "r250", "r263" ] }, "ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIntangibleSoftwareNetSummaryOfIntangibleSoftwareDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of intangible asset", "negatedTerseLabel": "Impairment", "label": "Impairment loss recognised in profit or loss, intangible assets and goodwill", "negatedLabel": "Impairment loss recognised in profit or loss, intangible assets and goodwill" } }, "en": { "role": { "documentation": "The amount of impairment loss recognised in profit or loss for intangible assets and goodwill. [Refer: Impairment loss recognised in profit or loss; Intangible assets and goodwill]" } } }, "auth_ref": [ "r343" ] }, "ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of intangible asset", "label": "Impairment loss recognised in profit or loss, intangible assets other than goodwill", "negatedLabel": "Impairment loss recognised in profit or loss, intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The amount of impairment loss recognised in profit or loss for intangible assets other than goodwill. [Refer: Impairment loss recognised in profit or loss; Intangible assets other than goodwill]" } } }, "auth_ref": [ "r94" ] }, "ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureAccountsReceivableSummaryOfAccountsReceivableDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Less: provision for impairment of account receivables", "label": "Impairment loss (reversal of impairment loss) recognised in profit or loss, trade receivables", "netLabel": "Net impairment loss (reversal of impairment loss) recognised in profit or loss, trade receivables" } }, "en": { "role": { "documentation": "The amount of impairment loss or reversal of impairment loss recognised in profit or loss for trade receivables. [Refer: Impairment loss recognised in profit or loss; Reversal of impairment loss recognised in profit or loss; Trade receivables]" } } }, "auth_ref": [ "r330" ] }, "vrax_ImputedInterestOnLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "ImputedInterestOnLeaseLiabilities", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: imputed interest", "label": "Imputed interest on lease liabilities", "documentation": "Imputed interest on lease liabilities." } } }, "auth_ref": [] }, "ifrs-full_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Profit or loss [abstract]" } } }, "auth_ref": [] }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncomeTaxExpenseContinuingOperations", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxReconciliationOfIncomeTaxesAtStatutoryRatesDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Income tax expense", "label": "Provision for profit tax", "terseLabel": "Provision", "totalLabel": "Total income tax expense (recovery)" } }, "en": { "role": { "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]" } } }, "auth_ref": [ "r37", "r43", "r44", "r45", "r78", "r131", "r197" ] }, "ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncomeTaxesPaidClassifiedAsOperatingActivities", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes", "label": "Income taxes paid, classified as operating activities" } }, "en": { "role": { "documentation": "The cash outflow for income taxes paid, classified as operating activities." } } }, "auth_ref": [ "r351" ] }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseInCashAndCashEquivalents", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Net decrease in cash", "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes", "netLabel": "Net increase (decrease) in cash and cash equivalents after effect of exchange rate changes", "totalLabel": "Net change in cash" } }, "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } } }, "auth_ref": [ "r109" ] }, "ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseInNumberOfOrdinarySharesIssued", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued for cash, shares", "label": "Increase (decrease) in number of ordinary shares issued" } }, "en": { "role": { "documentation": "The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]" } } }, "auth_ref": [ "r330" ] }, "vrax_IncreaseDecreaseInNumberOfOrdinarySharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "IncreaseDecreaseInNumberOfOrdinarySharesIssuedForServices", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares issued for services, shares", "documentation": "Increase decrease in number of ordinary shares issued for services.", "verboseLabel": "Shares issued for services" } } }, "auth_ref": [] }, "vrax_IncreaseDecreaseInNumberOfOrdinarySharesIssuedForSettlementOfRelatedPartyPayable": { "xbrltype": "sharesItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "IncreaseDecreaseInNumberOfOrdinarySharesIssuedForSettlementOfRelatedPartyPayable", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares issued for settlement of related party payable, shares", "documentation": "Increase decrease in number of ordinary shares issued for settlement of related party payable." } } }, "auth_ref": [] }, "vrax_IncreaseDecreaseInNumberOfSharesIssuedForRoundingOnShareConsolidation": { "xbrltype": "sharesItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "IncreaseDecreaseInNumberOfSharesIssuedForRoundingOnShareConsolidation", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued for rounding on Share Consolidation, shares", "label": "Increase Decrease In Number Of Shares Issued For Rounding On Share Consolidation", "documentation": "Increase decrease in number of shares issued for rounding on share consolidation." } } }, "auth_ref": [] }, "vrax_IncreaseDecreaseInNumberOfSharesIssuedForSettlementOfDebt": { "xbrltype": "sharesItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "IncreaseDecreaseInNumberOfSharesIssuedForSettlementOfDebt", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued for settlement of debt, shares", "label": "Increase Decrease In Number Of Shares Issued For Settlement Of Debt", "documentation": "Increase decrease in number of shares issued for settlement of debt." } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughConversionOfConvertibleInstruments", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued for conversion of convertible debt", "label": "Increase (decrease) through conversion of convertible instruments, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the conversion of convertible instruments." } } }, "auth_ref": [ "r328" ] }, "ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughExerciseOfWarrantsEquity", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant exercise", "label": "Increase (decrease) through exercise of warrants, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the exercise of warrants." } } }, "auth_ref": [ "r328" ] }, "vrax_IncreaseDecreaseThroughExerciseOfWarrantsEquityShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "IncreaseDecreaseThroughExerciseOfWarrantsEquityShares", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant exercise, shares", "label": "Increase Decrease Through Exercise Of Warrants Equity Shares", "documentation": "Increase decrease through exercise of warrants equity, shares." } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosurePropertyPlantEquipmentNetSummaryOfPropertyPlantEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effects of currency translation", "label": "Increase (decrease) through net exchange differences, property, plant and equipment" } }, "en": { "role": { "documentation": "The increase (decrease) in property, plant and equipment resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r55" ] }, "ifrs-full_IncreaseDecreaseThroughTransferToStatutoryReserve": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughTransferToStatutoryReserve", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Imputed interest", "label": "Increase (decrease) through transfer to statutory reserve, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from transfers to a statutory reserve. [Refer: Statutory reserve]" } } }, "auth_ref": [ "r328" ] }, "vrax_IncrementalBorrowingRate": { "xbrltype": "percentItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "IncrementalBorrowingRate", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "incremental borrowing rate", "label": "incremental borrowing rate", "documentation": "incremental borrowing rate." } } }, "auth_ref": [] }, "vrax_IncrementalFairValueOfWarrantsRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "IncrementalFairValueOfWarrantsRecognized", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Incremental fair value of warrants recognized", "label": "Incremental Fair Value Of Warrants Recognized", "documentation": "Incremental fair value of warrants recognized." } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r262", "r271", "r281", "r298", "r307", "r311", "r319" ] }, "vrax_InducementLetterMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "InducementLetterMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inducement Letter", "label": "Inducement Letter [Member]", "documentation": "Inducement letter." } } }, "auth_ref": [] }, "ifrs-full_InformationAboutMajorCustomers": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InformationAboutMajorCustomers", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer information", "label": "Information about major customers" } }, "en": { "role": { "documentation": "Information about the entity's major customers and the extent of the entity's reliance on them." } } }, "auth_ref": [ "r207" ] }, "ifrs-full_InformationOnHowEntityDeterminedWhetherCreditRiskOfFinancialInstrumentsHasIncreasedSignificantlySinceInitialRecognition": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InformationOnHowEntityDeterminedWhetherCreditRiskOfFinancialInstrumentsHasIncreasedSignificantlySinceInitialRecognition", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Information on how entity determined whether credit risk of financial instruments has increased significantly since initial recognition", "label": "Information on how entity determined whether credit risk of financial instruments has increased significantly since initial recognition" } }, "en": { "role": { "documentation": "Information on how an entity determined whether the credit risk of financial instruments has increased significantly since initial recognition, including if and how: (a) financial instruments are considered to have low credit risk; and (b) the presumption that there have been significant increases in credit risk since initial recognition when financial assets are more than 30 days past due, has been rebutted. [Refer: Credit risk [member]]" } } }, "auth_ref": [ "r186" ] }, "vrax_InitialPublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "InitialPublicOfferingMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "IPO", "label": "Initial Public Offering [Member]", "documentation": "Initial public offering." } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r317" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r251", "r323" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r251", "r323" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r251", "r323" ] }, "ifrs-full_IntangibleAssetsAndGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IntangibleAssetsAndGoodwill", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIntangibleSoftwareNetScheduleOfSoftwareDevelopmentCostsDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIntangibleSoftwareNetSummaryOfIntangibleSoftwareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Book Value", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "label": "Intangible assets and goodwill", "totalLabel": "Total intangible assets and goodwill" } }, "en": { "role": { "documentation": "The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]" } } }, "auth_ref": [ "r332" ] }, "ifrs-full_IntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "verboseLabel": "Intangible assets", "terseLabel": "Intangible software, net", "periodStartLabel": "Intangible assets other than goodwill at beginning of period", "periodEndLabel": "Intangible assets other than goodwill at end of period", "label": "Intangible assets other than goodwill", "totalLabel": "Total intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]" } } }, "auth_ref": [ "r9", "r95" ] }, "vrax_IntangibleAssetsOtherThanGoodwillDeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "IntangibleAssetsOtherThanGoodwillDeferredTaxAssets", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxSummaryOfNetDeferredTaxAssetLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "label": "Intangible assets other than goodwill deferred tax assets", "documentation": "Intangible assets other than goodwill deferred tax assets." } } }, "auth_ref": [] }, "ifrs-full_IntangibleAssetsOtherThanGoodwillMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IntangibleAssetsOtherThanGoodwillMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIntangibleSoftwareNetSummaryOfIntangibleSoftwareDetails" ], "lang": { "en-us": { "role": { "label": "Intangible assets other than goodwill [member]" } }, "en": { "role": { "documentation": "This member stands for intangible assets other than goodwill. It also represents the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r96", "r223", "r233" ] }, "vrax_IntangibleAssetsUnderDevelopmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "IntangibleAssetsUnderDevelopmentDescription", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIntangibleSoftwareNetScheduleOfSoftwareDevelopmentCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets Under Development", "label": "Intangible assets under development description", "documentation": "Intangible assets under development description." } } }, "auth_ref": [] }, "vrax_IntangibleSoftwareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "IntangibleSoftwareMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIntangibleSoftwareNetSummaryOfIntangibleSoftwareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Software", "label": "Intangible Software [Member]", "documentation": "Intangible software." } } }, "auth_ref": [] }, "ifrs-full_InterestExpenseOnBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestExpenseOnBorrowings", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureNotePayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Interest expense on borrowings" } }, "en": { "role": { "documentation": "The amount of interest expense on borrowings. [Refer: Interest expense; Borrowings]" } } }, "auth_ref": [ "r330" ] }, "ifrs-full_InterestExpenseOnDebtInstrumentsIssued": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestExpenseOnDebtInstrumentsIssued", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Imputed interest for debt", "label": "Interest expense on debt instruments issued" } }, "en": { "role": { "documentation": "The amount of interest expense on debt instruments issued. [Refer: Interest expense; Debt instruments issued]" } } }, "auth_ref": [ "r330" ] }, "ifrs-full_InterestExpenseOnLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestExpenseOnLeaseLiabilities", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesSummaryOfLeaseLiabilityActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense on operating lease liabilities", "label": "Interest expense on lease liabilities" } }, "en": { "role": { "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r147" ] }, "ifrs-full_InterestPaidClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestPaidClassifiedAsOperatingActivities", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest paid, classified as operating activities", "negatedTerseLabel": "Interest", "terseLabel": "Interest" } }, "en": { "role": { "documentation": "The cash outflow for interest paid, classified as operating activities." } } }, "auth_ref": [ "r107" ] }, "ifrs-full_InterestRevenueExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestRevenueExpense", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "terseLabel": "Interest expense, net", "label": "Interest expense" } }, "en": { "role": { "documentation": "The amount of income or expense arising from interest. [Refer: Interest expense; Interest income]" } } }, "auth_ref": [ "r198", "r203", "r336" ] }, "ifrs-full_Inventories": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Inventories", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureInventoriesAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureInventoriesSummaryOfInventoriesDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Inventories, net", "totalLabel": "Inventories, net", "verboseLabel": "Inventories", "terseLabel": "Inventory" } }, "en": { "role": { "documentation": "The amount of current inventories. [Refer: Inventories]" } } }, "auth_ref": [ "r10", "r62", "r212" ] }, "ifrs-full_InventoryWritedown2011": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InventoryWritedown2011", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureInventoriesSummaryOfInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory written off to general and administrative cost", "negatedLabel": "Inventory write down", "label": "Inventory write-down" } }, "en": { "role": { "documentation": "The amount of expense recognised related to the write-down of inventories to net realisable value. [Refer: Inventories]" } } }, "auth_ref": [ "r39", "r64" ] }, "vrax_InvestorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "InvestorsMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investor", "label": "Investors [Member]", "documentation": "Investors." } } }, "auth_ref": [] }, "vrax_IssuanceOfUnregisteredWarrantsToPurchaseOrdinaryShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "IssuanceOfUnregisteredWarrantsToPurchaseOrdinaryShares", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Issuance of unregistered warrants to purchase ordinary shares.", "label": "Issuance of unregistered warrants to purchase ordinary shares" } } }, "auth_ref": [] }, "vrax_IssuanceOfWarrantsToPurchaseOrdinaryShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "IssuanceOfWarrantsToPurchaseOrdinaryShares", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Issuance of warrants to purchase ordinary shares.", "label": "Issuance of warrants to purchase ordinary shares" } } }, "auth_ref": [] }, "ifrs-full_IssueOfConvertibleInstruments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IssueOfConvertibleInstruments", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Issue of convertible instruments", "terseLabel": "Transfer of Class B to Class A", "label": "Issue of convertible instruments" } }, "en": { "role": { "documentation": "The change in equity resulting from the issuing of convertible instruments." } } }, "auth_ref": [ "r328" ] }, "ifrs-full_IssueOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IssueOfEquity", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued for cash", "label": "Issue of equity" } }, "en": { "role": { "documentation": "The increase in equity through the issue of equity instruments." } } }, "auth_ref": [ "r4" ] }, "vrax_IssueOfEquityForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "IssueOfEquityForServices", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares issued for services", "documentation": "Issue of equity for services." } } }, "auth_ref": [] }, "vrax_IssueOfEquityForSettlementOfRelatedPartyPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "IssueOfEquityForSettlementOfRelatedPartyPayable", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "shares", "terseLabel": "Shares issued for settlement of related party payable", "documentation": "Issue of equity for settlement of related party payable." } } }, "auth_ref": [] }, "ifrs-full_IssuedCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IssuedCapital", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "verboseLabel": "Ordinary shares, $0.001 par value, 50,000,000 shares Authorised; 2,573,903 and 1,554,709 issued and outstanding as of March 31, 2024 and 2023, respectively", "terseLabel": "Issued capital", "label": "Issued capital", "totalLabel": "Total issued capital" } }, "en": { "role": { "documentation": "The nominal value of capital issued." } } }, "auth_ref": [ "r216" ] }, "ifrs-full_IssuedCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IssuedCapitalMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "Ordinary shares", "terseLabel": "Ordinary Shares", "label": "Issued capital [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } } }, "auth_ref": [ "r5" ] }, "vrax_IssuedForRoundingOnShareConsolidation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "IssuedForRoundingOnShareConsolidation", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued for rounding on Share Consolidation", "label": "Issued For Rounding On Share Consolidation", "documentation": "Issued for rounding on share consolidation." } } }, "auth_ref": [] }, "vrax_IssuedForSettlementOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "IssuedForSettlementOfDebt", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued for settlement of debt", "label": "Issued For Settlement Of Debt", "documentation": "Issued for settlement of debt." } } }, "auth_ref": [] }, "vrax_JamesFosterChiefExecutiveOfficerAndDirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "JamesFosterChiefExecutiveOfficerAndDirectorMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartyCompensationForOfficersAndDirectorsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "James Foster, Chief Executive Officer and Director", "label": "James Foster, Chief Executive Officer and Director [Member]", "documentation": "James Foster, Chief Executive Officer and Director member." } } }, "auth_ref": [] }, "vrax_JamesFosterMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "JamesFosterMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartyPayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "James Foster", "label": "James Foster [Member]", "documentation": "James Foster." } } }, "auth_ref": [] }, "vrax_JasonDavisChiefFinancialOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "JasonDavisChiefFinancialOfficerMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartyCompensationForOfficersAndDirectorsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Jason Davis, Chief Financial Officer", "label": "Jason Davis, Chief Financial Officer [Member]", "documentation": "Jason Davis, Chief Financial Officer member." } } }, "auth_ref": [] }, "vrax_KeyManagementCompensationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "KeyManagementCompensationAbstract", "lang": { "en-us": { "role": { "label": "Key management compensation [abstract]", "documentation": "Key management compensation." } } }, "auth_ref": [] }, "vrax_KeyManagementPersonnelBonus": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "KeyManagementPersonnelBonus", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartyCompensationForOfficersAndDirectorsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bonus", "label": "Key Management Personnel Bonus", "documentation": "Key management personnel bonus." } } }, "auth_ref": [] }, "ifrs-full_KeyManagementPersonnelCompensation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "KeyManagementPersonnelCompensation", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartyCompensationForOfficersAndDirectorsDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "terseLabel": "Compensation award", "label": "Key management personnel compensation" } }, "en": { "role": { "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]" } } }, "auth_ref": [ "r71" ] }, "ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "KeyManagementPersonnelCompensationOtherLongtermBenefits", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartyCompensationForOfficersAndDirectorsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Key management personnel compensation, other long-term employee benefits" } }, "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of other long-term employee benefits. [Refer: Other long-term employee benefits; Key management personnel of entity or parent [member]]" } } }, "auth_ref": [ "r69" ] }, "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "KeyManagementPersonnelCompensationSharebasedPayment", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartyCompensationForOfficersAndDirectorsDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Option Awards", "terseLabel": "Share based payment", "label": "Key management personnel compensation, share-based payment" } }, "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]" } } }, "auth_ref": [ "r70" ] }, "vrax_KeyManagementPersonnelSalary": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "KeyManagementPersonnelSalary", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartyCompensationForOfficersAndDirectorsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Salary", "label": "Key Management Personnel Salary", "documentation": "Key management personnel salary." } } }, "auth_ref": [] }, "vrax_LabEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "LabEquipmentMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosurePropertyPlantEquipmentNetSummaryOfPropertyPlantEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lab Equipment", "label": "Lab Equipment [Member]", "documentation": "Lab equipment member." } } }, "auth_ref": [] }, "vrax_LabSpaceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "LabSpaceMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lab Space", "label": "Lab Space [Member]", "documentation": "Lab space." } } }, "auth_ref": [] }, "vrax_LaboratoryEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "LaboratoryEquipmentMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Laboratory Equipment", "label": "Laboratory Equipment Member", "documentation": "Laboratory equipment." } } }, "auth_ref": [] }, "ifrs-full_LaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LaterThanFiveYearsMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "More Than Five Years", "label": "Later than five years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than five years." } } }, "auth_ref": [ "r152", "r153", "r164", "r239", "r240", "r242" ] }, "ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LaterThanFourYearsAndNotLaterThanFiveYearsMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesScheduleOfAnnualRentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "To June 30, 2028", "label": "Later than four years and not later than five years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than four years and not later than five years." } } }, "auth_ref": [ "r152", "r153", "r164", "r239", "r242", "r330" ] }, "ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LaterThanOneYearAndNotLaterThanFiveYearsMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "One to Five Years", "label": "Later than one year and not later than five years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than one year and not later than five years." } } }, "auth_ref": [ "r238", "r242" ] }, "ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LaterThanOneYearAndNotLaterThanTwoYearsMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesScheduleOfAnnualRentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "To June 30, 2025", "label": "Later than one year and not later than two years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than one year and not later than two years." } } }, "auth_ref": [ "r152", "r153", "r164", "r239", "r242", "r330" ] }, "ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LaterThanThreeYearsAndNotLaterThanFourYearsMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesScheduleOfAnnualRentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "To June 30, 2027", "label": "Later than three years and not later than four years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than three years and not later than four years." } } }, "auth_ref": [ "r152", "r153", "r164", "r239", "r242", "r330" ] }, "ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LaterThanTwoYearsAndNotLaterThanThreeYearsMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesScheduleOfAnnualRentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "To June 30, 2026", "label": "Later than two years and not later than three years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than two years and not later than three years." } } }, "auth_ref": [ "r152", "r153", "r164", "r239", "r242", "r330" ] }, "vrax_LeaseInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "LeaseInsurance", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease insurance", "label": "Lease insurance", "documentation": "Lease insurance." } } }, "auth_ref": [] }, "ifrs-full_LeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LeaseLiabilities", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesSummaryOfLeaseLiabilityActivityDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Liabilities", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "verboseLabel": "Annual rent", "label": "Lease liabilities", "totalLabel": "Total lease liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration." } } }, "auth_ref": [ "r146" ] }, "vrax_LeaseSecurityDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "LeaseSecurityDeposit", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Security deposit", "label": "Lease Security Deposit", "documentation": "Lease security deposit." } } }, "auth_ref": [] }, "vrax_LeaseServiceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "LeaseServiceCosts", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease service costs", "label": "Lease service costs", "documentation": "Lease service costs." } } }, "auth_ref": [] }, "vrax_LeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "LeaseTerm", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease term", "label": "Lease term", "documentation": "Lease term." } } }, "auth_ref": [] }, "ifrs-full_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Liabilities", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Liabilities", "negatedLabel": "Liabilities", "periodStartLabel": "Liabilities at beginning of period", "periodEndLabel": "Liabilities at end of period", "totalLabel": "Total liabilities" } }, "en": { "role": { "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r16", "r133", "r134", "r135", "r198", "r202" ] }, "ifrs-full_LiquidityRiskMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LiquidityRiskMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liquidity Risk", "label": "Liquidity risk [member]" } }, "en": { "role": { "documentation": "This member stands for the risk that an entity will encounter difficulty in meeting obligations associated with financial liabilities that are settled by delivering cash or another financial asset. [Refer: Financial assets; Financial liabilities]" } } }, "auth_ref": [ "r159", "r160", "r161", "r236" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "vrax_LogicoBioproductCorpMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "LogicoBioproductCorpMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Logico Bioproduct Corp", "label": "Logico Bioproduct Corp [Member]", "documentation": "Logico bioproduct corp." } } }, "auth_ref": [] }, "vrax_LogicoBioproductsCorpMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "LogicoBioproductsCorpMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFunctionalAndPresentationCurrencyDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfConsolidatedSubsidiariesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Logico Bioproducts Corp.", "label": "Logico Bioproducts Corp [Member]", "documentation": "Logico Bioproducts Corp." } } }, "auth_ref": [] }, "vrax_LogicoShanghaiMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "LogicoShanghaiMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Logico Shanghai", "label": "Logico Shanghai [Member]", "documentation": "Logico Shanghai." } } }, "auth_ref": [] }, "vrax_LossesAndUnutilizedCapitalAllowancesCarriedBackPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "LossesAndUnutilizedCapitalAllowancesCarriedBackPeriod", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Losses and unutilized capital allowances carried back period", "label": "Losses and unutilized capital allowances carried back period", "documentation": "Losses and unutilized capital allowances carried back period." } } }, "auth_ref": [] }, "vrax_LossesAndUnutilizedCapitalAllowancesCarriedBackSubjectToCap": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "LossesAndUnutilizedCapitalAllowancesCarriedBackSubjectToCap", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Losses and unutilized capital allowances carried back subject to cap", "label": "Losses and unutilized capital allowances carried back subject to cap", "documentation": "Losses and unutilized capital allowances carried back subject to cap." } } }, "auth_ref": [] }, "ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "MajorComponentsOfTaxExpenseIncomeAbstract", "lang": { "en-us": { "role": { "label": "Major components of tax expense (income) [abstract]" } } }, "auth_ref": [] }, "ifrs-full_MajorOrdinaryShareTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "MajorOrdinaryShareTransactionsMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Major Ordinary Share Transactions", "label": "Major ordinary share transactions [member]" } }, "en": { "role": { "documentation": "This member stands for major ordinary share transactions. [Refer: Ordinary shares [member]]" } } }, "auth_ref": [ "r218" ] }, "vrax_MarchPrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "MarchPrivatePlacementMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "March private placement.", "label": "March Private Placement [Member]", "terseLabel": "March Private Placement" } } }, "auth_ref": [] }, "vrax_MarkTernouthChiefTechnicalOfficerAndDirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "MarkTernouthChiefTechnicalOfficerAndDirectorMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartyCompensationForOfficersAndDirectorsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mark Ternouth, Chief Technical Officer and Director", "label": "Mark Ternouth, Chief Technical Officer and Director [Member]", "documentation": "Mark Ternouth, Chief Technical Officer and Director member." } } }, "auth_ref": [] }, "ifrs-full_MaturityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "MaturityAxis", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureCommitmentsScheduleOfCommitmentsForMinimumLeasePaymentsDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesScheduleOfAnnualRentDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Maturity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r19", "r142", "r152", "r153", "r156", "r157", "r158", "r164", "r183", "r191", "r221", "r239" ] }, "vrax_MaximumAmountToBeUtilizedOnLossCarryforwardInFutureYears": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "MaximumAmountToBeUtilizedOnLossCarryforwardInFutureYears", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum amount to be utilized on loss carryforward in future years", "label": "Maximum amount to be utilized on loss carryforward in future years", "documentation": "Maximum amount to be utilized on loss carryforward in future years." } } }, "auth_ref": [] }, "ifrs-full_MaximumExposureToCreditRisk": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "MaximumExposureToCreditRisk", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum credit exposure", "label": "Maximum exposure to credit risk" } }, "en": { "role": { "documentation": "The amount that best represents the maximum exposure to credit risk without taking into account any collateral held or other credit enhancements (for example, netting agreements that do not qualify for offset in accordance with IAS 32). [Refer: Credit risk [member]]" } } }, "auth_ref": [ "r189" ] }, "vrax_MaximumPercentageOfCurrentYearProfitUtilizedOnLossCarryforward": { "xbrltype": "percentItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "MaximumPercentageOfCurrentYearProfitUtilizedOnLossCarryforward", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum percentage of current year profit utilized on loss carryforward", "label": "Maximum percentage of current year profit utilized on loss carryforward", "documentation": "Maximum percentage of current year profit utilized on loss carryforward." } } }, "auth_ref": [] }, "vrax_MaximumPercentageOfTaxableIncomeToBeUtilizedInFutureYears": { "xbrltype": "percentItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "MaximumPercentageOfTaxableIncomeToBeUtilizedInFutureYears", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum percentage of taxable income to be utilized in future years", "label": "Maximum percentage of taxable income to be utilized in future years", "documentation": "Maximum percentage of taxable income to be utilized in future years." } } }, "auth_ref": [] }, "vrax_MaximumPeriodOfNetOperatingLossesCarriedForward": { "xbrltype": "durationItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "MaximumPeriodOfNetOperatingLossesCarriedForward", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum period of net operating losses carried forward", "label": "Maximum period of net operating losses carried forward", "documentation": "Maximum period of net operating losses carried forward." } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r290" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r290" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r310" ] }, "vrax_ModifiedStrikePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "ModifiedStrikePrice", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Modified strike price", "documentation": "Modified strike price." } } }, "auth_ref": [] }, "vrax_MonthlyLeasePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "MonthlyLeasePayment", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Monthly lease payment", "label": "Monthly Lease Payment", "documentation": "Monthly lease payment." } } }, "auth_ref": [] }, "vrax_MonthlyRentOnLeases": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "MonthlyRentOnLeases", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Monthly rent on leases", "label": "Monthly rent on leases", "documentation": "Monthly rent on leases." } } }, "auth_ref": [] }, "vrax_MrPatrickFosterFatherOfMrJamesFosterMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "MrPatrickFosterFatherOfMrJamesFosterMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mr. Patrick Foster, father of Mr. James Foster", "label": "Mr Patrick Foster Father Of Mr James Foster [Member]", "documentation": "Mr Patrick Foster Father Of Mr James Foster." } } }, "auth_ref": [] }, "vrax_MsAnneFosterMotherOfMrJamesFosterMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "MsAnneFosterMotherOfMrJamesFosterMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ms. Anne Foster, mother of Mr. James Foster", "label": "Ms Anne Foster mother Of Mr James Foster [Member]", "documentation": "Ms Anne Foster mother Of Mr James Foster." } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r318" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r291" ] }, "vrax_NelsonHaightIndependentDirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "NelsonHaightIndependentDirectorMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartyCompensationForOfficersAndDirectorsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nelson Haight, Independent Director", "label": "Nelson Haight, Independent Director [Member]", "documentation": "Nelson Haight, Independent Director member." } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)" } } }, "auth_ref": [] }, "vrax_NetProceedsFromIssueOfOrdinaryShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "NetProceedsFromIssueOfOrdinaryShares", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds", "label": "Net Proceeds From Issue Of Ordinary Shares", "documentation": "Net proceeds from issue of ordinary shares." } } }, "auth_ref": [] }, "vrax_NewShanghaiLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "NewShanghaiLeaseMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New Shanghai Lease", "label": "New Shanghai Lease [Member]", "documentation": "New Shanghai lease." } } }, "auth_ref": [] }, "vrax_NewWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "NewWarrantsMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "New Warrants [Member]", "terseLabel": "New Warrants", "documentation": "New warrants." } } }, "auth_ref": [] }, "vrax_NigelMccrackenChiefOperatingOfficerAndDirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "NigelMccrackenChiefOperatingOfficerAndDirectorMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartyCompensationForOfficersAndDirectorsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nigel McCracken, Chief Operating Officer and Director", "label": "Nigel McCracken, Chief Operating Officer and Director [Member]", "documentation": "Nigel McCracken, Chief Operating Officer and Director." } } }, "auth_ref": [] }, "vrax_NonCapitalLossesAvailableForFuturePeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "NonCapitalLossesAvailableForFuturePeriod", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxSummaryOfNetDeferredTaxAssetLiabilityDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxSummaryOfTemporaryDifferencesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-capital losses available for future period", "label": "Non Capital Losses Available For Future Period", "documentation": "Non capital losses available for future period.", "periodStartLabel": "Non-capital losses available for future period", "periodEndLabel": "Non-capital losses available for future period" } } }, "auth_ref": [] }, "vrax_NonCapitalLossesAvailableForFuturePeriodFiniteLived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "NonCapitalLossesAvailableForFuturePeriodFiniteLived", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxSummaryOfTemporaryDifferencesDetails" ], "lang": { "en-us": { "role": { "documentation": "Non capital losses available for future period finite lived.", "label": "Non Capital Losses Available For Future Period Finite Lived", "periodStartLabel": "Non-capital losses available for future period - finite", "periodEndLabel": "Non-capital losses available for future period - finite", "terseLabel": "Non-capital losses available for future period - finite" } } }, "auth_ref": [] }, "vrax_NonCashCompensationExpenseAllocatedBetweenGeneralAndAdministrativeAndResearchAndDevelopmentExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "NonCashCompensationExpenseAllocatedBetweenGeneralAndAdministrativeAndResearchAndDevelopmentExpenses", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash compensation expense allocated between general and administrative and research and development expenses", "label": "Non-cash compensation expense allocated between general and administrative and research and development expenses", "documentation": "Non-cash compensation expense allocated between general and administrative and research and development expenses." } } }, "auth_ref": [] }, "vrax_NonCashCompensationExpenseIncludedInGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "NonCashCompensationExpenseIncludedInGeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Non-cash compensation expense (included in general and administrative expense).", "label": "Non-Cash Compensation Expense (Included in General and Administrative Expense)", "terseLabel": "Non-cash compensation expense (included in general and administrative expense)" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r290" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r259", "r271", "r281", "r298", "r307" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r288" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r287" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r298" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r318" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r318" ] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodAxis", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Non-adjusting events after reporting period [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r41" ] }, "ifrs-full_NonadjustingEventsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NonadjustingEventsMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Non-adjusting events after reporting period [member]" } }, "en": { "role": { "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used." } } }, "auth_ref": [ "r41" ] }, "ifrs-full_NoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncontrollingInterests", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "verboseLabel": "Non-Controlling Interest", "label": "Non-controlling interests" } }, "en": { "role": { "documentation": "The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Subsidiaries [member]]" } } }, "auth_ref": [ "r14", "r116", "r121" ] }, "ifrs-full_NoncontrollingInterestsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncontrollingInterestsMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Non Controlling Interest" } }, "en": { "role": { "documentation": "This member stands for equity in a subsidiary not attributable, directly or indirectly, to the parent." } } }, "auth_ref": [ "r5" ] }, "ifrs-full_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentAssets", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current assets", "totalLabel": "Total non-current assets" } }, "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } } }, "auth_ref": [ "r20", "r124", "r228" ] }, "ifrs-full_NoncurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentAssetsAbstract", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current assets", "label": "Non-current assets [abstract]" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentLeaseLiabilities", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current operating lease liabilities", "label": "Non-current lease liabilities" } }, "en": { "role": { "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r146" ] }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentLiabilitiesAbstract", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current liabilities:", "label": "Non-current liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentTradeReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentTradeReceivables", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureAccountsReceivableSummaryOfAccountsReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable", "label": "Non-current trade receivables" } }, "en": { "role": { "documentation": "The amount of non-current trade receivables. [Refer: Trade receivables]" } } }, "auth_ref": [ "r214" ] }, "ifrs-full_NotLaterThanOneYearMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NotLaterThanOneYearMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureCommitmentsScheduleOfCommitmentsForMinimumLeasePaymentsDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesScheduleOfAnnualRentDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Less Than One Year", "verboseLabel": "To June 30, 2024", "terseLabel": "Fiscal year ending March 31, 2024" } }, "en": { "role": { "documentation": "This member stands for a time band of not later than one year." } } }, "auth_ref": [ "r18", "r152", "r153", "r164", "r239", "r242" ] }, "vrax_NotePayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "NotePayable", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureNotePayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Note payable.", "label": "Note Payable", "terseLabel": "Note payable" } } }, "auth_ref": [] }, "vrax_NovemberOrdinaryWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "NovemberOrdinaryWarrantsMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "November ordinary warrants.", "label": "November Ordinary Warrants [Member]", "terseLabel": "November Ordinary Warrants" } } }, "auth_ref": [] }, "vrax_NovemberPrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "NovemberPrivatePlacementMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "November private placement.", "label": "November Private Placement [Member]", "terseLabel": "November Private Placement" } } }, "auth_ref": [] }, "vrax_NumberOfCustomer": { "xbrltype": "integerItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "NumberOfCustomer", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Number of customer", "documentation": "Number of customer." } } }, "auth_ref": [] }, "vrax_NumberOfFractionalSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "NumberOfFractionalSharesIssued", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Number of fractional shares issued", "documentation": "Number of fractional shares issued." } } }, "auth_ref": [] }, "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityRelatedToOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments granted in share-based payment arrangement", "terseLabel": "Warrants Granted" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement." } } }, "auth_ref": [ "r178", "r353" ] }, "vrax_NumberOfOfficeAndLabSpacesLeased": { "xbrltype": "integerItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "NumberOfOfficeAndLabSpacesLeased", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of office and lab spaces leased", "label": "Number Of Office And Lab Spaces Leased", "documentation": "Number Of Office And Lab SpacesLeased." } } }, "auth_ref": [] }, "vrax_NumberOfOfficeSpacesLeased": { "xbrltype": "integerItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "NumberOfOfficeSpacesLeased", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of office spaces leased", "label": "Number of office spaces leased", "documentation": "Number of office spaces leased." } } }, "auth_ref": [] }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityRelatedToOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments exercisable in share-based payment arrangement", "terseLabel": "Warrants exercisable" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement." } } }, "auth_ref": [ "r353" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityRelatedToOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments exercised or vested in share-based payment arrangement", "negatedLabel": "Warrants Exercised" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement." } } }, "auth_ref": [ "r353" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityRelatedToOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments forfeited in share-based payment arrangement", "negatedLabel": "Warrants Cancelled" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement." } } }, "auth_ref": [ "r353" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityRelatedToOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments outstanding in share-based payment arrangement", "periodStartLabel": "Warrants outstanding, Beginning balance", "periodEndLabel": "Warrants outstanding, Ending balance" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement." } } }, "auth_ref": [ "r353" ] }, "ifrs-full_NumberOfOutstandingShareOptions": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfOutstandingShareOptions", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStatusOfOutstandingStockOptionsAndChangesDetails" ], "lang": { "en-us": { "role": { "label": "Number of share options outstanding in share-based payment arrangement", "periodStartLabel": "Beginning balance", "periodEndLabel": "Stock Options, Ending balance", "terseLabel": "Number of stock options outstanding" } }, "en": { "role": { "documentation": "The number of share options outstanding in a share-based payment arrangement." } } }, "auth_ref": [ "r165", "r170", "r174" ] }, "vrax_NumberOfPreFundedWarrantsIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "NumberOfPreFundedWarrantsIssued", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of pre-funded warrants issued.", "label": "Number of pre-funded warrants issued", "terseLabel": "Number of pre-funded warrants issued" } } }, "auth_ref": [] }, "vrax_NumberOfRemainingLeaseAgreement": { "xbrltype": "integerItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "NumberOfRemainingLeaseAgreement", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Number of remaining lease agreement", "documentation": "Number of remaining lease agreement." } } }, "auth_ref": [] }, "vrax_NumberOfReportableSegments1": { "xbrltype": "integerItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "NumberOfReportableSegments1", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reportable segment", "label": "Number Of Reportable Segments1", "documentation": "Number of reportable segments1." } } }, "auth_ref": [] }, "vrax_NumberOfRoomsLeased": { "xbrltype": "integerItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "NumberOfRoomsLeased", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of rooms leased", "label": "Number of rooms leased", "documentation": "Number of rooms leased." } } }, "auth_ref": [] }, "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStatusOfOutstandingStockOptionsAndChangesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options, Exercisable", "verboseLabel": "Nmber of stock options vested and exercisable", "label": "Number of share options exercisable in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options exercisable in a share-based payment arrangement." } } }, "auth_ref": [ "r171" ] }, "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStatusOfOutstandingStockOptionsAndChangesDetails" ], "lang": { "en-us": { "role": { "label": "Number of share options exercised in share-based payment arrangement", "terseLabel": "Exercised" } }, "en": { "role": { "documentation": "The number of share options exercised in a share-based payment arrangement." } } }, "auth_ref": [ "r168" ] }, "ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfShareOptionsExpiredInSharebasedPaymentArrangement", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStatusOfOutstandingStockOptionsAndChangesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Stock Options, Expired", "label": "Number of share options expired in share-based payment arrangement", "terseLabel": "Number of stock options cancelled" } }, "en": { "role": { "documentation": "The number of share options expired in a share-based payment arrangement." } } }, "auth_ref": [ "r169" ] }, "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStatusOfOutstandingStockOptionsAndChangesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Stock Options, Forfeiture", "negatedTerseLabel": "Stock options, forfeiture", "label": "Number of share options forfeited in share-based payment arrangement", "terseLabel": "Stock Options, Forfeiture and cancelled" } }, "en": { "role": { "documentation": "The number of share options forfeited in a share-based payment arrangement." } } }, "auth_ref": [ "r167" ] }, "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStatusOfOutstandingStockOptionsAndChangesDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Number of share options granted in share-based payment arrangement", "terseLabel": "Options issued", "verboseLabel": "Stock Options, Granted" } }, "en": { "role": { "documentation": "The number of share options granted in a share-based payment arrangement." } } }, "auth_ref": [ "r166" ] }, "ifrs-full_NumberOfSharesAuthorised": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfSharesAuthorised", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPositionParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares authorised", "label": "Number of shares authorised", "verboseLabel": "Grant of options and shares permits and available for issuance" } }, "en": { "role": { "documentation": "The number of shares authorised." } } }, "auth_ref": [ "r25" ] }, "ifrs-full_NumberOfSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfSharesIssued", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPositionParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares issued", "label": "Number of shares issued", "totalLabel": "Total number of shares issued" } }, "en": { "role": { "documentation": "The number of shares issued by the entity." } } }, "auth_ref": [ "r328" ] }, "vrax_NumberOfSharesIssuedForConversionOfConvertibleDebt": { "xbrltype": "sharesItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "NumberOfSharesIssuedForConversionOfConvertibleDebt", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued for conversion of convertible debt. shares", "label": "Number Of Shares Issued For Conversion Of Convertible Debt", "documentation": "Number of shares issued for conversion of convertible debt." } } }, "auth_ref": [] }, "vrax_NumberOfSharesIssuedForSettlementOfRelatedPartyAccruedInterest": { "xbrltype": "sharesItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "NumberOfSharesIssuedForSettlementOfRelatedPartyAccruedInterest", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares issued for settlement of related party accrued interest", "label": "Number of shares issued for settlement of related party accrued interest", "documentation": "Number of shares issued for settlement of related party accrued interest." } } }, "auth_ref": [] }, "vrax_NumberOfSharesIssuedForSettlementOfRelatedPartyPayable": { "xbrltype": "sharesItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "NumberOfSharesIssuedForSettlementOfRelatedPartyPayable", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Number of shares issued for settlement of related party payable", "documentation": "Number of shares issued for settlement of related party payable." } } }, "auth_ref": [] }, "ifrs-full_NumberOfSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfSharesOutstanding", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPositionParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares outstanding", "periodEndLabel": "Number of shares, ending balance", "periodStartLabel": "Number of shares, beginning balance", "label": "Number of shares outstanding" } }, "en": { "role": { "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]" } } }, "auth_ref": [ "r27" ] }, "vrax_NumberOfSharesSurrendered": { "xbrltype": "sharesItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "NumberOfSharesSurrendered", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Surrender of ViraxClear Shares, shares", "label": "Number Of Shares Surrendered", "documentation": "Number of shares surrendered." } } }, "auth_ref": [] }, "vrax_NumberOfSharesToBePurchasedByStockOptionsIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "NumberOfSharesToBePurchasedByStockOptionsIssued", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of shares to be purchased by stock options issued.", "label": "Number of Shares to be Purchased by Stock Options Issued", "terseLabel": "Number of shares to be purchased by stock options issued" } } }, "auth_ref": [] }, "vrax_NumberOfSuppliers": { "xbrltype": "integerItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "NumberOfSuppliers", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of suppliers", "label": "Number of suppliers", "documentation": "Number of suppliers." } } }, "auth_ref": [] }, "vrax_NumberOfVotesEntitled": { "xbrltype": "decimalItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "NumberOfVotesEntitled", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of votes entitled", "label": "Number of votes entitled", "documentation": "Number of votes entitled." } } }, "auth_ref": [] }, "vrax_NumberOfWarrantsCancelled": { "xbrltype": "sharesItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "NumberOfWarrantsCancelled", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants cancelled.", "label": "Number of warrants cancelled", "terseLabel": "Number of warrants cancelled" } } }, "auth_ref": [] }, "vrax_NumberOfWarrantsIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "NumberOfWarrantsIssued", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants issued.", "label": "Number of warrants issued", "terseLabel": "Number of warrants issued" } } }, "auth_ref": [] }, "vrax_OldShanghaiLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "OldShanghaiLeaseMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Old Shanghai Lease", "label": "Old Shanghai lease [Member]", "documentation": "Old Shanghai lease." } } }, "auth_ref": [] }, "vrax_OneOfTheOfficersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "OneOfTheOfficersMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "One of the Officers.", "label": "One of the Officers [member]", "terseLabel": "One of the Officers" } } }, "auth_ref": [] }, "vrax_OpenTaxYears": { "xbrltype": "gYearListItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "OpenTaxYears", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Open tax year", "label": "Open Tax Years", "documentation": "Open tax years" } } }, "auth_ref": [] }, "ifrs-full_OperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OperatingExpense", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating expense" } }, "en": { "role": { "documentation": "The amount of all operating expenses." } } }, "auth_ref": [ "r336" ] }, "vrax_OperatingExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "OperatingExpenseAbstract", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Operating expenses:", "documentation": "Operating expense [abstract]." } } }, "auth_ref": [] }, "vrax_OperatingLeaseAgreementCommencementDate": { "xbrltype": "stringItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "OperatingLeaseAgreementCommencementDate", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease agreement commencement date", "label": "Operating Lease Agreement Commencement Date", "documentation": "Operating lease agreement commencement date." } } }, "auth_ref": [] }, "vrax_OperatingLeaseAgreementTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "OperatingLeaseAgreementTerm", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease agreement term", "label": "Operating Lease Agreement Term", "documentation": "Operating lease agreement term." } } }, "auth_ref": [] }, "vrax_OptionsExercisableGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "OptionsExercisableGrantDateFairValue", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStatusOfOutstandingStockOptionsAndChangesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options, Grant Date Fair Value, Exercisable", "label": "Options Exercisable Grant Date Fair Value", "documentation": "Options exercisable grant date fair value." } } }, "auth_ref": [] }, "vrax_OptionsExpiredDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "OptionsExpiredDateFairValue", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStatusOfOutstandingStockOptionsAndChangesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options, Grant Date Fair Value, Expired", "label": "Options Expired Date Fair Value", "documentation": "Options expired date fair value." } } }, "auth_ref": [] }, "vrax_OptionsForfeitureAndCancelledGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "OptionsForfeitureAndCancelledGrantDateFairValue", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStatusOfOutstandingStockOptionsAndChangesDetails" ], "lang": { "en-us": { "role": { "documentation": "Options forfeiture and cancelled, grant date fair value.", "label": "Options Forfeiture and Cancelled, Grant Date Fair Value", "terseLabel": "Stock Options, Grant Date Fair Value, Forfeiture and cancelled" } } }, "auth_ref": [] }, "vrax_OptionsForfeitureGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "OptionsForfeitureGrantDateFairValue", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStatusOfOutstandingStockOptionsAndChangesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options, Grant Date Fair Value, Forfeiture", "label": "Options Forfeiture Grant Date Fair Value", "documentation": "Options forfeiture grant date fair value." } } }, "auth_ref": [] }, "vrax_OptionsGrantedAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "OptionsGrantedAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStatusOfOutstandingStockOptionsAndChangesDetails" ], "lang": { "en-us": { "role": { "documentation": "Options, granted, aggregate intrinsic value.", "label": "Options, Granted, Aggregate Intrinsic Value", "terseLabel": "Stock Options, Aggregate Intrinsic Value, Granted" } } }, "auth_ref": [] }, "vrax_OptionsGrantedGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "OptionsGrantedGrantDateFairValue", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStatusOfOutstandingStockOptionsAndChangesDetails" ], "lang": { "en-us": { "role": { "documentation": "Options granted, grant date fair value.", "label": "Options Granted, Grant Date Fair Value", "terseLabel": "Stock Options, Grant Date Fair Value, Granted" } } }, "auth_ref": [] }, "vrax_OptionsOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "OptionsOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStatusOfOutstandingStockOptionsAndChangesDetails" ], "lang": { "en-us": { "role": { "documentation": "Options, outstanding, aggregate intrinsic value.", "label": "Options, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Stock Options, Aggregate Intrinsic Value, Outstanding" } } }, "auth_ref": [] }, "vrax_OptionsOutstandingGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "OptionsOutstandingGrantDateFairValue", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStatusOfOutstandingStockOptionsAndChangesDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Stock Options, Grant Date Fair Value, Outstanding Ending Balance", "periodStartLabel": "Stock Options, Grant Date Fair Value, Outstanding Beginning Balance", "documentation": "Options outstanding, grant date fair value.", "label": "Options Outstanding, Grant Date Fair Value", "terseLabel": "Stock Options, Grant Date Fair Value, Outstanding" } } }, "auth_ref": [] }, "vrax_OrdinarySharesClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "OrdinarySharesClassAMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLossPerShareScheduleOfLossPerShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Class A Ordinary Shares", "terseLabel": "Class A", "label": "Ordinary Shares Class A", "documentation": "Ordinary shares class A." } } }, "auth_ref": [] }, "vrax_OrdinarySharesClassBMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "OrdinarySharesClassBMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLossPerShareScheduleOfLossPerShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Class B Ordinary Shares", "terseLabel": "Class B", "label": "Ordinary Shares Class B", "documentation": "Ordinary shares class b." } } }, "auth_ref": [] }, "vrax_OrdinarySharesConversionBasis": { "xbrltype": "stringItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "OrdinarySharesConversionBasis", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary shares conversion basis", "label": "Ordinary shares conversion basis", "documentation": "Ordinary shares conversion basis." } } }, "auth_ref": [] }, "vrax_OrdinarySharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "OrdinarySharesIssuedPricePerShare", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary shares issued price per share", "label": "Ordinary Shares Issued Price Per Share", "documentation": "Ordinary shares issued price per share." } } }, "auth_ref": [] }, "ifrs-full_OrdinarySharesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OrdinarySharesMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLossPerShareScheduleOfLossPerShareDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Ordinary shares [member]", "terseLabel": "Ordinary Shares" } }, "en": { "role": { "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used." } } }, "auth_ref": [ "r84", "r335" ] }, "ifrs-full_OtherComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherComprehensiveIncomeAbstract", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive loss:", "label": "Other comprehensive income [abstract]" } } }, "auth_ref": [] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "Foreign currency adjustment", "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations", "totalLabel": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r22", "r38" ] }, "vrax_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationAttributableToOwnersOfParent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationAttributableToOwnersOfParent", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency adjustment", "label": "Other comprehensive income, net of tax, exchange differences on translation attributable to owners of parent", "documentation": "Other comprehensive income, net of tax, exchange differences on translation attributable to owners of parent." } } }, "auth_ref": [] }, "vrax_OtherIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "OtherIncomeExpenseAbstract", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Other income (expense):", "documentation": "Other Income Expense [Abstract]" } } }, "auth_ref": [] }, "vrax_OtherIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "OtherIncomeExpenseNet", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Other Income Expense Net", "documentation": "Other Income Expense Net", "verboseLabel": "Other income (expense)" } } }, "auth_ref": [] }, "vrax_OtherIncomeExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "OtherIncomeExpenses", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Total other income (expense), net", "label": "Other Income Expenses", "documentation": "Other Income Expenses" } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r290" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r257", "r269", "r279", "r305" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r260", "r272", "r282", "r308" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r260", "r272", "r282", "r308" ] }, "ifrs-full_ParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ParValuePerShare", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPositionParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Par value per share", "verboseLabel": "Par value", "label": "Par value per share" } }, "en": { "role": { "documentation": "The nominal value per share." } } }, "auth_ref": [ "r26" ] }, "vrax_PatrickFosterMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "PatrickFosterMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartyPayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Patrick Foster", "label": "Patrick Foster [Member]", "documentation": "Patrick Foster." } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r286" ] }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Lease payments", "label": "Payments of lease liabilities, classified as financing activities", "negatedTerseLabel": "Payments of lease liabilities" } }, "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r226" ] }, "vrax_PaymentsOnNotePayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "PaymentsOnNotePayable", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Payments on note payable.", "label": "Payments on note payable", "negatedLabel": "Payments on note payable" } } }, "auth_ref": [] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r289" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r289" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r288" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r298" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r291" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r287" ] }, "vrax_PercentageOfCapitalOwned": { "xbrltype": "percentItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "PercentageOfCapitalOwned", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of capital owned", "label": "Percentage of capital owned", "documentation": "Percentage of capital owned." } } }, "auth_ref": [] }, "ifrs-full_PercentageOfEntitysRevenue": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PercentageOfEntitysRevenue", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percenatge of revenue", "label": "Percentage of entity's revenue" } }, "en": { "role": { "documentation": "The percentage of the entity's revenue. [Refer: Revenue]" } } }, "auth_ref": [ "r355" ] }, "vrax_PercentageOfPurchases": { "xbrltype": "percentItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "PercentageOfPurchases", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of purchases", "label": "Percentage of purchases", "documentation": "Percentage of purchases." } } }, "auth_ref": [] }, "vrax_PlacementAgentWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "PlacementAgentWarrantsMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Placement agent warrants.", "label": "Placement Agent Warrants [Member]", "terseLabel": "Placement Agent Warrants" } } }, "auth_ref": [] }, "vrax_PreFundedWarrantsToPurchaseOrdinaryShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "PreFundedWarrantsToPurchaseOrdinaryShares", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Pre-funded warrants to purchase ordinary shares.", "label": "Pre-funded warrants to purchase ordinary shares", "terseLabel": "Pre-funded warrants to purchase ordinary shares" } } }, "auth_ref": [] }, "vrax_PrepaidDirectorsAndOfficersInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "PrepaidDirectorsAndOfficersInsurance", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosurePrepaidExpensesAndDepositsSummaryOfPrepaidExpensesAndDepositsDetails" ], "lang": { "en-us": { "role": { "documentation": "Prepaid directors and officers insurance.", "label": "Prepaid directors and officers insurance" } } }, "auth_ref": [] }, "vrax_PrepaidExpensesAndDepositsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "PrepaidExpensesAndDepositsAbstract", "lang": { "en-us": { "role": { "documentation": "Prepaid expenses and deposits.", "label": "Prepaid Expenses And Deposits Abstract" } } }, "auth_ref": [] }, "vrax_PrepaidSecurityExchangeFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "PrepaidSecurityExchangeFee", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosurePrepaidExpensesAndDepositsSummaryOfPrepaidExpensesAndDepositsDetails" ], "lang": { "en-us": { "role": { "documentation": "Prepaid security exchange fee.", "label": "Prepaid Security Exchange Fee", "terseLabel": "Prepaid Nasdaq fee" } } }, "auth_ref": [] }, "ifrs-full_PresentationOfLeasesForLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PresentationOfLeasesForLesseeAbstract", "lang": { "en-us": { "role": { "label": "Presentation of leases for lessee [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProceedsFromExerciseOfWarrants", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Proceeds from warrant exercise", "terseLabel": "Net proceeds from exercise of warrants", "label": "Proceeds from exercise of warrants" } }, "en": { "role": { "documentation": "The cash inflow from the exercise of share purchase warrants." } } }, "auth_ref": [ "r347" ] }, "ifrs-full_ProceedsFromIssueOfOrdinaryShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProceedsFromIssueOfOrdinaryShares", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross proceeds", "label": "Proceeds from issue of ordinary shares" } }, "en": { "role": { "documentation": "The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]" } } }, "auth_ref": [ "r347" ] }, "ifrs-full_ProceedsFromIssuingShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProceedsFromIssuingShares", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Net proceeds", "terseLabel": "Proceeds from shares issuance for cash", "label": "Proceeds from issuing shares" } }, "en": { "role": { "documentation": "The cash inflow from issuing shares." } } }, "auth_ref": [ "r225" ] }, "vrax_ProceedsFromNotePayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "ProceedsFromNotePayable", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Proceeds from note payable.", "label": "Proceeds from note payable", "terseLabel": "Proceeds from note payable" } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersScheduleOfDisaggregationOfRevenueFromContractsWithCustomersDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [] }, "ifrs-full_ProductsAndServicesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProductsAndServicesAxis", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Products and services [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r204", "r231" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersScheduleOfDisaggregationOfRevenueFromContractsWithCustomersDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": [] }, "ifrs-full_ProductsAndServicesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProductsAndServicesMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Products and services [member]" } }, "en": { "role": { "documentation": "This member stands for the entity's products and services. It also represents the standard value for the 'Products and services' axis if no other member is used." } } }, "auth_ref": [ "r204", "r231" ] }, "ifrs-full_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfitLoss", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "negatedLabel": "Net loss", "terseLabel": "Net Loss", "label": "Profit (loss)" } }, "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r3", "r30", "r106", "r113", "r115", "r198", "r200", "r228", "r234" ] }, "ifrs-full_ProfitLossAttributableToNoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfitLossAttributableToNoncontrollingInterests", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedLabel": "Net loss attributable to non-controlling interest", "verboseLabel": "Net loss attributable to non-controlling interest", "label": "Profit (loss), attributable to non-controlling interests" } }, "en": { "role": { "documentation": "The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]" } } }, "auth_ref": [ "r32", "r120" ] }, "ifrs-full_ProfitLossAttributableToOwnersOfParent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfitLossAttributableToOwnersOfParent", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLossPerShareScheduleOfLossPerShareDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Loss for the year attributable to Virax", "verboseLabel": "Net loss attributable to Virax shareholders", "totalLabel": "Net loss attributable to Virax", "label": "Profit (loss), attributable to owners of parent" } }, "en": { "role": { "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r33" ] }, "ifrs-full_ProfitLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfitLossBeforeTax", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxReconciliationOfIncomeTaxesAtStatutoryRatesDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before income taxes", "terseLabel": "Earnings (loss) for the year", "label": "Income (loss) before income taxes" } }, "en": { "role": { "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r180", "r209", "r210", "r243", "r244" ] }, "ifrs-full_ProfitLossFromContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfitLossFromContinuingOperations", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assessable profit", "label": "Profit (loss) from continuing operations", "totalLabel": "Profit (loss) from continuing operations" } }, "en": { "role": { "documentation": "The profit (loss) from continuing operations. [Refer: Continuing operations [member]; Profit (loss)]" } } }, "auth_ref": [ "r30", "r128", "r198", "r200" ] }, "ifrs-full_ProfitLossFromOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfitLossFromOperatingActivities", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Operating loss", "verboseLabel": "Operating loss", "label": "Profit (loss) from operating activities" } }, "en": { "role": { "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r222", "r336" ] }, "ifrs-full_PropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosurePropertyPlantEquipmentNetSummaryOfPropertyPlantEquipmentNetDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant & equipment, net", "negatedPeriodEndLabel": "Balance", "negatedPeriodStartLabel": "Balance", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "label": "Property, plant and equipment", "totalLabel": "Total property, plant and equipment" } }, "en": { "role": { "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r8", "r56" ] }, "ifrs-full_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, plant and equipment [abstract]" } } }, "auth_ref": [] }, "ifrs-full_PropertyPlantAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PropertyPlantAndEquipmentMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosurePropertyPlantEquipmentNetSummaryOfPropertyPlantEquipmentNetDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, plant and equipment [member]" } }, "en": { "role": { "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r57", "r223", "r233" ] }, "ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProportionOfOwnershipInterestsHeldByNoncontrollingInterests", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfConsolidatedSubsidiariesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership", "label": "Proportion of ownership interests held by non-controlling interests" } }, "en": { "role": { "documentation": "The proportion of ownership interests in a subsidiary held by non-controlling interests. [Refer: Subsidiaries [member]; Non-controlling interests]" } } }, "auth_ref": [ "r119" ] }, "vrax_ProvisionForProfitTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "ProvisionForProfitTax", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Provision", "terseLabel": "Provision for profit tax", "documentation": "Provision for profit tax." } } }, "auth_ref": [] }, "vrax_PurchaseOfInternallyDevelopedSoftwareClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "PurchaseOfInternallyDevelopedSoftwareClassifiedAsInvestingActivities", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Investment - internally developed software", "terseLabel": "Investment - internally developed software", "label": "Purchase of internally Developed Software Classified As Investing Activities", "documentation": "Purchase of internally developed software classified as investing activities." } } }, "auth_ref": [] }, "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of property, plant & equipment", "label": "Purchase of property, plant and equipment, classified as investing activities" } }, "en": { "role": { "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r224" ] }, "vrax_PurchasePricePerOrdinaryShareAndAssociatedPreferredOptions": { "xbrltype": "perShareItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "PurchasePricePerOrdinaryShareAndAssociatedPreferredOptions", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Purchase price per ordinary share and associated preferred options.", "label": "Purchase price per ordinary share and associated preferred options", "terseLabel": "Purchase price per ordinary share and associated preferred options" } } }, "auth_ref": [] }, "vrax_PurchasePricePerPreFundedWarrantAndAssociatedPreferredOptions": { "xbrltype": "perShareItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "PurchasePricePerPreFundedWarrantAndAssociatedPreferredOptions", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Purchase price per pre-funded warrant and associated preferred options.", "label": "Purchase price per pre-funded warrant and associated preferred options", "terseLabel": "Purchase price per pre-funded warrant and associated preferred options" } } }, "auth_ref": [] }, "vrax_PurchaserMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "PurchaserMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Purchaser.", "label": "Purchaser [Member]", "terseLabel": "Purchaser" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r286" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r286" ] }, "ifrs-full_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RangeAxis", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfCalculationOfFairValueOfAwardsUsingBlackscholesOptionpricingModelAffectedByStockPriceOnDateOfGrant" ], "lang": { "en-us": { "role": { "label": "Range [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r137", "r158", "r174", "r229", "r230", "r354" ] }, "ifrs-full_RangesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RangesMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfCalculationOfFairValueOfAwardsUsingBlackscholesOptionpricingModelAffectedByStockPriceOnDateOfGrant" ], "lang": { "en-us": { "role": { "label": "Ranges [member]" } }, "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } } }, "auth_ref": [ "r137", "r158", "r174", "r229", "r230", "r354" ] }, "ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract", "lang": { "en-us": { "role": { "label": "Reconciliation of accounting profit multiplied by applicable tax rates [abstract]" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r252", "r264", "r274", "r300" ] }, "vrax_ReducedExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "ReducedExercisePrice", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Reduced exercise price", "documentation": "Reduced exercise price." } } }, "auth_ref": [] }, "ifrs-full_ReductionOfIssuedCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ReductionOfIssuedCapital", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Surrender of ViraxClear Shares", "label": "Reduction of issued capital" } }, "en": { "role": { "documentation": "The decrease in equity resulting from a reduction in issued capital. [Refer: Issued capital]" } } }, "auth_ref": [ "r328" ] }, "ifrs-full_RelatedPartiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RelatedPartiesMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Parties", "label": "Related parties [member]" } }, "en": { "role": { "documentation": "This member stands for related parties. Related parties are persons or entities that are related to the entity that is preparing its financial statements (the reporting entity). (a) A person or a close member of that person\u2019s family is related to a reporting entity if that person: (i) has control or joint control over the reporting entity; (ii) has significant influence over the reporting entity; or (iii) is a member of the key management personnel of the reporting entity or of a parent of the reporting entity. (b) An entity is related to a reporting entity if any of the following conditions applies: (i) The entity and the reporting entity are members of the same group (which means that each parent, subsidiary and fellow subsidiary is related to the others). (ii) One entity is an associate or joint venture of the other entity (or an associate or joint venture of a member of a group of which the other entity is a member). (iii) Both entities are joint ventures of the same third party. (iv) One entity is a joint venture of a third entity and the other entity is an associate of the third entity. (v) The entity is a post-employment benefit plan for the benefit of employees of either the reporting entity or an entity related to the reporting entity. If the reporting entity is itself such a plan, the sponsoring employers are also related to the reporting entity. (vi) The entity is controlled or jointly controlled by a person identified in (a). (vii) A person identified in (a)(i) has significant influence over the entity or is a member of the key management personnel of the entity (or of a parent of the entity). (viii) The entity, or any member of a group of which it is a part, provides key management personnel services to the reporting entity or to the parent of the reporting entity. [Refer: Joint ventures [member]; Key management personnel of entity or parent [member]]" } } }, "auth_ref": [ "r75" ] }, "vrax_RelatedPartyCompensationForOfficersAndDirectorsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "RelatedPartyCompensationForOfficersAndDirectorsTextBlock", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Related Party Compensation for Officers and Directors", "label": "Related Party Compensation for Officers and Directors [Text Block]", "documentation": "Related party compensation for Officers and Directors text block" } } }, "auth_ref": [] }, "ifrs-full_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related party transactions [abstract]" } } }, "auth_ref": [] }, "ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019": { "xbrltype": "durationItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIntangibleSoftwareNetScheduleOfSoftwareDevelopmentCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining Amortization Period", "label": "Remaining amortisation period of intangible assets material to entity" } }, "en": { "role": { "documentation": "The remaining amortisation period of individual intangible assets that are material to the entity\u2019s financial statements. [Refer: Depreciation and amortisation expense]" } } }, "auth_ref": [ "r97" ] }, "ifrs-full_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Research & development", "verboseLabel": "Research & Development", "label": "Research and development expense" } }, "en": { "role": { "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss." } } }, "auth_ref": [ "r98" ] }, "ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ReserveOfEquityComponentOfConvertibleInstrumentsMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Reserve of equity component of convertible instruments [member]", "terseLabel": "Shares for Conversion of Convertible Debt" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing components of convertible instruments classified as equity." } } }, "auth_ref": [ "r329" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r253", "r265", "r275", "r301" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r254", "r266", "r276", "r302" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r261", "r273", "r283", "r309" ] }, "ifrs-full_RetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RetainedEarnings", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "negatedLabel": "Accumulated deficit", "verboseLabel": "Accumulated deficit", "label": "Retained earnings", "totalLabel": "Total retained earnings" } }, "en": { "role": { "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r216", "r217" ] }, "ifrs-full_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RetainedEarningsMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Accumulated Deficit" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r5", "r211" ] }, "ifrs-full_Revenue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Revenue", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales", "label": "Revenue", "totalLabel": "Total revenue", "verboseLabel": "Revenue" } }, "en": { "role": { "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims." } } }, "auth_ref": [ "r36", "r127", "r180", "r195", "r199", "r204", "r205", "r207", "r209", "r210", "r228" ] }, "ifrs-full_RevenueFromContractsWithCustomers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RevenueFromContractsWithCustomers", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersScheduleOfDisaggregationOfRevenueFromContractsWithCustomersDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues", "label": "Revenue from contracts with customers", "verboseLabel": "Revenue" } }, "en": { "role": { "documentation": "The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity\u2019s ordinary activities in exchange for consideration." } } }, "auth_ref": [ "r139", "r140" ] }, "vrax_RightOfUseAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "RightOfUseAssetsNet", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesSummaryOfRightOfUseAssetsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Right-of-use assets, net", "documentation": "Right-of-use assets, net" } } }, "auth_ref": [] }, "ifrs-full_RightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RightofuseAssets", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesSummaryOfRightOfUseAssetsActivityDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets, net", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "label": "Right-of-use assets" } }, "en": { "role": { "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee." } } }, "auth_ref": [ "r145", "r150" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r318" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r318" ] }, "country_SG": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "SG", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Singapore", "label": "SINGAPORE" } } }, "auth_ref": [] }, "currency_SGD": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "SGD", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRiskManagementOverviewDisclosureOfMonetaryAssetsAndLiabilitiesDenominatedInForeignCurrenciesDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDisclosureOfEffectOfChangesInForeignExchangeRatesDetails" ], "lang": { "en-us": { "role": { "label": "Singapore, Dollars", "terseLabel": "Singapore Dollar", "verboseLabel": "SGD" } } }, "auth_ref": [] }, "vrax_SalesOfTestKitsInViraxClearMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "SalesOfTestKitsInViraxClearMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales of Test Kits in ViraxClear", "label": "Sales of Test Kits in Virax Clear [Member]", "documentation": "Sales of test kits in ViraxClear." } } }, "auth_ref": [] }, "vrax_SalesOfTestKitsInViraxVetMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "SalesOfTestKitsInViraxVetMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales of Test Kits in ViraxVet", "label": "Sales of Test Kits in Virax Vet [Member]", "documentation": "Sales of Test Kits in ViraxVet." } } }, "auth_ref": [] }, "vrax_ScheduleOfAnnualRentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "ScheduleOfAnnualRentTableTextBlock", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Annual Rent", "label": "Schedule of Annual Rent [Table Text Block]", "documentation": "Schedule of annual rent." } } }, "auth_ref": [] }, "vrax_ScheduleOfSoftwareDevelopmentCostsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "ScheduleOfSoftwareDevelopmentCostsTableTextBlock", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIntangibleSoftwareNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Software Development Costs", "label": "Schedule of software development costs [Table Text Block]", "documentation": "Schedule of software development costs." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r246" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r248" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "auth_ref": [] }, "vrax_SeriesAPreferredInvestmentOptionsToPurchaseOrdinaryShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "SeriesAPreferredInvestmentOptionsToPurchaseOrdinaryShares", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Series A preferred investment options to purchase ordinary shares.", "label": "Series A preferred investment options to purchase ordinary shares", "terseLabel": "Series A preferred investment options to purchase ordinary shares" } } }, "auth_ref": [] }, "vrax_SeriesBPreferredInvestmentOptionsToPurchaseOrdinaryShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "SeriesBPreferredInvestmentOptionsToPurchaseOrdinaryShares", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Series B preferred investment options to purchase ordinary shares.", "label": "Series B preferred investment options to purchase ordinary shares", "terseLabel": "Series B preferred investment options to purchase ordinary shares" } } }, "auth_ref": [] }, "vrax_ServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "ServicesMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Services", "label": "Services [Member]", "documentation": "Services." } } }, "auth_ref": [] }, "vrax_ShanghaiXituConsultingCoLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "ShanghaiXituConsultingCoLimitedMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFunctionalAndPresentationCurrencyDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfConsolidatedSubsidiariesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shanghai Xitu Consulting Co., Limited", "label": "Shanghai Xitu Consulting Co Limited [Member]", "documentation": "Shanghai xitu consulting co limited." } } }, "auth_ref": [] }, "vrax_ShanghaiXituConsultingCoLtdFkaShanghaiLogicoBioproductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "ShanghaiXituConsultingCoLtdFkaShanghaiLogicoBioproductsMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFunctionalAndPresentationCurrencyDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfConsolidatedSubsidiariesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shanghai Xitu Consulting Co., Ltd (FKA- Shanghai Logico Bioproducts)", "label": "Shanghai Xitu Consulting Co Ltd FKA Shanghai Logico Bioproducts [Member]", "documentation": "Shanghai Xitu Consulting Co Ltd FKA Shanghai Logico Bioproducts." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types" } } }, "auth_ref": [] }, "vrax_ShareBasedPaymentArrangementVestingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "ShareBasedPaymentArrangementVestingPeriod", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting period", "label": "Share Based Payment Arrangement Vesting Period", "documentation": "Share based payment arrangement vesting period." } } }, "auth_ref": [] }, "vrax_ShareConsolidationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "ShareConsolidationMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Consolidation", "label": "Share consolidation [Member]", "documentation": "Share consolidation." } } }, "auth_ref": [] }, "ifrs-full_ShareIssueRelatedCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ShareIssueRelatedCost", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Offering expenses", "label": "Share issue related cost" } }, "en": { "role": { "documentation": "The amount of cost related to the issuance of shares." } } }, "auth_ref": [ "r328" ] }, "vrax_SharePricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "SharePricePerShare", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share price per share", "label": "Share price per share", "documentation": "Share price per share." } } }, "auth_ref": [] }, "ifrs-full_SharebasedPaymentArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SharebasedPaymentArrangementsMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-based payment arrangements [member]" } }, "en": { "role": { "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used." } } }, "auth_ref": [ "r175" ] }, "vrax_SharesIssuedForConversionOfConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "SharesIssuedForConversionOfConvertibleDebt", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued for conversion of convertible debt", "label": "Shares issued for conversion of convertible debt", "documentation": "Shares issued for conversion of convertible debt." } } }, "auth_ref": [] }, "vrax_SharesIssuedForSettlementOfRelatedPartyAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "SharesIssuedForSettlementOfRelatedPartyAccruedInterest", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued for settlement of related party accrued interest", "label": "Shares issued for settlement of related party accrued interest", "documentation": "Shares issued for settlement of related party accrued interest." } } }, "auth_ref": [] }, "vrax_SharesIssuedForSettlementOfRelatedPartyPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "SharesIssuedForSettlementOfRelatedPartyPayable", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Shares issued for settlement of related party payable", "terseLabel": "Shares issued for settlement of related party payable", "label": "Shares issued for settlement of related party payable", "documentation": "Shares issued for settlement of related party payable." } } }, "auth_ref": [] }, "ifrs-full_SignificantInvestmentsInSubsidiariesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SignificantInvestmentsInSubsidiariesAxis", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFunctionalAndPresentationCurrencyDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfConsolidatedSubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Subsidiaries [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r80", "r82", "r132" ] }, "vrax_SingaporeCoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "SingaporeCoMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureContingentLiabilitiesAndContingentAssetsAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SingaporeCo", "label": "Singapore Co [Member]", "documentation": "Singapore co." } } }, "auth_ref": [] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of cash flows [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfChangesInEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of changes in equity [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfChangesInEquityLineItems", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement of changes in equity [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfChangesInEquityTable", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement of changes in equity [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } } }, "auth_ref": [ "r5" ] }, "ifrs-full_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of financial position [abstract]" } } }, "auth_ref": [] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r256", "r268", "r278", "r304" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)" } } }, "auth_ref": [] }, "vrax_StockIssuedDuringPeriodSharesCashlessWarrantExercise": { "xbrltype": "sharesItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "StockIssuedDuringPeriodSharesCashlessWarrantExercise", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "Cashless warrant exercise", "documentation": "Stock issued during period shares cashless warrant exercised.", "label": "Stock Issued During Period Shares Cashless Warrant Exercise", "terseLabel": "Cashless warrant exercise, shares" } } }, "auth_ref": [] }, "vrax_StockIssuedDuringPeriodSharesPreFundedWarrantExercise": { "xbrltype": "sharesItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "StockIssuedDuringPeriodSharesPreFundedWarrantExercise", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares pre-funded warrant exercise.", "label": "Stock Issued During Period Shares Pre-funded Warrant Exercise", "terseLabel": "Pre-funded warrant exercise, shares" } } }, "auth_ref": [] }, "vrax_StockIssuedDuringPeriodValueCashlessWarrantExercise": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "StockIssuedDuringPeriodValueCashlessWarrantExercise", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Stock issued during period value cashless warrant exercise.", "label": "Stock Issued During Period Value Cashless Warrant Exercise", "terseLabel": "Cashless warrant exercise" } } }, "auth_ref": [] }, "vrax_StockIssuedDuringPeriodValuePreFundedWarrantExercise": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "StockIssuedDuringPeriodValuePreFundedWarrantExercise", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Stock issued during period value pre-funded warrant exercise.", "label": "Stock Issued During Period Value Pre-funded Warrant Exercise", "terseLabel": "Pre-funded warrant exercise" } } }, "auth_ref": [] }, "vrax_StockIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "StockIssuedForServices", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Stock issued for services.", "label": "Stock issued for services", "terseLabel": "Stock issued for services" } } }, "auth_ref": [] }, "vrax_StockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "StockOptionsMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStatusOfOutstandingStockOptionsAndChangesDetails" ], "lang": { "en-us": { "role": { "documentation": "Stock options member.", "label": "Stock Options [Member]", "terseLabel": "Stock Options" } } }, "auth_ref": [] }, "vrax_StrikePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "StrikePrice", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Strike price", "documentation": "Strike price." } } }, "auth_ref": [] }, "ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract", "lang": { "en-us": { "role": { "label": "Subclassifications of assets, liabilities and equities [abstract]" } } }, "auth_ref": [] }, "vrax_SubscriptionReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "SubscriptionReceivableMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Subscription Receivable", "label": "Subscription Receivable [member]", "documentation": "Subscription Receivable." } } }, "auth_ref": [] }, "vrax_SubscriptionsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "SubscriptionsReceivable", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subscriptions receivable", "label": "Subscriptions receivable", "documentation": "Subscriptions receivable." } } }, "auth_ref": [] }, "vrax_SummaryOfCalculationOfFairValueOfAwardsUsingBlackScholesOptionPricingModelAffectedByStockPriceOnDateOfGrantAsWellAsAssumptionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "SummaryOfCalculationOfFairValueOfAwardsUsingBlackScholesOptionPricingModelAffectedByStockPriceOnDateOfGrantAsWellAsAssumptionsExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "documentation": "Summary of calculation of fair value of awards using black-scholes option-pricing model affected by stock price on date of grant as well as assumptions explanatory", "label": "Summary of Calculation of Fair Value of Awards using Black-Scholes Option-Pricing Model Affected by Stock price on Date of Grant as well as Assumptions Explanatory", "terseLabel": "Summary of Calculation of Fair Value of Awards using Black-Scholes Option-Pricing Model Affected by Stock Price on Date of Grant as well as Assumptions" } } }, "auth_ref": [] }, "vrax_SummaryOfDeferredRevenueExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "SummaryOfDeferredRevenueExplanatory", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureDeferredRevenueTables" ], "lang": { "en-us": { "role": { "documentation": "Summary of deferred revenue explanatory.", "label": "Summary of Deferred Revenue Explanatory", "terseLabel": "Summary of Deferred Revenue" } } }, "auth_ref": [] }, "vrax_SummaryOfSignificantAccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "SummaryOfSignificantAccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Summary Of Significant Accounting Policies [Abstract]", "documentation": "Summary of significant accounting policies." } } }, "auth_ref": [] }, "vrax_SupplementalDisclosureOfCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "SupplementalDisclosureOfCashFlowInformationAbstract", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of cash flow information", "label": "Supplemental disclosure of cash flow information [abstract]", "documentation": "Supplemental disclosure of cash flow information." } } }, "auth_ref": [] }, "vrax_SupplementalDisclosureOfNonCashInvestingAndFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "SupplementalDisclosureOfNonCashInvestingAndFinancingActivitiesAbstract", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:", "label": "Supplemental disclosure of non cash investing and financing activities [abstract]", "documentation": "Supplemental disclosure of non cash investing and financing activities." } } }, "auth_ref": [] }, "vrax_SupplierConcentrationOfRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "SupplierConcentrationOfRiskMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier Concentration Risk", "label": "Supplier Concentration of Risk [Member]", "documentation": "Supplier concentration of risk." } } }, "auth_ref": [] }, "vrax_SupplierInformation": { "xbrltype": "stringItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "SupplierInformation", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier information", "label": "Supplier information", "documentation": "Supplier information." } } }, "auth_ref": [] }, "vrax_SurrenderAmountDue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "SurrenderAmountDue", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Surrender amount due", "label": "Surrender amount due", "documentation": "Surrender amount due." } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r297" ] }, "vrax_TaxEffectOfExpectedIncomeTaxRecovery": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "TaxEffectOfExpectedIncomeTaxRecovery", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxReconciliationOfIncomeTaxesAtStatutoryRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected income tax (recovery)", "label": "Tax Effect Of Expected Income Tax Recovery", "documentation": "Tax effect of expected income tax recovery." } } }, "auth_ref": [] }, "ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxReconciliationOfIncomeTaxesAtStatutoryRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in unrecognized deductible temporary differences", "label": "Tax effect of expense not deductible in determining taxable profit (tax loss)" } }, "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to expenses not deductible in determining taxable profit (tax loss). [Refer: Accounting profit]" } } }, "auth_ref": [ "r44" ] }, "ifrs-full_TaxEffectOfForeignTaxRates": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TaxEffectOfForeignTaxRates", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxReconciliationOfIncomeTaxesAtStatutoryRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in statutory, foreign tax, foreign exchange rates and other", "label": "Tax effect of foreign tax rates" } }, "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer: Accounting profit]" } } }, "auth_ref": [ "r44" ] }, "vrax_TaxEffectOfPermanentDifferences": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "TaxEffectOfPermanentDifferences", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxReconciliationOfIncomeTaxesAtStatutoryRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Permanent Difference", "label": "Tax Effect Of Permanent Differences", "documentation": "Tax effect of permanent differences." } } }, "auth_ref": [] }, "vrax_TaxEffectOfProvisionToNetOperatingLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "TaxEffectOfProvisionToNetOperatingLosses", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxReconciliationOfIncomeTaxesAtStatutoryRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision to NOLs", "label": "Tax Effect Of Provision To Net Operating Losses", "documentation": "Tax effect of provision to net operating losses." } } }, "auth_ref": [] }, "ifrs-full_TemporaryDifferenceMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TemporaryDifferenceMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxSummaryOfTemporaryDifferencesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Temporary Differences", "label": "Temporary differences [member]" } }, "en": { "role": { "documentation": "This member stands for differences between the carrying amount of an asset or liability in the statement of financial position and its tax base. Temporary differences may be either: (a) taxable temporary differences; or (b) deductible temporary differences. [Refer: Carrying amount [member]]" } } }, "auth_ref": [ "r48" ] }, "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxSummaryOfTemporaryDifferencesDetails" ], "lang": { "en-us": { "role": { "label": "Temporary difference, unused tax losses and unused tax credits [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r48" ] }, "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxSummaryOfTemporaryDifferencesDetails" ], "lang": { "en-us": { "role": { "label": "Temporary difference, unused tax losses and unused tax credits [member]" } }, "en": { "role": { "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits. It also represents the standard value for the 'Temporary difference, unused tax losses and unused tax credits' axis if no other member is used. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } } }, "auth_ref": [ "r48" ] }, "vrax_ThirdPartyShareholdersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "ThirdPartyShareholdersMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Third Party Shareholders", "label": "Third Party Shareholders [Member]", "documentation": "Third party shareholders." } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "auth_ref": [] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "auth_ref": [] }, "ifrs-full_TopOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TopOfRangeMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfCalculationOfFairValueOfAwardsUsingBlackscholesOptionpricingModelAffectedByStockPriceOnDateOfGrant" ], "lang": { "en-us": { "role": { "label": "Top of range [member]", "terseLabel": "Top of Range" } }, "en": { "role": { "documentation": "This member stands for top of a range." } } }, "auth_ref": [ "r137", "r158", "r174", "r229", "r230", "r354" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r289" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r296" ] }, "ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TradeAndOtherCurrentPayablesToRelatedParties", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current payables to related parties", "verboseLabel": "Accounts payable - related parties" } }, "en": { "role": { "documentation": "The amount of current payables due to related parties. [Refer: Related parties [member]; Payables to related parties]" } } }, "auth_ref": [ "r334" ] }, "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Current trade payables" } }, "en": { "role": { "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]" } } }, "auth_ref": [ "r213", "r334" ] }, "ifrs-full_TradeAndOtherCurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TradeAndOtherCurrentReceivables", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Owing amount", "label": "Trade and other current receivables", "totalLabel": "Total trade and other current receivables" } }, "en": { "role": { "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]" } } }, "auth_ref": [ "r11", "r23" ] }, "ifrs-full_TradeAndOtherCurrentReceivablesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TradeAndOtherCurrentReceivablesAbstract", "lang": { "en-us": { "role": { "label": "Trade and other current receivables [abstract]" } } }, "auth_ref": [] }, "ifrs-full_TradeAndOtherReceivablesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TradeAndOtherReceivablesAbstract", "lang": { "en-us": { "role": { "label": "Trade and other receivables [abstract]" } } }, "auth_ref": [] }, "vrax_TradePayablesAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "TradePayablesAndAccruedLiabilities", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade payables and accrued liabilities", "label": "Trade payables and accrued liabilities", "documentation": "Trade payables and accrued liabilities." } } }, "auth_ref": [] }, "ifrs-full_TradeReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TradeReceivables", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureAccountsReceivableSummaryOfAccountsReceivableDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net account receivables", "verboseLabel": "Net account receivables", "terseLabel": "Accounts receivable from customers", "label": "Trade receivables" } }, "en": { "role": { "documentation": "The amount due from customers for goods and services sold." } } }, "auth_ref": [ "r214" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r317" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r319" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r320" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r321" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r319" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r319" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r322" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r320" ] }, "ifrs-full_TreasuryShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TreasuryShares", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury shares", "label": "Treasury shares", "negatedLabel": "Treasury shares" } }, "en": { "role": { "documentation": "An entity\u2019s own equity instruments, held by the entity or other members of the consolidated group." } } }, "auth_ref": [ "r83", "r216" ] }, "ifrs-full_TreasurySharesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TreasurySharesMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Treasury shares [member]", "terseLabel": "Treasury Shares" } }, "en": { "role": { "documentation": "This member stands for the entity\u2019s own equity instruments, held by the entity or other members of the consolidated group." } } }, "auth_ref": [ "r5" ] }, "vrax_TwoThousandAndTwentyThreePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "TwoThousandAndTwentyThreePlanMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "2023 plan member].", "label": "Two Thousand and Twenty Three Plan [Member]", "terseLabel": "2023 Plan" } } }, "auth_ref": [] }, "vrax_TwoThousandAndTwentyTwoPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "TwoThousandAndTwentyTwoPlanMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "2022 plan member.", "label": "Two Thousand and Twenty Two Plan [Member]", "terseLabel": "2022 Plan" } } }, "auth_ref": [] }, "vrax_TypeOfIntangibleAsset": { "xbrltype": "stringItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "TypeOfIntangibleAsset", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIntangibleSoftwareNetScheduleOfSoftwareDevelopmentCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Type of Intangible Asset", "label": "Type of intangible asset", "documentation": "Type of intangible asset." } } }, "auth_ref": [] }, "ifrs-full_TypesOfRisksAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TypesOfRisksAxis", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRiskManagementOverviewDisclosureOfMonetaryAssetsAndLiabilitiesDenominatedInForeignCurrenciesDetails" ], "lang": { "en-us": { "role": { "label": "Types of risks [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r159", "r160", "r161", "r163", "r181", "r184", "r185" ] }, "ifrs-full_TypesOfRisksMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TypesOfRisksMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRiskManagementOverviewDisclosureOfMonetaryAssetsAndLiabilitiesDenominatedInForeignCurrenciesDetails" ], "lang": { "en-us": { "role": { "label": "Risks [member]" } }, "en": { "role": { "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used." } } }, "auth_ref": [ "r159", "r160", "r161", "r163", "r181", "r184", "r185" ] }, "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TypesOfSharebasedPaymentArrangementsAxis", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Types of share-based payment arrangements [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r175" ] }, "ifrs-full_UndiscountedOperatingLeasePaymentsToBeReceived": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "UndiscountedOperatingLeasePaymentsToBeReceived", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureCommitmentsScheduleOfCommitmentsForMinimumLeasePaymentsDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total lease payments", "label": "Undiscounted operating lease payments to be received" } }, "en": { "role": { "documentation": "The amount of undiscounted operating lease payments to be received. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset." } } }, "auth_ref": [ "r153" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r316" ] }, "vrax_UnfiledCurrentValueAddedTaxReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "UnfiledCurrentValueAddedTaxReceivables", "crdr": "debit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureVatReceivableAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureVatReceivableSummaryOfVatReceivableDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Unfiled VAT receivable with HMRC", "terseLabel": "Unfiled VAT receivable", "label": "Unfiled Current Value Added Tax Receivables", "documentation": "Unfiled current value added tax receivables." } } }, "auth_ref": [] }, "ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureIncomeTaxSummaryOfNetDeferredTaxAssetLiabilityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Unrecognized deferred tax assets", "verboseLabel": "Unrecognized deferred tax assets", "terseLabel": "Unrecognized deferred tax asset from net operating losses", "label": "Unused tax losses for which no deferred tax asset recognised" } }, "en": { "role": { "documentation": "The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]" } } }, "auth_ref": [ "r46" ] }, "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment": { "xbrltype": "durationItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated useful lives", "label": "Useful life measured as period of time, property, plant and equipment" } }, "en": { "role": { "documentation": "The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r50" ] }, "country_VG": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "VG", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "British Virgin Island", "label": "VIRGIN ISLANDS, BRITISH" } } }, "auth_ref": [] }, "vrax_ViraxBiolabsFzLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "ViraxBiolabsFzLlcMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFunctionalAndPresentationCurrencyDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfConsolidatedSubsidiariesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Virax Biolabs FZ-LLC", "label": "Virax Biolabs FZ-LLC [Member]", "documentation": "Virax Biolabs FZ-LLC." } } }, "auth_ref": [] }, "vrax_ViraxBiolabsGroupHoldingsLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "ViraxBiolabsGroupHoldingsLtdMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFunctionalAndPresentationCurrencyDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfConsolidatedSubsidiariesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Virax Biolabs Group Holdings Ltd", "label": "Virax Biolabs Group Holdings Ltd [Member]", "documentation": "Virax Biolabs Group Holdings Ltd." } } }, "auth_ref": [] }, "vrax_ViraxBiolabsGroupLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "ViraxBiolabsGroupLimitedMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFunctionalAndPresentationCurrencyDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfConsolidatedSubsidiariesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Virax Biolabs Group Limited", "label": "Virax Biolabs Group Limited [Member]", "documentation": "Virax biolabs group limited." } } }, "auth_ref": [] }, "vrax_ViraxBiolabsHkcoLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "ViraxBiolabsHkcoLimitedMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Virax Biolabs HKCo Limited", "label": "Virax Biolabs HKCo Limited [Member]", "documentation": "Virax biolabs hkco limited." } } }, "auth_ref": [] }, "vrax_ViraxBiolabsLimitedFkaShanghaiBiotechnologyDevicesLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "ViraxBiolabsLimitedFkaShanghaiBiotechnologyDevicesLtdMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFunctionalAndPresentationCurrencyDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfConsolidatedSubsidiariesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Virax Biolabs Limited (FKA- Shanghai Biotechnology Devices Ltd)", "label": "Virax Biolabs Limited FKA Shanghai Biotechnology Devices Ltd [Member]", "documentation": "Virax Biolabs Limited FKA Shanghai Biotechnology Devices Ltd." } } }, "auth_ref": [] }, "vrax_ViraxBiolabsLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "ViraxBiolabsLimitedMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFunctionalAndPresentationCurrencyDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfConsolidatedSubsidiariesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Virax Biolabs Limited", "label": "Virax Biolabs Limited [Member]", "documentation": "Virax biolabs limited.", "terseLabel": "Virax Biolabs Group Limited" } } }, "auth_ref": [] }, "vrax_ViraxBiolabsPteLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "ViraxBiolabsPteLimitedMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFunctionalAndPresentationCurrencyDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfConsolidatedSubsidiariesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Virax Biolabs Pte. Limited", "label": "Virax Biolabs Pte Limited [Member]", "documentation": "Virax biolabs pte limited." } } }, "auth_ref": [] }, "vrax_ViraxBiolabsTradingBVMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "ViraxBiolabsTradingBVMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFunctionalAndPresentationCurrencyDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfConsolidatedSubsidiariesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Virax Biolabs Trading B.V.", "label": "Virax Biolabs Trading B.V. [Member]", "documentation": "Virax Biolabs Trading B.V." } } }, "auth_ref": [] }, "vrax_ViraxBiolabsUkLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "ViraxBiolabsUkLimitedMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFunctionalAndPresentationCurrencyDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfConsolidatedSubsidiariesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Virax Biolabs (UK) Limited", "label": "Virax Biolabs UK Limited [Member]", "documentation": "Virax biolabs uk limited." } } }, "auth_ref": [] }, "vrax_ViraxBiolabsUkOperatingLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "ViraxBiolabsUkOperatingLimitedMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFunctionalAndPresentationCurrencyDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfConsolidatedSubsidiariesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Virax Biolabs UK Operating LLC", "terseLabel": "Virax Biolabs UK Operating Limited", "label": "Virax Biolabs UK Operating Limited [Member]", "documentation": "Virax Biolabs UK Operating Limited." } } }, "auth_ref": [] }, "vrax_ViraxBiolabsUsaManagementIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "ViraxBiolabsUsaManagementIncMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFunctionalAndPresentationCurrencyDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfConsolidatedSubsidiariesDetails" ], "lang": { "en-us": { "role": { "documentation": "Virax Biolabs USA Management, Inc.", "label": "Virax Biolabs USA Management, Inc. [Member]", "terseLabel": "Virax Biolabs USA Management, Inc." } } }, "auth_ref": [] }, "vrax_ViraxCaymanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "ViraxCaymanMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Virax Cayman", "label": "Virax Cayman [Member]", "documentation": "Virax cayman." } } }, "auth_ref": [] }, "vrax_ViraxClearAndViraxCareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "ViraxClearAndViraxCareMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "ViraxClear and ViraxCare Revenue", "documentation": "Virax clear and virax care." } } }, "auth_ref": [] }, "vrax_ViraxClearMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "ViraxClearMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersScheduleOfDisaggregationOfRevenueFromContractsWithCustomersDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "ViraxClear", "terseLabel": "Virax Clear", "label": "Virax Clear Member", "documentation": "Virax Clear." } } }, "auth_ref": [] }, "vrax_ViraxImmuneTCellMedicalDeviceCompanyLimitedFkaStorkNutritionAsiaLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "ViraxImmuneTCellMedicalDeviceCompanyLimitedFkaStorkNutritionAsiaLimitedMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFunctionalAndPresentationCurrencyDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfConsolidatedSubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Virax Immune T Cell Medical Device Company Limited FKA Stork Nutrition Asia Limited [Member]", "documentation": "Virax Immune T Cell Medical Device Company Limited FKA Stork Nutrition Asia Limited.", "terseLabel": "ViraxImmune T-Cell Medical Device Company Limited (FKA- Stork Nutrition Asia Limited)" } } }, "auth_ref": [] }, "vrax_ViraxImmuneTCellMedicalDeviceCompanyLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "ViraxImmuneTCellMedicalDeviceCompanyLimitedMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFunctionalAndPresentationCurrencyDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfConsolidatedSubsidiariesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Virax Immune T- Cell Medical Device Company Limited", "label": "Virax Immune T Cell Medical Device Company Limited [Member]", "documentation": "Virax immune t cell medical device company limited." } } }, "auth_ref": [] }, "vrax_ViraxVetMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "ViraxVetMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ViraxVet", "label": "Virax Vet [Member]", "documentation": "ViraxVet." } } }, "auth_ref": [] }, "vrax_WarrantExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "WarrantExercisePrice", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Warrant exercise price", "documentation": "Warrant exercise price." } } }, "auth_ref": [] }, "vrax_WarrantsIssuedPurchasePricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "WarrantsIssuedPurchasePricePerShare", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Warrants issued purchase price per share.", "label": "Warrants issued purchase price per share", "terseLabel": "Warrants issued purchase price per share" } } }, "auth_ref": [] }, "ifrs-full_WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WarrantsMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityRelatedToOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants", "label": "Warrants [member]" } }, "en": { "role": { "documentation": "This member stands for a class of antidilutive instrument representing warrants." } } }, "auth_ref": [ "r341" ] }, "vrax_WarrantsPurchased": { "xbrltype": "sharesItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "WarrantsPurchased", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Warrants purchased", "documentation": "Warrants purchased." } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityRelatedToOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of other equity instruments exercisable in share-based payment arrangement", "periodEndLabel": "Weighted Average Exercise Price, Ending balance", "terseLabel": "Weighted Average Exercise Price, Warrants exercisable" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r353" ] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityRelatedToOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement", "terseLabel": "Weighted Average Exercise Price, Warrants Exercised" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r353" ] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityRelatedToOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of other equity instruments forfeited in share-based payment arrangement", "terseLabel": "Weighted Average Exercise Price, Warrants Cancelled" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r353" ] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityRelatedToOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of other equity instruments granted in share-based payment arrangement", "terseLabel": "Weighted Average Exercise Price, Warrants Granted" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) granted in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r353" ] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityRelatedToOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement", "periodEndLabel": "Weighted Average Exercise Price, Warrants Ending balance", "periodStartLabel": "Weighted Average Exercise Price, Warrants Beginning balance" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r353" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStatusOfOutstandingStockOptionsAndChangesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options, Exercise price, Exercisable", "label": "Weighted average exercise price of share options exercisable in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r171" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStatusOfOutstandingStockOptionsAndChangesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options, Exercise price, Expired", "label": "Weighted average exercise price of share options expired in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options expired in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r169" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStatusOfOutstandingStockOptionsAndChangesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options, Exercise price, Forfeiture", "label": "Weighted average exercise price of share options forfeited in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r167" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStatusOfOutstandingStockOptionsAndChangesDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of share options granted in share-based payment arrangement", "terseLabel": "Stock Options, Exercise price, Granted" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r166" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStatusOfOutstandingStockOptionsAndChangesDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement", "periodStartLabel": "Stock Options, Exercise price, Beginning balance", "periodEndLabel": "Stock Options, Exercise price, Ending balance" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r165", "r170" ] }, "ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageFairValueAtMeasurementDateShareOptionsGranted", "crdr": "credit", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average fair value at measurement date, share options granted", "terseLabel": "Fair value" } }, "en": { "role": { "documentation": "The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r177" ] }, "vrax_WeightedAverageRemainingContractualLifeOfOtherEquityInstuments": { "xbrltype": "durationItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "WeightedAverageRemainingContractualLifeOfOtherEquityInstuments", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityRelatedToOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Life (Years)", "documentation": "Weighted average remaining contractual life of other equity instuments.", "label": "Weighted average remaining contractual life of other equity instuments" } } }, "auth_ref": [] }, "vrax_WeightedAverageRemainingContractualLifeOfOtherEquityInstumentsVestedAndExercisable": { "xbrltype": "durationItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "WeightedAverageRemainingContractualLifeOfOtherEquityInstumentsVestedAndExercisable", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityRelatedToOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual life of other equity instuments vested and exercisable.", "label": "Weighted average remaining contractual life of other equity instuments vested and exercisable", "terseLabel": "Weighted Average Remaining Contractual Life (Years), Warrants exercisable" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": { "xbrltype": "durationItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStatusOfOutstandingStockOptionsAndChangesDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average remaining contractual life of outstanding share options", "terseLabel": "Stock Options, Weighted Average Remaining Term (Years), Outstanding" } }, "en": { "role": { "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r174" ] }, "vrax_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019Exercisable": { "xbrltype": "durationItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019Exercisable", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStatusOfOutstandingStockOptionsAndChangesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options, Weighted Average Remaining Term (Years), Exercisable", "label": "Weighted Average Remaining Contractual Life Of Outstanding Share Options 2019 Exercisable", "documentation": "Weighted average remaining contractual life of outstanding share options 2019 exercisable." } } }, "auth_ref": [] }, "vrax_WeightedAverageRemainingContractualLifeOfShareOptionsGranted": { "xbrltype": "durationItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "WeightedAverageRemainingContractualLifeOfShareOptionsGranted", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStatusOfOutstandingStockOptionsAndChangesDetails" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual life of share options granted.", "label": "Weighted Average Remaining Contractual Life of Share Options, Granted", "terseLabel": "Stock Options, Weighted Average Remaining Term (Years), Granted" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageSharePrice2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageSharePrice2019", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average price of shares", "label": "Weighted average share price" } }, "en": { "role": { "documentation": "The weighted average share price. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r173" ] }, "ifrs-full_WeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageShares", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureLossPerShareScheduleOfDilutedLossPerShareDetails", "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average number of ordinary shares used in basic and diluted loss per share (Ordinary shares)", "label": "Weighted average number of ordinary shares used in calculating basic earnings per share", "terseLabel": "Ordinary shares" } }, "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } } }, "auth_ref": [ "r86" ] }, "ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "verboseLabel": "Basic and diluted weighted average shares outstanding", "label": "Weighted average ordinary shares used in calculating basic and diluted earnings per share [abstract]" } } }, "auth_ref": [] }, "vrax_YairErezIndependentDirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://www.viraxbiolabs.com/20240331", "localname": "YairErezIndependentDirectorMember", "presentation": [ "http://www.viraxbiolabs.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartyCompensationForOfficersAndDirectorsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Yair Erez, Independent Director", "label": "Yair Erez, Independent Director [Member]", "documentation": "Yair Erez, Independent Director member." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard", "URIDate": "2023-03-23" }, "r1": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_104&doctype=Standard", "URIDate": "2023-03-23" }, "r2": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_a&doctype=Standard", "URIDate": "2023-03-23" }, "r3": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_i&doctype=Standard", "URIDate": "2023-03-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r5": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106&doctype=Standard", "URIDate": "2023-03-23" }, "r6": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "41", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_41&doctype=Standard", "URIDate": "2023-03-23" }, "r7": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "51", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_51&doctype=Standard", "URIDate": "2023-03-23" }, "r8": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_a&doctype=Standard", "URIDate": "2023-03-23" }, "r9": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_c&doctype=Standard", "URIDate": "2023-03-23" }, "r10": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_g&doctype=Standard", "URIDate": "2023-03-23" }, "r11": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_h&doctype=Standard", "URIDate": "2023-03-23" }, "r12": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_i&doctype=Standard", "URIDate": "2023-03-23" }, "r13": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "o", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_o&doctype=Standard", "URIDate": "2023-03-23" }, "r14": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "q", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_q&doctype=Standard", "URIDate": "2023-03-23" }, "r15": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "r", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_r&doctype=Standard", "URIDate": "2023-03-23" }, "r16": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard", "URIDate": "2023-03-23" }, "r17": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "56", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_56&doctype=Standard", "URIDate": "2023-03-23" }, "r18": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "61", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61_a&doctype=Standard", "URIDate": "2023-03-23" }, "r19": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "61", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61&doctype=Standard", "URIDate": "2023-03-23" }, "r20": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard", "URIDate": "2023-03-23" }, "r21": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "69", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_69&doctype=Standard", "URIDate": "2023-03-23" }, "r22": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard", "URIDate": "2023-03-23" }, "r23": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2023-03-23" }, "r24": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2023-03-23" }, "r25": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_i&doctype=Standard", "URIDate": "2023-03-23" }, "r26": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r27": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_iv&doctype=Standard", "URIDate": "2023-03-23" }, "r28": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2023-03-23" }, "r29": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79&doctype=Standard", "URIDate": "2023-03-23" }, "r30": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "81A", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_a&doctype=Standard", "URIDate": "2023-03-23" }, "r31": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "81A", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_c&doctype=Standard", "URIDate": "2023-03-23" }, "r32": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "81B", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81B_a_i&doctype=Standard", "URIDate": "2023-03-23" }, "r33": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "81B", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81B_a_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r34": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "81B", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81B_b_i&doctype=Standard", "URIDate": "2023-03-23" }, "r35": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "81B", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81B_b_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r36": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "82", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_a&doctype=Standard", "URIDate": "2023-03-23" }, "r37": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "82", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_d&doctype=Standard", "URIDate": "2023-03-23" }, "r38": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "91", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_91_a&doctype=Standard", "URIDate": "2023-03-23" }, "r39": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "98", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_98_a&doctype=Standard", "URIDate": "2023-03-23" }, "r40": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "99", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_99&doctype=Standard", "URIDate": "2023-03-23" }, "r41": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2023-01-01", "Paragraph": "21", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&anchor=para_21&doctype=Standard", "URIDate": "2023-03-23" }, "r42": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI", "URIDate": "2023-03-23" }, "r43": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_79&doctype=Standard", "URIDate": "2023-03-23" }, "r44": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2023-03-23" }, "r45": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r46": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_e&doctype=Standard", "URIDate": "2023-03-23" }, "r47": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "g", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g_i&doctype=Standard", "URIDate": "2023-03-23" }, "r48": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g&doctype=Standard", "URIDate": "2023-03-23" }, "r49": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI", "URIDate": "2023-03-23" }, "r50": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_c&doctype=Standard", "URIDate": "2023-03-23" }, "r51": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2023-03-23" }, "r52": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_i&doctype=Standard", "URIDate": "2023-03-23" }, "r53": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r54": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_vii&doctype=Standard", "URIDate": "2023-03-23" }, "r55": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_viii&doctype=Standard", "URIDate": "2023-03-23" }, "r56": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2023-03-23" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73&doctype=Standard", "URIDate": "2023-03-23" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "75", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_75_a&doctype=Standard", "URIDate": "2023-03-23" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "75", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_75_b&doctype=Standard", "URIDate": "2023-03-23" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI", "URIDate": "2023-03-23" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "36", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_36_a&doctype=Standard", "URIDate": "2023-03-23" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "36", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_36_b&doctype=Standard", "URIDate": "2023-03-23" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "36", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_36_d&doctype=Standard", "URIDate": "2023-03-23" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "36", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_36_e&doctype=Standard", "URIDate": "2023-03-23" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "2", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS02_g36-39_TI", "URIDate": "2023-03-23" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2023-01-01", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_53&doctype=Standard", "URIDate": "2023-03-23" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2023-01-01", "Paragraph": "57", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_57_c&doctype=Standard", "URIDate": "2023-03-23" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS21_g51-57_TI", "URIDate": "2023-03-23" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17_c&doctype=Standard", "URIDate": "2023-03-23" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2023-03-23" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17&doctype=Standard", "URIDate": "2023-03-23" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "18", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2023-03-23" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "18", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_18&doctype=Standard", "URIDate": "2023-03-23" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "18A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_18A&doctype=Standard", "URIDate": "2023-03-23" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "19", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19&doctype=Standard", "URIDate": "2023-03-23" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard", "URIDate": "2023-03-23" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Section": "Disclosures", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI", "URIDate": "2023-03-23" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2023-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2023-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2023-03-23" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2023-01-01", "Paragraph": "16", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2023-01-01", "Paragraph": "16", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b&doctype=Standard", "URIDate": "2023-03-23" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2023-03-23" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "32", "IssueDate": "2023-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard", "URIDate": "2023-03-23" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2023-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard", "URIDate": "2023-03-23" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2023-01-01", "Paragraph": "67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_67&doctype=Standard", "URIDate": "2023-03-23" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2023-01-01", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2023-03-23" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI", "URIDate": "2023-03-23" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard", "URIDate": "2023-03-23" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "130", "Subparagraph": "d", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_130_d_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2023-01-01", "Paragraph": "86", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_86&doctype=Standard", "URIDate": "2023-03-23" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_b&doctype=Standard", "URIDate": "2023-03-23" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2023-03-23" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_i&doctype=Standard", "URIDate": "2023-03-23" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_iv&doctype=Standard", "URIDate": "2023-03-23" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2023-03-23" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118&doctype=Standard", "URIDate": "2023-03-23" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "122", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_122_b&doctype=Standard", "URIDate": "2023-03-23" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard", "URIDate": "2023-03-23" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS38_g118-128_TI", "URIDate": "2023-03-23" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2023-01-01", "Paragraph": "76", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_76&doctype=Standard", "URIDate": "2023-03-23" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2023-03-23" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_d&doctype=Standard", "URIDate": "2023-03-23" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2023-01-01", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_50&doctype=Standard", "URIDate": "2023-03-23" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2023-03-23" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_10&doctype=Standard", "URIDate": "2023-03-23" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "18", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2023-03-23" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_31&doctype=Standard", "URIDate": "2023-03-23" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "40", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_40_a&doctype=Standard", "URIDate": "2023-03-23" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard", "URIDate": "2023-03-23" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "46", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_46&doctype=Standard", "URIDate": "2023-03-23" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "50", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2023-03-23" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2023-03-23" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2023-03-23" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2023-03-23" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "10", "IssueDate": "2023-01-01", "Paragraph": "22", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=10&code=ifrs-tx-2023-en-r&anchor=para_22&doctype=Standard", "URIDate": "2023-03-23" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "11", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_11_a&doctype=Standard", "URIDate": "2023-03-23" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_12_b&doctype=Standard", "URIDate": "2023-03-23" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "12", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_12_c&doctype=Standard", "URIDate": "2023-03-23" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "12", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_12_e&doctype=Standard", "URIDate": "2023-03-23" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "12", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_12_f&doctype=Standard", "URIDate": "2023-03-23" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "19B", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_19B_b&doctype=Standard", "URIDate": "2023-03-23" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ix", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_vi&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B13", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B13", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_d&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B13", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B4", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2023-03-23" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2023-03-23" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2023-03-23" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93&doctype=Standard", "URIDate": "2023-03-23" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "14", "IssueDate": "2023-01-01", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2023-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2023-03-23" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "105", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_105&doctype=Standard", "URIDate": "2023-03-23" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "113", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_113_a&doctype=Standard", "URIDate": "2023-03-23" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "114", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_114&doctype=Standard", "URIDate": "2023-03-23" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "116", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_116_a&doctype=Standard", "URIDate": "2023-03-23" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "120", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_120_b_i&doctype=Standard", "URIDate": "2023-03-23" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS15_g110-129_TI", "URIDate": "2023-03-23" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Section": "Presentation", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS15_g105-109_TI", "URIDate": "2023-03-23" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2023-03-23" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2023-03-23" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "53", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_b&doctype=Standard", "URIDate": "2023-03-23" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "53", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_g&doctype=Standard", "URIDate": "2023-03-23" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "53", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_h&doctype=Standard", "URIDate": "2023-03-23" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "53", "Subparagraph": "j", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_j&doctype=Standard", "URIDate": "2023-03-23" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53&doctype=Standard", "URIDate": "2023-03-23" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "94", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_94&doctype=Standard", "URIDate": "2023-03-23" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "97", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_97&doctype=Standard", "URIDate": "2023-03-23" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI", "URIDate": "2023-03-23" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Section": "Presentation", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI", "URIDate": "2023-03-23" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "109", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_109&doctype=Standard", "URIDate": "2023-03-23" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "109A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_109A&doctype=Standard", "URIDate": "2023-03-23" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "120", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_120&doctype=Standard", "URIDate": "2023-03-23" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "124", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_124&doctype=Standard", "URIDate": "2023-03-23" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "125", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_125&doctype=Standard", "URIDate": "2023-03-23" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_127&doctype=Standard", "URIDate": "2023-03-23" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "128", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_128_a_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "128", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_128_a&doctype=Standard", "URIDate": "2023-03-23" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "132", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_132_b&doctype=Standard", "URIDate": "2023-03-23" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_i&doctype=Standard", "URIDate": "2023-03-23" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_iv&doctype=Standard", "URIDate": "2023-03-23" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_v&doctype=Standard", "URIDate": "2023-03-23" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_vi&doctype=Standard", "URIDate": "2023-03-23" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_vii&doctype=Standard", "URIDate": "2023-03-23" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b&doctype=Standard", "URIDate": "2023-03-23" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_c&doctype=Standard", "URIDate": "2023-03-23" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2023-03-23" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard", "URIDate": "2023-03-23" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "47", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_a_i&doctype=Standard", "URIDate": "2023-03-23" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2023-03-23" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2023-03-23" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2023-01-01", "Paragraph": "B67", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2023-01-01", "Paragraph": "33", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2023-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2023-03-23" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "21C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_21C&doctype=Standard", "URIDate": "2023-03-23" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "22A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_22A&doctype=Standard", "URIDate": "2023-03-23" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "23B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_23B_a&doctype=Standard", "URIDate": "2023-03-23" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_33&doctype=Standard", "URIDate": "2023-03-23" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard", "URIDate": "2023-03-23" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35F", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35F_a&doctype=Standard", "URIDate": "2023-03-23" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35H", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2023-03-23" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35I&doctype=Standard", "URIDate": "2023-03-23" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35K", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35K_a&doctype=Standard", "URIDate": "2023-03-23" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2023-03-23" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "42E", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_42E_e&doctype=Standard", "URIDate": "2023-03-23" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard", "URIDate": "2023-03-23" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B52", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B52&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Section": "Defined terms", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA_TI", "URIDate": "2023-03-23" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_a&doctype=Standard", "URIDate": "2023-03-23" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_e&doctype=Standard", "URIDate": "2023-03-23" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2023-03-23" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard", "URIDate": "2023-03-23" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_a&doctype=Standard", "URIDate": "2023-03-23" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2023-03-23" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2023-03-23" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_d&doctype=Standard", "URIDate": "2023-03-23" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_e&doctype=Standard", "URIDate": "2023-03-23" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_32&doctype=Standard", "URIDate": "2023-03-23" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "33", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_33_a&doctype=Standard", "URIDate": "2023-03-23" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_33&doctype=Standard", "URIDate": "2023-03-23" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard", "URIDate": "2023-03-23" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expired 2023-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "22", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_22&doctype=Standard", "URIDate": "2023-03-23" }, "r209": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_102&doctype=Standard", "URIDate": "2023-03-23" }, "r210": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard", "URIDate": "2023-03-23" }, "r211": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_108&doctype=Standard", "URIDate": "2023-03-23" }, "r212": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "68", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_68&doctype=Standard", "URIDate": "2023-03-23" }, "r213": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_70&doctype=Standard", "URIDate": "2023-03-23" }, "r214": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2023-03-23" }, "r215": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_c&doctype=Standard", "URIDate": "2023-03-23" }, "r216": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2023-03-23" }, "r217": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "IG6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2023-03-23" }, "r218": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "10", "IssueDate": "2023-01-01", "Paragraph": "22", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&anchor=para_22_f&doctype=Standard", "URIDate": "2023-03-23" }, "r219": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "37", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37_g&doctype=Standard", "URIDate": "2023-03-23" }, "r220": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "138", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_138_a&doctype=Standard", "URIDate": "2023-03-23" }, "r221": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "147", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_147_c&doctype=Standard", "URIDate": "2023-03-23" }, "r222": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "32", "IssueDate": "2023-01-01", "Paragraph": "IE33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2023-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2023-03-23" }, "r223": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_127&doctype=Standard", "URIDate": "2023-03-23" }, "r224": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "16", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_16_a&doctype=Standard", "URIDate": "2023-03-23" }, "r225": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2023-03-23" }, "r226": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2023-03-23" }, "r227": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Section": "A Statement of cash flows for an entity other than a financial institution", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI", "URIDate": "2023-03-23" }, "r228": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B10", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r229": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "B6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r230": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "IE63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2023-03-23" }, "r231": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "B89", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_B89_a&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r232": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "B89", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r233": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53&doctype=Standard", "URIDate": "2023-03-23" }, "r234": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2023-03-23" }, "r235": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "96", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_96_b&doctype=Standard", "URIDate": "2023-03-23" }, "r236": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_32&doctype=Standard", "URIDate": "2023-03-23" }, "r237": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35N", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35N&doctype=Standard", "URIDate": "2023-03-23" }, "r238": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B11", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11_d&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r239": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B11", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r240": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B35", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r241": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r242": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "IG31A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance", "URIDate": "2023-03-23" }, "r243": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard", "URIDate": "2023-03-23" }, "r244": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2023-03-23" }, "r245": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r246": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r247": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r248": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r250": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r251": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r252": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r253": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r254": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r255": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r256": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r257": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r258": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r259": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r260": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r261": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r262": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r263": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r264": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r265": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r266": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r267": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r268": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r269": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r270": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r271": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r272": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r273": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r274": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r275": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r276": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r277": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r278": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r279": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r280": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r281": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r282": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r283": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r284": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r286": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r287": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r288": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r289": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r290": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r291": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r292": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r293": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r294": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r295": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r296": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r297": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r298": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r299": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r300": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r301": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r302": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r303": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r304": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r305": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r306": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r307": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r308": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r309": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r310": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r311": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r312": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r313": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r314": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r315": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r316": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r317": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r318": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r319": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r320": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r321": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r322": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r323": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r324": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r325": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r326": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r327": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "10", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_10_e&doctype=Standard", "URIDate": "2023-03-23" }, "r328": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2023-03-23" }, "r329": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_108&doctype=Standard", "URIDate": "2023-03-23" }, "r330": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard", "URIDate": "2023-03-23" }, "r331": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_117&doctype=Standard", "URIDate": "2023-03-23" }, "r332": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard", "URIDate": "2023-03-23" }, "r333": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2023-03-23" }, "r334": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78&doctype=Standard", "URIDate": "2023-03-23" }, "r335": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2023-03-23" }, "r336": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "85", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_85&doctype=Standard", "URIDate": "2023-03-23" }, "r337": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37&doctype=Standard", "URIDate": "2023-03-23" }, "r338": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2023-03-23" }, "r339": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_37&doctype=Standard", "URIDate": "2023-03-23" }, "r340": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "33", "IssueDate": "2023-01-01", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2023-03-23" }, "r341": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "33", "IssueDate": "2023-01-01", "Paragraph": "70", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_c&doctype=Standard", "URIDate": "2023-03-23" }, "r342": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2023-03-23" }, "r343": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_iv&doctype=Standard", "URIDate": "2023-03-23" }, "r344": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118&doctype=Standard", "URIDate": "2023-03-23" }, "r345": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "40", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2023-03-23" }, "r346": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "41", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2023-03-23" }, "r347": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17&doctype=Standard", "URIDate": "2023-03-23" }, "r348": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "20", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_a&doctype=Standard", "URIDate": "2023-03-23" }, "r349": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "20", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2023-03-23" }, "r350": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard", "URIDate": "2023-03-23" }, "r351": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard", "URIDate": "2023-03-23" }, "r352": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard", "URIDate": "2023-03-23" }, "r353": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard", "URIDate": "2023-03-23" }, "r354": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard", "URIDate": "2023-03-23" }, "r355": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard", "URIDate": "2023-03-23" } } }